sartorius stedim biotech group reference document order intake sale revenue underlying ebitda margin million million financial schedule analyst conference sfaf paris france march annual general shareholder meeting aubagne france april payment dividends april publication firstquarter figure april publication firsthalf figure july publication ninemonth figure october publication preliminary figure fiscal january order intake underlying ebitda million sale revenue underlying ebitda margin annual general shareholder meeting aubagne france april publication firstquarter figure april subject approval annual general shareholder meeting key figure figure given million according ifrs unless otherwise specified oder intake sale revenue earnings order intake contact sale revenue underlying ebitda petra kirchhoff andreas theisen underlying ebitda sale revenue vice president director net profit noncontrolling interest corporate communication ir investor relation underlying net profit noncontrolling interest phone phone petrakirchhoffsartoriuscom andreastheisensartoriuscom research development cost financial data per share earnings per share earnings per share dividend per share publication bilan published financial reporting system firesys balance sheet total sartorius stedim biotech sa michael konrad gmbh equity corporate communication frankfurt main germany equity ratio c aubagne cedex france photography financials peter ginter capital expenditure excluding financial asset goodwill editorial deadline lohmar germany capital expenditure sale revenue february depreciation amortization net cash flow operating activity published net debt february ratio net debt underlying ebitda total number employee december adjusted extraordinary item information ebitda net profit underlying presentation please refer group business development chapter glossary excluding amortization defined ifrs fair value adjustment hedging instrument amount suggested board director conseil dadministration subject approval annual general shareholder meeting excluding tap biosystems translation information key financial indicator please refer glossary original frenchlanguage document de référence mission sartorius stedim biotech leading provider cuttingedge equipment service devel opment quality assurance production process biopharmaceutical industry integrated solution covering fermentation filtration purifi cation fluid management lab technology supporting biopharmaceutical industry around world develop produce drug safely timely economically nextgeneration process sartorius stedim biotech focus singleuse technology addedvalue service meet rapidly changing technology requirement industry serf strongly rooted scientific community closely allied customer technology partner company dedicated philosophy turning science solution reference document present original french document de référence section document included translated reference document filed interest investor covered autorité de marchés financier another part reference document february accordance article règlement général may used copy present reference document connection offering security obtained following supplemented prospectus note dopération autorité de marchés financier issued sartorius stedim biotech sa endorsement reference document zi le paluds avenue de jouques made issuer engages responsibility c aubagne cedex signatory group website wwwsartoriusstedimcom autorité de marchés financier website reference document incorporates reference wwwamffranceorg preceding reference document filed february filed march following information included reference present reference document year consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group management report appearing page respectively reference document filed autorité de marchés financier february number year consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group management report appearing page respectively reference document filed autorité de marchés financier march number shareholder chairman message executive committee sartorius stedim biotech share management report structure management group strategy goal group business development net worth financial position sustainability report table concordance statutory auditor report sustainability report opportunity risk report forecast report financial statement parent company sartorius stedim biotech sa december reference document contains statement concerning future performance sartorius stedim biotech sa statement based assumption estimate although convinced forwardlooking statement realistic cannot guarantee actually apply assumption harbor risk uncertainty could lead actual result diverging substantially expected one planned update forwardlooking statement translation original frenchlanguage reference document document de référence sartorius shall assume liability correctness translation original french reference document legally binding version furthermore sartorius stedim biotech sa reserve right responsible topicality correctness completeness quality information provided liability claim regarding damage caused use information provided including kind information incomplete incorrect therefore rejected throughout reference document difference may apparent result rounding addition content corporate governance annual financial statement sartorius stedim biotech sa note board director committee chairman report pursuant article annual financial statement l french commercial code statutory auditor report remuneration executive financial statement nonexecutive member board statutory auditor report prepared accordance article l independent auditor fee supplementary information information legal nature special report statutory auditor consolidated financial related party agreement commitment statement note resolution submitted annual combined shareholder meeting april statement proﬁt loss information reference document comprehensive income annual financial report statement financial position code afep medef statement cash flow glossary statement change equity address note financial statement note statement proﬁt loss note individual balance sheet item disclosure statutory auditor report consolidated financial statement shareholder chairman message dear shareholder pleased report yet another year year success also strategic excellent performance sartorius stedim standpoint key element total solution biotech group fourth year succession provider strategy continuously add new offering posted doubledigit topline growth sale portfolio product development slightly exceeded management guidance increasing alliance bolton acquisition therefore constant currency business expanded across pleased report recently acquired entire portfolio driven strong business cell culture medium well tap small organic growth excellent development recent scale singleuse bioreactors developed well acquisition geographic perspective north sartorius stedim biotech umbrella even america led growth also somewhat ahead business plan believe recent acquisition especially positive effect proved ability smoothly share sale key north american integrate new company people market meanwhile surpassed mark organization help extend global reach innovative product expanded also satisfied profit development portfolio adding singleuse product aseptic underlying ebitda slightly sampling acquired majority stake proportionally mainly driven u startup allpure technology economy scale company underlying ebitda margin reached expected fiscal also marked achievement continuous profitability expansion past year product development example took demonstrates strength consumablesdriven important step new generation bag business model strategy total solution meet industry demand full scalability provider whole see u well track increased standardization singleuse device achieve strategic growth target result international sale initiative defined three year ago deploying new strategy better penetrate account entire product portfolio also progressed strong profitable growth resulted significant multiyear investment program increase underlying earnings per share goettingen site combining two plant reaching based positive single site expanding production capacity result board director submit proposal well building demonstration application annual general shareholder meeting raise laboratory shanghai facility dividend yet per share positive performance prospect also reflected development share price soared outperformed french stock market continue invest global success achieved show potential infrastructure capability keep behind company employee therefore growth company also continue special thanks go employee worldwide expand footprint north america asia creativity dedication constantly important pillar strategic growth initiative strive enhance business performance also addition strive outpace market appreciate continued support customer north america leverage market growth asia partner shareholder cordially invite continue u road success set ambitious target aiming increase sale revenue around operational profit margin projected rise approximately sincerely continued investment global infrastructure capacity result capex ratio range based strong fundamental industry see excellent prospect business also medium long term biotech continuing outperform growing global pharma market joachim kreuzburg remaining innovation engine industry chairman board ceo biosimilars provide additional opportunity grow market health cost pressure mounting regulatory requirement increasing singleuse production technology beginning dominate major biomanufacturing step due lower production cost higher flexibility provide ssb one pioneer singleuse technology constantly strive make production process customer biopharma industry even reliable efficient executive committee joachim kreuzburg chairman board chief executive ofﬁcer head finance human resource compliance legal affair corporate communication hold doctorate economics university degree mechanical engineering joachim kreuzburg also ceo ssbs parent corporation sartorius ag chairman sartorius group executive committee oscarwerner reif executive vice president research development manages group global research development unit hold doctorate chemical engineering studied chemistry molecular biology germany usa oscarwerner reif also member sartorius group executive committee volker niebel executive vice president operation responsible production supply chain management business process management information technology hold university degree business administration economics volker niebel also belongs sartorius group executive committee reinhard vogt executive vice president marketing sale service charge marketing sale service hold vocational diploma industrial business administration reinhard vogt also member executive board sartorius ag member sartorius group executive committee shareholder sartorius stedim biotech share sartorius stedim biotech share fact share isin fr liquidity provider gilbert dupont stock exchange euronext paris market segment local security compartment large cap index sbf cac share cac mid small cac small cac health care number share thereof sartorius ag thereof free float voting right thereof sartorius ag thereof free float december stock market characterized high volatility strong share price development reporting year stock market around world sartorius stedim biotech share price showed volatile performance whole performed better french stock market supported primarily expansive monetary whole close end policy ecb first half year share price rose end geopolitical tension worsening economic prospect fueled uncertainty course second half sbf example reached share hit lowest closing price year time high point middle year january highest closing price june went point registered end reporting period october supported low interest december environment ended year point represents overall gain shareholder sartorius stedim biotech share sartorius stedim biotech share january december sartorius stedim biotech share sartorius stedim biotech share sartorius stedim biotech share comparison sbf cac mid small nasdaq biotechnology index indexed january december sbf cac sartorius nasdaq midstedim biotechnology small index biotech share sartorius stedim biotech share sbf cac mid small nasdaq biotechnology index shareholder sartorius stedim biotech share investor relation activity information publication relating company share may found website sartorius stedim biotech investor relation activity wwwsartoriusstedimcom focus maintaining ongoing open dialogue shareholder potential investor financial analyst analyst besides providing firsthalf annual report well recommendation financial analyst serve holding quarterly telephone conference also important foundation decision private regularly published press release presenting institutional investor investing share significant company business development currently four institution regularly prepare report material event reporting year update sartorius stedim biotech share moreover management team available capital market participant site goettingen research coverage germany aubagne france conference institute date recommendation road show conducted financial market portzamparc january hold center london uk paris france frankfurt gilbert dupont january add main germany new york usa hold oneon oddo midcap january buy one meeting additionally september hosted first capital market day goettingen société générale january hold germany providing indepth view business strategy positioning well future business potential key figure sartorius stedim biotech share reporting share price date high low dividends total dividend paid million payout ratio dividend yield market capitalization million average daily trading number share trading volume share million cac mid small million sbf million daily closing price amount suggested board director subject approval annual general shareholder meeting based underlying net result dividend relation corresponding closing price year source euronext bloomberg shareholder sartorius stedim biotech share dividend shareholder structure sartorius stedim biotech group applies dividend pursuant authorization annual general policy intended ensure shareholder adequately shareholder meeting board director july rewarded company success accordingly resolved cancel company generally endeavor distribute treasury share representing approx company underlying net profit company total share capital time definition see p nominal value per share increased board director submit proposal annual general shareholder meeting april result number issued share without exer pay dividend fiscals per share cisable option totaled december net profit million would compared yearend represent gain previous year issued capital sartorius stedim biotech sa figure therefore total profit distributed however went million million would increase million year ago million corresponding dividend payout ratio would compared previous share convey double voting right year relation share closing price total voting right december dividend yield would reporting date previous year cancellation treasury share sartorius ag hold share capital dividend outstanding voting right share free float corresponding outstanding voting right shareholding structure share capital sartorius ag free float amount suggested board director subject approval annual general shareholder meeting management report management report structure management group structure management group group legal structure reporting year minor change company portfolio sartorius stedim biotech sartorius stedim biotech globally operating acquired majority stake u startup allpure company employee worldwide technology llc company initially con subsidiary country parent solidated april company sartorius stedim biotech group sartorius stedim biotech sa holding company control group direct indirect financial controlling affiliate key performance indicator approximately share capital around sartorius stedim biotech group managed using voting right sartorius stedim number key performance indicator biotech sa held sartorius ag subsidiary also decisive determination variable remuneration component executive committee manager organization management group key management parameter sartorius stedim sartorius stedim biotech group consistently biotech u measure development organized function worldwide company volume currencyadjusted growth order intake accordingly managed along core operating sale revenue function key profitability measure ebitda adjusted global functional organization creates extraordinary item ie underlying ebitda effective platform central strategic control corresponding margin beyond indicator ebit fast efficient collaboration within group relevant net profit year net profit also enables company realize total solution earnings per share reported provider strategy position effectively respect global customer important indicator ratio net debt underlying ebitda group managed executive member board director sartorius stedim biotech sa addition following financial nonfinancial implementing group various strategy indicator reported regular basis project local level responsibility national affiliate management body local equity ratio company manage organization accordance capex ratio applicable statutory provision article net working capital association rule procedure keeping net cash flow operating activity principle corporate governance apply number employee throughout sartorius stedim biotech group worldwide rule annual financial forecast published management beginning fiscal year group refers development sale change group portfolio revenue underlying ebitda expected capex ratio additionally indicated group sale consolidated financial statement include revenue order intake mostly similar level parent company sartorius stedim biotech sa sartorius stedim biotech due structure major affiliate sartorius stedim biotech sa generally show considerable timing controlling interest pursuant ifrs difference subject similar growth assumption reason order intake usually budgeted separately component financial forecast management report strategy goal strategy goal sartorius stedim biotech leading international provides considerable cost time saving supplier product technology manu reduce risk contamination sartorius stedim facture medication vaccine biological biotech extensive portfolio singleuse basis socalled biopharmaceuticals technology industry part strategy total solution provider product company address attractive offer biopharmaceutical industry product market aboveaverage growth potential portfolio cover nearly step sale distribution activity carried production process cover cell culture medium globally field force customer seed fermentation cultivation various manufacturing process validated respective bioreactor size cell propagation well range authority product quality supply security technology equipment filter essential aseptic bag cell harvesting purification concentration way final filling see leading market position process filtration fluid management fermentation sartorius stedim biotech focus particular membrane chromatography good stepping stone singleuse product represent around three sustained dynamic profitable growth quarter sale revenue include inter alia future besides realizing organic growth potential filter bag cell culture medium customer company also intends continue expanding singleuse product innovative alternative complementary acquisition alliance conventional reusable stainless steel system integrated product service along customer process chain upstream bioprocessing downstream bioprocessing medium seed production cell removal capture polishing viral formulation preparation fermentation fermentation clariﬁcation clearance final fill service evaluation optimization engineering design implementation technical service management report strategy goal sector condition continued aboveaverage growth biotechnology market sartorius stedim biotech serf customer mainly biopharmaceutical industry make global market pharmaceutical manufactured business particularly sensitive development using biotech method grew overproportionately industry reporting year around outperforming global pharmaceutical market attributable mainly launch many new biopharmaceuticals strong growth pharmaceutical market past year expanded indication existing medicine proportion sale revenue international market research institute ims health accounted biologically produced medication estimate global pharmaceutical market risen last year stand around grown around compared gain currently therapeutic protein play important role treatment condition including diabetes chronic anemia still make significant acceleration growth primarily largest category active pharmaceutical attributed comparably low number patent ingredient manufactured using biotech method expiration developed market many new monoclonal antibody also continuing gain drug approved addition introduction importance used instance government health insurance usa treatment cancer hiv autoimmune disease positive impact multiple sclerosis rheumatism according study conducted boston consulting pharmerging market continued expand dynamically group monoclonal antibody whole reporting period growth undergoing clinical development phase iiii market driven expansion state significantly healthcare higher private spending strong trend towards singleuse system growth regional pharma market biopharmaceutical production compared classic procedure biotechnological production process vastly complex costintensive reason manufacturer supplier intensively working develop efficient production technology singleuse product playing crucial role effort require significantly less capital expenditure moreover reduce cost cleaning validation minimize downtime beyond advantage singleuse product provide considerable flexibility help accelerate time market thanks particular cost efficiency singleuse product already well europe usa japan pharmerging markets established many process step chine brésil russie inde algérie argentine colombie égypte indonésie mexique nigeria pakistan pologne roumanie arabie saoudite afrique du sud thaïlande turquie ukraine venezuela vietnam source ims health management report strategy goal continued soft demand public research sector proportion demand laboratory product come public sector research many country research budget declining result excessive public debt according frost sullivan demand public research sector reporting year slightly prioryear level competition primary mean company biotechnology market differentiate competitor innovative prowess quality performance product biotechnology sector constantly discovering new area application expects supplier equally fast moving creative developing new equipment manufacture biotech product new supplier particular seek exploit opportunity inherent environment gain foothold market carefully targeted niche product established supplier meanwhile expanding product range continuously generate round sale revenue validated process replacing product production cycle expensive receive high proportion followup repeat business particular strength sartorius stedim biotech lie integrated process solution investigation development substance lab production end product offer broadest range industry strategic focus singleuse product give u another edge competition sartorius stedim biotech occupies strong position market worldwide field bioprocess filtration fermentation fluid management membrane chromatography competitor multinationals based usa emd millipore pall general electric healthcare among main rival process area thermo fisher emd millipore key player laboratory field also face competition smaller company applikon individual segment source boston consulting group medizinische biotechnologie deutschland medical biotechnology germany ims global outlook medicine evaluate pharma world preview june management report group business development group business development order intake sale revenue sale revenue region reporting year business sartorius stedim europe biotech group performed positively substantial doubledigit gain order intake sale north america revenue earnings order intake sale revenue million asia pacific market acc customer location main region reported strong gain sale revenue especially europe north america acquisition mentioned contributed significantly growth europe region generating highest sale accounting around total group order intake revenue reported increase sale revenue sale revenue constant currency million order intake reporting year climbed north america represented sartorius million constant currency compared stedim biotech sale revenue registered highest high prioryear revenue base sale revenue rose growth dynamic reporting period sale period constant region significantly increased constant currency million slightly surpassing currency million guidance issued outset year constant currency organic growth around asia pacific accounted around total sale exceeded expectation driven recording gain constant product line also recent acquisition cell currency million culture medium business tap biosystems developed dynamically reporting period performed better anticipated beginning year management report group business development sale revenue region earnings million unless otherwise specified sartorius stedim biotech group earnings interest tax depreciation amortization ebitda used key profitability measure provide complete transparent presentation group profitability report earnings adjusted extraordinary item underlying ebitda information definition please refer glossary page underlying presentation reconciled ebitda key indicator see glossary following page reporting year earnings sartorius stedim europe north asia biotech advanced significantly based strong america pacific market growth sale revenue due economy scale underlying ebitda increased overproportionally million respective margin rose line guidance provided beginning reporting year sales growth growth million underlying ebitda margin group europe north america asia pacific market acc customer location constant currency underlying ebitda million underlying ebitda margin adjusted extraordinary item extraordinary item amounted million previous year million essentially related integration tap biosystems corporate project including extraordinary item depreciation amortization group ebit see glossary rose million million respective margin increased management report group business development underlying net profit noncontrolling interest appropriation profit group surged million year ago million fiscal profit figure board director submit proposal calculated adjusting extraordinary item annual general shareholder meeting april eliminating noncash amortization million payment dividend per share fiscal previous year million fair value adjustment previous year total hedging instrument well corresponding profit distributed would accordingly increase tax effect item underlying million year earlier million earnings per share year relation closing price share earlier december would result dividend yield previous year underlying earnings per share million ebit operating result extraordinary effect amortization ifrs financial result valuation hedging instrument normalized income tax underlying net result noncontrolling interest underlying net result excluding noncontrolling interest underlying earnings per share see glossary definition total listed management report net worth financial position net worth financial position cash flow cash flow statement summary net cash flow operating activity million sartorius stedim biotech group increased net cash flow million million reporting period operating activity gain essentially driven higher earnings net cash flow investing activity acquisition net cash flow net cash flow operating activity financing activity million cash cash equivalent gross debt owed bank net debt owed bank consolidated balance sheet balance sheet total sartorius stedim biotech group increased moderately million million yearend reporting date december noncurrent asset rose million million primarily due investment production capacity million net cash flow investing activity substantially higher last year current asset grew million figure million planned increase million increase driven mainly reflects higher investment expansion aforementioned buildup working capital product capacity partly compensated decrease cash cash equivalent cash outflow million related acquisition reporting period attributable takeover majority stake allpure technology llc key working capital figure day figure million reflected acquisition cell culture medium business tap biosystems group rate turnover inventory net cash flow investing activity inventory x acquisition thus amounted million compared sale revenue million accordingly group financed entire investment acquisition rate turnover operating cash flow receivables trade receivables x net cash flow financing activity sale revenue million reflects payment dividend payback debt see note rate turnover net working capital net working capital x sale revenue sum inventory trade receivables less trade payable management report net worth financial position equity million financing treasury million sartorius stedim biotech group equity ratio rose markedly sartorius stedim biotech group financed december welldiversified basis reporting year attractive credit market condition used noncurrent liability million refinance existing syndicated credit facility december compared million maturity moreover financing facility december current liability pooled level sartorius ag majority year year million million shareholder sartorius stedim biotech therefore mainly reflects significant reduction syndicated loan sartorius stedim biotech gross debt well change maturity due volume million terminated december refinancing syndicated loan reporting since sartorius stedim biotech year using credit line volume million provided sartorius ag see page overall gross debt million decem information ber compared million year ended december net debt furthermore group longterm loan reporting date million relative agreement kreditanstalt für wiederaufbau million year ago kfw current volume million relating investment production capacity balance sheet structure another element financing structure asset equity liability factoring program maximum volume million moreover sartorius stedim biotech diverse bilateral credit line approximately million total financing sartorius stedim biotech group comprises instrument fixed variable interest financing facility variable interest rate partly hedged increase general interest rate level ratio net debt underlying ebitda represents key management indicator sartorius stedim biotech group significantly improved noncurrent asset equity year ended december current asset noncurrent liability current liability ratio net debt underlying ebitda ratio longterm capital fixed asset stood december management report net worth financial position sartorius stedim biotech group conduct business sartorius stedim biotech group stepped across globe thus affected currency research development activity reporting fluctuation group u dollar represents year increasing spending area important foreign currency besides million previous year million japanese yen british pound global respective ratio rd cost sale revenue manufacturing network production facility compared year earlier outside germany france north america uk switzerland india enables u research development cost compensate majority currency fluctuation million natural hedging generally hedge remaining net currency exposure period year ahead twothirds suitable currency transaction research development research development activity sartorius stedim biotech encompass inhouse development area core technology well integration product alliance partner university industry research development ratio sale revenue inhouse research development sartorius focus particular following technology area membrane core component type filter product several base technology broad spectrum application bioprocesses like single use container sensor well control technology eg fermentation morevover extensive expertise application development regional perspective largest rd site located goettingen additional key rd activity aubagne guxhagen bangalore royston overall research development activity become increasingly international one rd priority reporting year protect knowhow pursue targeted develop additional application new intellectual industrial property right policy polyethylene film thus continued effort systematically monitor compliance right bring new film market area storage review cost benefit viewpoint whether freezethaw application necessary continue maintain individual right connection acquisition allpure number application intellectual property technology began work reporting year right filed amounted compared develop new standardized product taking sample previous year result application bioreactors submitted past year issued patent trademark previous year also collaborating industrial balance sheet date total patent university partner development new control trademark portfolio previous year technology manufacturing process active medical ingredient socalled process analytical tool management report net worth financial position product range gained new sampling system number patent trademark acquisition majority stake u startup application allpure technology allpure system registered patent trademark based singleuse technology allows sample taken bioreactor sterile closed environment technology replaces traditional product sale reusable sampling system pose greater risk contamination sartorius stedim biotech provides product cover virtually every step biopharmaceutical production process medium cell cultivation bioreactors extensive range service various size cell propagation filter purifying cell material system storage sophisticated manufacturing process employed transport intermediate finished product customer subject strict regulation offering complemented range service quality control quality assurance compliance including consulting validation application regulation subject regular check specific package relevant authority offer extensive range service encompassing validation consulting sartorius stedim biotech launched new generation activity well equipment installation existing product line reporting year added maintenance repair help customer comply several completely new product notably applicable regulatory requirement area fluid management fermentation sale distribution activity expanded new generation singleuse bag sartorius stedim biotech market product portfolio together cooperation partner developed exclusively direct channel maintains new polyethylene film based launched team field sale representative also new singleuse bag fermentation application global key account management organization reporting year one main benefit coordinate support sale distribution activity new film interact cell key account sartorius stedim biotech began material stable cell growth ensured new film reporting year introduce new global crm combine robustness flexibility system provide support sale time meaning also used large distribution activity also stepped sale volume fermentation storage process distribution activity asia wide range application another advantage reporting year connection implementation customer single film strategy new application center validated pave way significant opened shanghai example allows reduction validation time cost presentation key product plus demonstration variety different application customer acquisition strengthen product range acquisition british company tap biosystems end added two smallvolume singleuse bioreactor system process development application product range innovative system enable customer perform large number cell culture experiment simultaneously providing quick costeffective way determine optimal development condition cell culture allows u begin working customer early stage process development management report net worth financial position production supply chain management production capacity expanded sartorius stedim biotech operates welldeveloped sartorius stedim biotech expanded production global production network plant europe capacity various site reporting year north america asia largest production site response dynamic growth bioprocess located germany france puerto rico business thus new bag production system sartorius stedim biotech also manufacturing commissioned yauco aubagne operation switzerland uk tunisia india mohamdia plant company installed new casting machine production filter membrane production site generally serf goettingen site reporting year center competence particular technology scheduled commissioned production group largest plant goettingen example capacity also expanded bangalore concentrate chiefly production membrane plant fermentation filter aubagne mohamdia site primarily manufacture singleuse bag plant yauco supply membrane filter singleuse bag central distribution center principally u market guxhagen site specializes bioreactors system sartorius stedim biotech partner built new bioprocess application collaborates closely highly automated logistics center goettingen bangalore site mainly manufacture stainless site reporting year facility handle product steel unit system shipping well supplying production unit goettingen plant intend implement central distribution center asian market future based suzhou site china management report sustainability report sustainability report sustainability one core value firmly methodological note embedded sartorius stedim biotech corporate culture ever since company established indicated otherwise indicator reported sustainable development company hr health safety refer entire major objective group excluding u startup allpure acquired figure thus represent primary business responsibility offer total headcount environmental indicator attractive product solution customer cover production site aubagne lourdes innovation well strategic operational mhamdia goettingen guxhagen stonehouse excellence key meeting objective u tagelswangen yauco bangalore royston sustainability mean pursuing business representing group total workforce objective use longterm broadly based approach encompassing social ecological interest data collected using sap social information take responsibility toward various emc environmental data case stakeholder seriously foster longterm relation local site transmit data via software system deliver benefit party involved therefore general rule required data reported monthly active management social ecological task hr ehs unit largest group site one success factor goettingen review consolidate data sartorius stedim biotech set process continuous line approach consider essential improvement groupwide recording reporting comply legal ethical standard manufacture environmental personnel data ecological responsibility keep environmental impact mind developing product innovation likewise hr policy aimed preserving right interest employee f economic actively using developing potential eo success u oyee co mpl l mp global workforce company site around l e ntia glo acti l te ian ba world employer contractor take active po ce part developing regional environment able corpo tain ra u anagement e e u c tio n l ctiv indicator social health safety p r ti n r ese rc h n ble ctio n environmental raw material data c n r cie l ai g c defined cover impact group b ili produ u st activity since sartorius stedim biotech ibu ti na l ty n g ec f reporting key personnel environmental sus indicator metric compliance french oci r oje p n pr grenelle ii environmental law recommended table al c f ica l io f e n r lo g ovum concordance shown page ar ra st f h e e c nn r r u c ct indicator based generally accepted ius tu sit e r e p rodu standard permit comparison company internally figure provide basis defining reviewing controlling environmental hr target management report sustainability report sustainable corporate management guideline defined anticorruption code intended help employee act ethically activity based corporate value accordance law daily work sustainability openness enjoyment value employee around globe required complete govern treat customer business partner training dealing ethically legally investor well work together within problematic situation whistleblower portal company addition value guide u telephone hotline enable employee supplier future development company customer partner report dubious conduct sartorius stedim biotech conduct business sartorius stedim biotech remuneration policy accordance legal regulation individual aim attract retain motivate employee country globally accepted ethical standard ensures internal external competitiveness action line good corporate conducting regular review local market governance control focusing sustainable value two global incentive program many added principle include compliance legal employee eligible participate linked internal group regulation protection success company achievement stakeholder interest transparent communication target defined annual performance review appropriate risk management proper accounting generally company applies industry standard auditing sartorius stedim biotech follows complies union agreement germany rule recommendation afepmedef france instance compensation paid according corporate governance code information pay rate set trade union even provided chairman report page based local performancerelated component reference document business partner request supplier compliance system preemptive nature associate respect human right signing aim prevent misconduct financial loss damage code conduct upholding applicable company image key principle system human right law regulation also code conduct anticorruption code ensuring principle complied comprising basic standard legally compliant throughout entire supply chain ethical behavior help ensure operate highest level integrity binding employee following code conduct sartorius stedim biotech support respect principle defined united nation universal declaration human right convention international labor organization ilo united nation global compact furthermore reject form compulsory andor child labor respect special need protect young employee sartorius stedim biotech employee committed taskoriented open friendly fair approach interacting colleague employee third party helping create atmosphere respectful cooperation tolerate employee discriminated disadvantaged harassed excluded based gender ethnic origin life philosophy race religion age disability appearance sexual preference identity origin political position uphold freedom association right individual fairly represented labor organization choosing pursuant local law management report sustainability report employment employee function employment number reported following include staff member except vocational trainee intern employee extended leaf absence participating early retirement plan number recorded head count ie employee counted regardless whether work full part time december sartorius stedim biotech group employed people total figure yet include employee u startup allpure technology sartorius stedim biotech acquired april production marketing research administration sale development recruited new staff response sustained strong service demand singleuse product included tap biosystems employee first time excluding allpure headcount increased excluding administrative function performed sartorius europe continued region highest corporate administration gmbh part number employee accounting nearly two sartorius stedim biotech group third workforce north america recorded highest increase reporting year mainly due new hire production site puerto rico sale marketing employee gender employee region male female europe north asia america pacific market excluding allpure excluding allpure management report sustainability report employee age attrition rate generally subject regional variation rate reporting year north america asia pacific number number europe rate market primarily includes bag manufacturing site mhamdia tunisia however uncommon africa germany traditionally one world lowest fluctuation rate site germany employ group staff rate line german average france attrition rate excluding allpure primarily due fixedterm contract excluding fixed term contract rate france number employee function show approximately twothirds employee work absenteeism rate express proportion manufacture area directly related production planned working time lost due general area new staff member hired absence average time missed due illness followed marketing sale service optimized day per employee day marketing activity decisive factor achieving growth target applying different perspective proportion woman entire workforce slightly decreased reporting year international company diversity average employee age remains market business region customer also year reflected workforce setting team ensure different perspective background combined productively also employee benefit expense totaled million filling management vacancy aim achieve mix reporting year million culture gender age group manager accounted wage salary excluding allpure germany france usa india example detail please see page represented second management level vice president continuing internationalize management lineup medium term new hire attrition rate average seniority absenteeism another priority diversity strategy ensure woman adequately represented manage ment position number post held woman new hire two tier management immediately redundancies executive board december attrition rate average seniority year absenteeism rate reporting period sartorius stedim biotech employed people people excluding allpure registered disabled number work redundancy companydriven dismissal layoff france germany express number people leaving company percentage average headcount including fixedterm contract retirement reason employee leaving company excluding time lost due longterm health condition maternity parental sabbatical leave sartorius biotech korea co ltd represents group total workforce included management report sustainability report developing potential sartorius college offer wide range training employee worldwide seminar continuing development opportunity employee extend foreign language grow successfully dynamic market environment skill professional qualification value selling need competent qualified employee course example teach field sale representative therefore make every effort enhance application specialist worldwide strategic appeal employer internally externally skill necessary provide firstclass customer advisory employer brand talent management service elearning platform within technical aim increase quantity quality talented training program provides interactive way staff available position required company employee marketing sale service focusing especially female employee unit prepare individually subsequent faceto face training session annual performance review conducted employee group subsidiary encourage individual help employee manage change process collective performance appraisal cover successfully sustainably sartorius stedim biotech identification development opportunity well operates strategic change management system review target performance site france tunisia puerto rico sartorius sartorius stedim biotech fill management vacancy stedim biotech provided hour training largely within rank accordingly corresponds average hour develops promotes employee management training average cost per employee potential international level special program scope training hour currently corresponds help junior manager develop refine total headcount sartorius stedim biotech management skill specific project directly intends broaden scope collected data thereby related company business sartorius stedim allowing representative statement biotech also provides separate development program group activity area line leadership guideline experienced management staff strengthen common managerial culture finding developing talented young staff structured expert career path program enables order enhance professional knowledge sartorius stedim biotech provide specific skill experience sartorius stedim biotech offer development opportunity scientist engineer young people opportunity work within rd function raise profile company many year using expert within outside company corresponding european union funding program result expert key sartorius stedim biotech marie curie scheme young scientist technology even greater incentive stay leonardo da vinci scheme international vocational company reporting year together education possible give intern also expert scientist developed possibility participate training thanks content program extended alliance kedge business school marseille internationally france intern aubagne site example attend master business administration sartorius stedim biotech generally encourages course offered employee gain new perspective area work company location international scholarship program meanwhile company also benefit employee think supporting talented student graduate act across department location department scientific technical field financially actively supported relocating staff also technically personally mentoring student within organization management report sustainability report freedom flexibility work employee health safety sartorius stedim biotech complies statutory group corporate health management policy contractual working time obligation cover physical psychosocial subsidiary working time varies depending local element health enhance employee performance environment business activity motivation reduce illnessrelated cost promote awareness personal health among generally set employee demanding task employee special action day individual delegate responsibility early stage give site example introduced advisory freedom define daily work schedule assistance service especially employee traveling instance german ssb site employee opt business foreign country staying abroad various workweek schedule flextime event medical emergency safety risk parttime work teleworking number part employee obtain assistance phone find time employee equates help onsite time vice president germany total head count may take advantage annual medical checkup selected partner clinic encouraging social dialog sartorius stedim biotech align job safety work organization condition according sartorius stedim biotech place great importance applicable law regulation strive improve communication employee interoffice memo technical organizational working condition newsletter employee magazine inform continuously reduce jobrelated medical staff example change within company condition risk health potential cause goal economic situation first global industrial accident effort responsive employee survey held yielded particularly concern employee well aubagne good result employee especially satisfied site example operate special program present job task immediate manager implement specific improvement suggested cooperation within company employee prevent potential health hazard developed followup plan action area given sartorius stedim biotech offer regular training slightly lower rating career advancement employee occupational health safety opportunity besides several activity local level environmental protection site germany planned new talent management reflects provided hour training ehs issue key finding employee survey hour estimated follows hour per employee average multiplied france well germany sartorius stedim headcount end year biotech staff represented three employee attendance rate council employee council hold regular staff meeting collective agreement signed french site german location cover profit sharing incentive system weekend work electronic voting annual performance review france five collective agreement health insurance signed reporting year address environmental health safety issue ehs management report sustainability report statistic accident work high standard quality environmental protection number work accident sartorius stedim biotech certified according number day lost due work accidents internationally recognized standard quality iso frequency rate environment iso result comply quality requirement severity rate manufacture product prudent use excluding allpure resource minimize environmental risk excluding accident occurred employee manufacturing site certified iso travel home work series international standard apart measured calendar day excluding sartorius biotech korea tagelswangen switzerland employ around co ltd represents group total workforce staff member environmental management represents number accident per theoretical working hour theoretical working hour system already certified compliance iso sartorius stedim india sartorius stedim represents number day lost accident per biotech gmbh goettingen received theoretical working hour certification energy management system introduced sartorius stedim biotech gmbh due higher headcount workrelated accident sartorius stedim biotech plastic goettingen site around world number day well sartorius stedim system guxhagen lost due work accident slightly increased compared compliance iso strive previous year number accident continuously improve existing management relation working hour however nearly system working toward gradual rollout workrelated accident production site appropriate minor nature review effectiveness expedient locally respective company accident prevention measure regularly based organizational unit need ensure law accident analysis regulation related environmental protection observed technical possibility reducing environmental risk identified ecological sustainability company international environmental health occupational safety steering group responsible sustainable production ecological product harmonizing continuously improving process innovation important longterm financial three area worldwide success planning operation look beyond immediate use resource sartorius stedim biotech supply product understand entire lifecycle product directly end consumer rather including customer process develop manufacturer pharmaceutical food product efficient safe also chemical also research development provide ecological benefit building laboratory ensure product satisfy renovating factory sartorius stedim biotech assesses stringent quality requirement employ potential environmental impact defines rigorous quality check advanced manufacturing mitigation strategy necessary supplier method process cleanroom technology also required meet specification method process subject constant green approach growth coupled review part continuous improvement policy proportionate use natural resource goal moreover refined appropriately sartorius stedim biotech achieves various level requirement evolve high standard quality information health safety measure adopted achieved sartorius stedim biotech product sartorius stedim biotech employee described process documented successful page completion host annual audit customer certification according standard reporting year environmental risk quality iso quality management identified require company make specific medical device iso respond rapidly provision annual financial statement product defect minimize adverse consequence sartorius stedim biotech established traceability system enables u recall entire product batch immediately necessary management report sustainability report improved emission monitoring electricity natural gas main energy source representing total energy since sartorius stedim biotech using consumption scope emission occurring mainly greenhouse gas protocol ghg global consumption electricity account close standard recording greenhouse gas emission company total emission apart guide reporting co emission thus energy saving reduction coeq nearly consider report co equivalent coeq co compared also result improved emission gas causing climate change accuracy conversion factor specific energy present stage account emission categorized source individual process furthermore scope scope scope record coeq emission electricity consumption value site caused directly production site scope stonehouse adjusted downwards account determines indirect emission arise power approximately decrease coeq generation external energy supplier sartorius stedim biotech yet report scope amount total carbon emission released intends integrate category gradually solvent emission occur mainly filter coeq accounting across value chain future manufacturing goettingen yauco site scope considers coeq emission associated metric ton reporting year factor manufacture precursor metric ton proportion figure product distribution operation relevance greenhouse gas emission taken account calculating coeq figure greenhouse gas emission sartorius stedim biotech sa developed follows efficient use energy energy consumption greenhouse gas sartorius stedim biotech strives adapt consequence climate change reduce total energy consumption mwh greenhouse gas emission linked business electricity improving company energy efficiency one natural gas major approach reducing carbon dioxide fuels emission largest group site goettingen energy sources account approximately energy total greenhouse gas emission consumption especially important effort coeq reporting year introduced energy scope management system certified iso scope site well second goettingen plant key indicator nearby guxhagen site system enables u coeq emission per employee identify strategic opportunity reduce coeq emission per sale revenue energy consumption adoption advanced tmio technology includes energyefficient data range cover diesel consumption electricity combined heat power chp plant generator data collection india site invoiced compressed air center controlling production instead based meter reading since without machinery resulted reduction around effect consumption would slightly increased metric ton annual carbon dioxide emission liquid gas added natural gas data collection invoiced instead based meter reading since intelligent control system enabled u realize without effect consumption would slightly additional energy saving second chp unit decreased went operation bring carbon emission coeq calculated university dioxide emission around metric ton annually applied science art goettingen using emission factor result measure overall energy listed professional software called gabi scope excluding fuel consumption car fleet consumption goettingen site increased much slower rate sale revenue last year management report sustainability report international site well sartorius stedim sustainable use water biotech continuously develops manufacturing process enhances building facility water sartorius stedim biotech u conserve resource particularly new building rinsing manufacture filter membrane increasing proportion renewable energy according precipitation bath method advanced source energy mix plant yauco casting machine help maximize water efficiency cover around energy requirement site site goettingen germany bangalore solar energy furthermore factory india company operates water treatment guxhagen tagelswangen source part system thus contributing sustainable use energy need local photovoltaic plant limited resource based low water strategy use geothermal energy implemented green facility yauco sartorius stedim biotech reduces consumption drinking whole strategy supplying local water approximately compared market far possible directly local conventional plant example using rain water production facility help shorten transportation route thus lower carbon dioxide emission water consumption reducing climate change water consumption cbm water consumption per employee cbm sartorius stedim biotech measuring scope well scope scope emission since waste water biological oxygen demandbod main production site aubagne single use bag using bilan carbone method developed french environment energy management contaminated wastewater without sanitary wastewater agency ademe record emission carbon dioxide greenhouse gas resulting entire process upstream downstream use raw material according production operation latest analysis legal regulation roughly corresponds value obtained previous year considering main source sartorius stedim biotech established material emission business workrelated travel management system test safety raw employee account around material use compliance environmental environmental footprint aubagne site freight protection occupational safety regulation transport packaging impact europe include international rohs directive incoming raw material represents restriction use certain hazardous emission following identification quantification substance electrical electronic equipment main source greenhouse gas emission european reach regulation registration local current action plan updated optimize evaluation authorisation chemical well distribution finished product include moving comparable international standard customer plan encourage carpooling public informed safety data sheet product safety transportation among measure information warning alert operating instruction hazardous substance present product management report sustainability report sartorius stedim biotech defined three type raw supplier pharmaceutical industry sartorius material particularly important manufacturing stedim biotech currently prohibited regulatory product chemical solvent membrane requirement using recycled plastic filter cartridge polymer singleuse material ground product safety yet consistently send stainless steel reusable bioreactors system plastic waste recycling disposed group gradually implementing environmentally responsible way energyrich quantitative indicator raw material composite plastic waste resulting bag sartorius stedim biotech purchased metric manufacture france reused generate energy ton chemical solvent metric incineration special power plant larger ton metric ton polymer recorded proportion polymer waste separated collected first time reporting year figure according type material polyamide indicates quantity purchased invoiced polyethylene recyling secondary material instead amount used sartorius stedim biotech complies european directive waste electrical electronic return recyclable material equipment weee sartorius stedim biotech strives reduce waste site germany using using waste sorting system contributes toward electronic signature hazardous material recycling reusable material lowering caustic solution oil since result proportion waste stored landfill document production hazardous waste provide digital proof proper recovery andor amount waste disposal ensuring waste fully tracked end end total amount waste waste recycling environmentally friendly expansion waste disposal group infrastructure waste per employee recycling rate expanding infrastructure sartorius stedim biotech complies local regulation practice land use company reduces impact organic solvent used manufacture environment selecting area premise membrane filter cartridge recovered already developed industrial zone none recycled goettingen facility account production site situated natural space solvent usage solvent reprocessing intact ecosystem possible maximize green plant site solvent recovered fed space minimize impermeable area facility back production operation without ever good example site bangalore leaving premise way maintain closed although generally estimate impact material cycle minimize transport requirement biodiversity negligible sartorius stedim biotech reduce quantity water used waste water strives meet special protection need produced conducting research biodiversity hotspot factory tunisia development also continuously reducing puerto rico located example site overall amount solvent required membrane puerto rico expanded serve manufacture use less polyethylene packaging central manufacturing logistics site sartorius stedim biotech switched delivery north american market meet highest u polypropylene sack silo manufacture standard green resourcesaving efficient injectionmolded component singleuse construction became first pharmaceutical product industry supplier worldwide achieve platinumlevel certification u green building council leed initiative management report sustainability report manufacturing plant mostly situated cleaning material process based single industrial area noise pollution resident use product around half conventional relevant issue company processes within new building extended although singleuse product clear ecological production facility integrate advanced ecological benefit usage generates waste yet utility technology lowering energy consistent reuse recycling improve consumption preventing waste limiting noise environmental performance well ultrapure pollution employee reducing scrap plastic utilize manufacture various single result manufacturing process use product contain around often exceed requirement imposed u local energy pure crude oil thus valuable environmental protection regulation secondary raw material high energy content polymer example mean recycled fuel heat power generation sustainable product innovation integrated solution sartorius stedim effort optimize environmental biotech flexact product range example performance product production method approach beyond ecological benefit begin research development stage generally offered singleuse technology flexact wherever safety functionality permit increase solution reduce need stationary installation proportion renewable raw material reduce equipment thus quantity material land packaging sartorius stedim biotech also work required versatile central control unit flexact partner industry scientific community instance used number different sustainable product solution efficient use biopharmaceutical process raw material instance explore possibility obtaining polymer membrane capsule technical refinement membrane filter series renewable raw material recycled substance enabled sartorius stedim biotech slash consumption determine greenhouse gas emission released ultrapure water wetting rinsing manufacture filter cartridge membrane around filter significantly lower adsorption lessens amount highvalue protein solution lost result pharmaceutical highperformance product improve manufacturer substantially reduce resource customer environmental footprint recovering higher yield singleuse product becoming increasingly service unit assist customer adapting widespread manufacture innovative effective solution optimally requirement site medication practical always analyze customer process whole economic aspect also provide ecological benefit identify potential financial ecological compared conventional steel glass equipment improvement way contribute increasing singleuse product eliminate resourceintensive efficiency environmental compatibility cleaning process ultrapure water well customer process subsequent wastewater processing study shown singleuse product far superior sinclair lindsay l et al environmental impact complex reusable system consumption disposable technology biopharm int november wwwbiopharmservicescomdocsenvironmentimpactdisposables energy water chemical product lifecycle pdf rawlings b pora h environmental impact singleuse expert compared approach based primarily reusable bioprocess system bioprocess int february reusable material based predominantly singleuse material across various scenario included typical industrial manufacturing process monoclonal antibody result clearcut manufacturer employing mostly singleuse solution use around less water less energy addition expert found deployment singleuse solution reduces size production unit manufacturer said require less space thus also saving energy material research confirmed energy needed sterilization management report sustainability report contributing society sustainable development longterm cooperation reliable partnership key tenet policy business activity many positive effect local organization maintain constructive open progress city community dialogue various local stakeholder informing sartorius stedim biotech based many year promptly comprehensively instance often one largest activity development could affect local private employer contractor example project funded reporting main manufacturing site thus supporting local year highlighted employment actively promoting regional development together cooperation partner yauco cooperate several public school company help shape economic social annually award around scholarship environment providing financial support outstanding student student lowincome project education culture social affair sport family sartorius stedim biotech also shared contribute toward making region cost equipping community sport group operate attractive current future supporting needy family thanksgiving sartorius stedim biotech employee alike donating american cancer society charity walk support cancer research bohemia new york social outreach activity targeting area beyond sartorius stedim biotech participated local home region concentrate field related adoptaschool program reporting year core business fostering research education program aim create school community supporting event scientific community remain partnership positively impact student chief priority achievement group level sartorius stedim biotech donated supporting regional employment development nonprofit organization afm téléthon focus innovative genetic therapy relatively large production facility sartorius stem cell cure wiskottaldrich syndrome stedim biotech aubagne yauco goettingen chronic immunodeficiency debilitating disease among key industrial employer respective affecting blood muscle eye instance region instance headquarters aubagne city inhabitant provide attractive longterm job people supporting student graduate increase around compared member large french employer organization sartorius stedim biotech ensures gain young medef sartorius stedim biotech collaborates closely talent dedicated program alliance national local institute help improve international scholarship program provides financial job market situation another job technical personal support student industrial sector provided production site graduate scientific technical discipline singleuse bag mhamdia tunisia program intended attract appropriately qualified expanded yauco plant provides employment young people particularly global growth around people directly sartorius stedim market company enhance international biotech around additional people project activity sartorius stedim biotech local service provider supplier maintenance machine building plant group headquarters aubagne collaborate security local workforce nearly people several school university included sartorius stedim biotech among large private école dingénieurs marseille enable recently employer university town goettingen qualified biotechnology engineer gain professional also major force local economy rural experience application engineer marketing region surrounding nearby guxhagen partnership french higher national school biomolecular engineering école nationale supérieure local subsidiary involved alongside de technologie de biomolécules help finance representative political industrial social scholarship awarded student choice community initiative strengthen also successfully collaborate école competitiveness respective region nationale supérieure de art métiers whose focus area directly indirectly related student given opportunity attend company business activity infrastructure logistics workshop california usa sartorius stedim environmental protection education promoting biotech participates many year actively management report sustainability report program nonprofit organization biotech partner helping young people lowincome family gain access scientific technical career sponsoring event scientific community addition maintaining longterm alliance scientific institution sartorius stedim biotech regularly contributes symposium convention annual conference bioprocess industry cover subject development antibody vaccine singleuse system microbiological analysis supported example annual aseptic processing conference usbased international society pharmaceutical engineering ispe annual meeting parenteral drug association pda well various regional ispe pda convention annual meeting nonprofit society industrial microbiology covered topic fermentation cell culture environmental microbiology among others sustainable purchasing policy sartorius stedim biotech requires business partner particularly supplier conduct business activity compliance prevailing law line corporate social responsibility ethical responsibility sustainable way company code conduct defines set value principle regarding human right anticorruption protection environment supplier confirm signature code conduct acknowledge agree uphold standard sartorius stedim biotech globally standardized procurement channel contract awarded fair transparent process meet generally recognized standard according general manufacturing policy sartorius stedim biotech high inhouse manu facturing rate case nearly filter membrane regarding trading good sartorius stedim biotech spent million reporting year mainly supply company based europe u equates rate sale revenue management report table concordance table concordance grenelle ii french decree april page sustainable corporate management sustainability policy scope reporting methodological note attestation regard exhaustiveness fairness information social information employment total workforce breakdown region function gender age new hire redundancy compensation benefit expense work organization organization working time absenteeism social relation organization social dialogue outcome collective agreement health safety health safety condition work signed agreement regarding occupational health safety work accident training people development policy implemented regarding people development training hour cost equal treatment gender equality employment people disability policy discrimination promotion compliance provision ilo convention compliance freedom association right collective bargaining elimination discrimination respect employment occupation elimination forced compulsory labour abolition child labour environmental information general environmental policy environmentrelated assessment certificate training employee ehs issue provision environmental risk pollution waste management emission air waste prevention recycling reduction measure noise pollution sustainable use ressources water consumption raw material measure undertaken improve efficiency usage total energy consumption breakdown electricity natural gas fuel land use climate change greenhouse gas emission biodiversity protection impact biodiversity societal information territorial economic social impact company activity impact employment regional development impact neighbouring community relation maintained stakeholder condition dialogue stakeholder philantrophic sponsorship action subcontractor supplier integration social environmental stake purchasing policy importance subcontracting integration csr relationship supplier subcontractor fair operating practice action implemented prevent corruption measure implemented promote health safety consumer action favour human right management report statutory auditor report sustainability report statutory auditor report sustainability report report one statutory auditor appointed responsibility statutory auditor independent thirdparty consolidated environmental social societal information based work responsibility published management report attest required csr information pre sented management report event year ended december st omission explained pursuant third paragraph article r french commercial code free translation english original attestation completeness csr information report issued french provided solely convenience english speaking reader report express limited assurance fact taken read conjunction construed whole csr information presented fairly accordance french law professional auditing material aspect accordance adopted standard applicable france reporting guideline formed opinion fair presentation csr information shareholder work carried team people capacity statutory auditor sartorius tween december february assist u stedim biotech sa appointed independent conducting work referred corporate thirdparty certification request responsibility expert approved french national accreditation body cofrac number hereby conducted following procedure accordance present report social environ professional auditing standard applicable france mental societal information prepared year order may determining meth ended december st presented manage odology according independent third party ment report hereinafter csr information entity conduct assignment concerning pursuant article l french com formed opinion fair presentation csr infor mercial code code de commerce mation international standard isae responsibility company attestation completeness csr information board director sartorius stedim biotech responsible preparing management report includ based interview management familiarized ing csr information accordance provision group sustainable development article r french commercial strategy regard social environmental code prepared accordance reporting pro impact company business societal tocols guideline used sartorius stedim biotech commitment appropriate resulting hereafter reporting guideline action program available consultation headquarters company summary presented compared csr information presented management report management report list set forth article r french commercial code independence quality control event omission certain consolidated independence defined regulatory text formation verified explanation provid profession code ethic well provision ed accordance third paragraph set forth article l french commercial article r french commercial code code furthermore set quality control system includes documented policy verified csr information covered con procedure designed ensure compliance rule solidated scope ie company subsidiary ethic professional auditing standard within meaning article l french applicable legal text regulation commercial code company control within meaning article l french commercial code subject limitation presented methodological memo management report management report statutory auditor report sustainability report based procedure considering limita regarding consolidated csr information tions mentioned attest required csr assessed consistency relation information presented management report standing group formed opinion fair presentation lastly assessed relevance explanation csr information relating necessary total partial omis sion certain information nature scope procedure believe sampling method size conducted around twenty interview peo sample used exercising professional ple responsible preparing csr information judgment enable u express limited assurance department charge data collection process higher level assurance would required appropriate responsible internal indepth verification due use sampling control risk management procedure order technique limit inherent opera tions information internal control system assess suitability reporting guideline risk material anomaly identified respect relevance completeness reliability csr information cannot totally eliminated neutrality understandability taking considera tion relevant sector best practice conclusion verify datacollection compilation processing based work subject control procedure implemented ensure mentioned qualification identify completeness consistency csr information terial anomaly likely call question fact review internal control risk management csr information taken whole presented procedure used prepare csr information fairly accordance reporting guideline determined nature scope test scope available wwwcofracfr control according nature significance isae assurance engagement audit review historical financial information csr information regard company social indicator total number employee characteristic social environmental challeng december employee age employee gender e activity sustainable development strate new hire redundancy personnel expense euro gy sector best practice absenteeism rate number workrelated accident including commuting accident number calendar day lost due work accident frequency rate severity rate concerning csr information number training hour considered important environmental indicator total hour training ehs consolidating entity consulted docu issue total amount waste ton water consumption mentary source conducted interview cor quantity chemical solvent purchased quantity roborate qualitative information organization polymer purchased energy consumption mwh electricity natural gas fuel total greenhouse gas emission coeq policy action performed analytical proce scope scope qualitative information dures quantitative information verified sustainable corporate management paragraph using sampling technique calculation remuneration encouraging social dialogue employee data consolidation verified consistency survey result employee health safety sustainable information presented man corporate management contributing toward regional employment development supporting student agement report graduate contributing toward regional employment development sustainable corporate management representative sample entity sartorius stedim system gmbh sartorius stedim biotech gmbh selected according activity contribu et sartorius stedim filter inc tion consolidated indicator location risk analysis held interview verify marseille february th correct application procedure performed substantive test using sampling technique consist french original signed one statutory auditor ing verifying calculation made reconcil ing data supporting evidence selected deloitte associes sample represented headcount christophe perrau julien rival environmental quanti associé associé tative information sustainability service management report opportunity risk report opportunity risk report every business activity entail opportunity risk throughout group opportunity short managed skill term nature considered annual budget done go long way determining future planning medium longerterm opportunity development company shareholder value tracked systematically part strategic planning managing risk opportunity sartorius stedim status opportunity management permanent biotech aim identify use business fixture corporate management system mean opportunity systematically well recognize also feature discussion decision evaluate risk early stage take measure making process toplevel management counter possible unrealistic expect risk management eliminate risk rather key area opportunity presented approach intentionally take certain risk presented section specific risk measure risk business activity order represent opportunity event develop successful unlocking opportunity however opposite positive direction reason discus endeavor important keep risk contained opportunity section specific risk within acceptable limit control carefully opportunity end chapter sartorius stedim biotech single unit tasked identifying managing opportunity risk area opportunity instead prefers make function integral component groupwide planning control supplier pharmaceutical laboratory system described internal control system industry sartorius stedim biotech operates compliance department responsible futureoriented highgrowth sector development group risk management system including organization respective assessment rank company one reporting process global market leader many product area believe high quality product strong brand recognition established customer managing opportunity relationship give u strong opportunity continue extending market leadership opportunity management center analysis target market sector environment well strict management process cost provides assessment trend give strong opportunity increase profitability key indication future business opportunity target area respect include continued identification potential development enhancement procurement chain ongoing context one key role relevant effort optimize production manager initially take place local rather central level marketfacing function opportunity discussed context strategic marketing product management presentation specific risk opportunity individual division play leading role beginning page respect central business development unit additionally support area market monitoring data analysis implementation strategic project part strategy review member group executive committee regularly meet manager operational responsibility business development unit discus short medium longterm opportunity potential various business area subsequent step prioritizing opportunity evaluating business management perspective deriving strategic measure allocating resource proceed accordance standardized decisionmaking process applies management report opportunity risk report risk management urgent reporting procedure place ensure new emerging significant risk opportunity management overall net worth financial position profitability responsibility maintenance effective risk identified audit committee receives management system ensuring comprehensive necessary detail without undue delay consistent management material risk rest audit committee coordinating developing system responsibility central internal risk classification control system compliance department audit committee monitor effectiveness risk first level risk management relates four management system furthermore carrying main risk category defined sartorius stedim statutory audit mandate annual financial biotech external risk operating risk financial risk statement consolidated financial statement corporate governance risk independent auditor examine whether early warning system place capable prompt second level consists additional subcategories identification risk could put future within main category legal risk company jeopardy production risk receivables risk organizational risk risk management system risk reporting process also includes allocation functional category example supply chain sale heart risk management system distribution human resource accordance sartorius stedim biotech risk management handbook group structural organization applies throughout entire group organization handbook includes categorize risk according scale definition framework structural implication also perform specific organization process risk reporting monitoring evaluation risk assigned value control effectiveness risk maximum impact time risk analysis management system based internationally word record maximum risk without recognized coso standard also number considering probability occurrence source contain stipulation effect risk mitigation measure handling risk including article association rule procedure group company internal guideline specific risk opportunity groupwide risk reporting system form cornerstone internal risk communication object general macroeconomic risk make possible address risk structured opportunity continuous manner document accordance relevant statutory regulatory nature various business area mean requirement sartorius stedim biotech whole insulated certain extent full force wider cyclical prescribed reporting process requires head effect macroeconomic effect little bearing central department managing director progress business group company review risk situation within area responsibility ongoing basis ability foresee mitigate direct report finding every quarter new indirect effect risk broader sense organizational unit joining consolidated group example currency crisis natural disaster company successively integrated associated damage commercially significant reporting process involves evaluating specific critical infrastructure limited risk probability occurrence scale potential impact well reporting case risk discussed section consider central risk management unit whenever defined probability occurrence low medium threshold breached case occurrence significant sartorius stedim biotech group whole individual group company management report opportunity risk report supply chain risk opportunity production risk opportunity supply chain extends way manufacture large proportion procurement production sale distribution product belong core area technical problem within sequence consequential expertise involve high level vertical effect including delay delivery global supply integration product reusable fermenters chain management system instituted bioreactors manufactured collaboration throughout production process prevent supplier production risk problem largely minimizes associated risk transferred external third party analyzing controlling operation manufacture product also bear involved strongly international alignment associated risk capacity bottleneck overcapacity organization open whole series opportunity production downtime excessive reject rate high various risk opportunity encountered level tiedup working capital contain within supply chain explained detail reduce risk planning production capacity carefully using versatile machine semiautomated individual workstation flextime work schedule procurement risk opportunity continuously monitoring production process moreover global manufacturing network enables u purchase wide range raw material compensate capacity bottleneck shifting component part service supplier production regional plant consequently exposed risk unexpected delivery bottleneck price increase global regard probability occurrence concerning supply chain management system reduces risk risk described low risk happen enabling u monitor supervise procurement occur significant individual group activity moreover conduct regular supplier company review also use early warning system continued increase number framework consider opportunity various agreement concluded safeguard supply production facility able concentrate supplier strategically important raw material specific production technology result fiscal addition always maintain reserve enhance production operation greater inventory strategic raw material work efficiency international production network also alternative supplier possible make possible capitalize cost advantage offered individual site furthermore continuous present see low probability occurrence improvement production simplifying risk described risk happen occur process increasing level automation likely limited significance help drive efficiency even higher sartorius stedim biotech group opportunity arise area procurement sale distribution risk opportunity growth enables u increase order quantity thereby strengthen position use variety channel sell distribute supplier increased globalization supplier pool product around world potential risk entailed hold prospect purchasing favorable unexpected change demand structure term moreover also possibility growing price pressure noncompliance expanded purchasing activity international supply agreement concluded customer market leading u identify supplier special employ targeted market analysis identify emerging product technical expertise could eventually demand trend individual segment early enhance competitive edge time respond appropriately technical innovation focus less pricesensitive sale market product validated production process biopharmaceutical industry reduce exposure risk growing price pressure minimized risk exposure area logistics recent year setting using central warehouse optimize distribution logistics management report opportunity risk report area well probability risk quality requirement growing occurring low medium according estimate stringent time least result case occurrence regulatory pressure actually regard first significant sartorius stedim biotech group foremost risk opportunity whole individual group company open new market prospect also challenging quality demand represent considerable barrier opportunity arise area sale entry potential new competitor provide distribution increasing breadth stimulus technical innovation product range bioprocess lab segment actively respond put u position sell new product existing customer business relationship established long term global rd risk opportunity presence provide opportunity moreover ongoing project strengthen direct sale especially devote considerable share resource lab segment also promise enhance research development potential risk area sale prospect may arise development result diverge market need exceeding planned development deadline unintentional transfer knowhow quality risk opportunity competitor advanced project management intensive rd controlling early involvement customer use sartorius stedim biotech product customer development process substantially wide range critical production process limit rd risk patent continuous tracking including manufacture pharmaceutical food technology competitor relevant u chemical research development secure technology position laboratory main risk encountered area noncompliance agreed quality criterion reason see low probability lead loss customer may present risk described might occur made liable compensation claim case could significant employ rigorous quality check stateoftheart sartorius stedim biotech group whole production method process cleanroom technology ensure product satisfy hand rd sphere also offer number stringent quality requirement potential opportunity intensive collaboration manufacturing method process subject partner rank among global market constant review continuous improvement leader field open opportunity process moreover refined appropriately u jointly develop innovative product requirement evolve successful completion especially high level innovation area host annual audit customer membrane technology turn expertise accreditation iso iso together specialist put u forefront global document high level quality achieved sartorius research development present u stedim biotech product process irrespective opportunity turn technical knowledge measure also maintain significant insurance potential sale even stronger position coverage product liability risk sartorius market stedim biotech established traceability system enables u recall entire production batch immediately necessary minimize adverse consequence event defect discovered product consider probability occurrence risk described low case occurrence significant sartorius stedim biotech group whole individual group company management report opportunity risk report customer risk opportunity acquisition risk opportunity sartorius stedim biotech source key customer nature acquisition provide many opportunity pharmaceutical chemical food industry sale growth extension product public sector research educational portfolio development new market institution customer usually relatively contrast purchase sale company part large organization existence company entail number inherent risk time strong credit rating incorrect valuation assumption insufficient business area highly diversified customer base usage anticipated synergy effect prevent group whole dependent risk take various measure particular individual key account significant degree acquisition process performing standard due factoring program additionally diligence review addition involve external place keep risk exposure trade receivables consultant expert purchase sale customer constant low level work process early possible especially focus continuously improve receivables management drafting transaction contract adequately counter risk especially clause assuring present see low probability specific characteristic contractual warranty risk associated customer might occur guarantee provision well agreement case occurrence would likely mechanism adjustment purchase price limited significance sartorius stedim biotech liability clause immediately acquisition group whole individual group company taken place integration phase initiated potential risk likewise detected early possible prevented minimized taking competitive risk opportunity appropriate counteraction sartorius stedim biotech leading competitive consider probability occurrence position market risk described low case competitor larger u share occurrence significant sartorius stedim status globally operating company example biotech group whole individual group include emd millipore pall serve large company number customer highly regulated sector like pharmaceutical food industry technology barrier market entry substantially personnel risk opportunity high regard risk new competitor emerging low furthermore global presence significantly sartorius stedim biotech employ large number mitigates regional risk highly qualified people possible scarcity required specialist represents opportunity well risk change competitive environment example instance company prof particularly consolidation market pose good training retaining staff opportunity risk sector find counter threat demographic change ongoing process change sartorius losing employee especially key position stedim biotech remains active participant offering performancerelated remuneration model made acquisition continuously recent year targeted continuing professional development option reinforce market position open new attractive social benefit continuous potential synergy education training junior staff member within organization interesting people development consider probability occurrence opportunity success measure risk described low case apparent low attrition rate recent year occurrence likely limited significance many year seniority people accumulate sartorius stedim biotech group however cannot average employment contract certain case entirely ruled risk might significant contain clause prohibiting move direct individual group company competitor management report opportunity risk report reason regard probability risk exchange rate risk opportunity occuring low risk happen occur likely limited importance sartorius generate around half consolidated sale stedim biotech group whole revenue foreign currency twothirds total revenue u dollar currency pegged u dollar positively negatively financial risk opportunity impacted currency effect especially converting currency balance sheet item global nature sartorius stedim biotech profit loss item respectively largely group operation mean business activity compensate general risk resulting inevitably exposed financial risk impact individual foreign currency taken significant aside risk associated number measure besides hedging currency group accounting exchange rate risk interest global production network thus enables u offset rate risk liquidity risk described lion share sale revenue received foreign addressed detail note currency within group cost likewise consolidated financial statement vice versa incurred foreign currency example financial risk notably exchange rate risk manufacture many product north interest rate risk balanced opportunity american market locally therefore approximately equal magnitude disadvantaged way competition u rival continuously monitor exchange rate consider probability occurrence net currency exposure ie proportion risk described following low risk foreign currency sale revenue remains happen occur significant settled cost use derivative sartorius stedim biotech group whole financial instrument notably spot forward individual group company swap transaction basis current anticipated net currency exposure foreign currency level make policy hedge risk associated group accounting exposure advance following month hedging transaction set one group except general typical risk inherent staff monitored another separate group accounting process specific risk concerning group accounting discernible typical accounting error connection example incorrect interest rate risk opportunity discretionary decision measurement asset liability use various common concluded fixed interest agreement standardized control mechanism integrated portion outstanding loan eliminate risk accounting process ensures error posed variable interest payment however recognized corrected early stage financial instrument outstanding reporting date subject interest based market rate almost twothirds currently covered interest rate swap interest rate risk opportunity apply remainder monitor interest rate trend interest rate exposure constantly facility arrange additional hedging transaction consider necessary economically advisable individual loan management report opportunity risk report liquidity risk opportunity observed technical possibility limiting environmental risk identified sartorius stedim biotech group actively manages ongoing basis liquidity centrally order check minimize liquidity risk optimize liquidity management assess probability occurrence within organization environmental risk low case occurrence significant group company use various long shortterm financial affected instrument purpose syndicated credit facility place far risk opportunity group refinanced ahead schedule december based highly attractive market condition besides risk already described sartorius prevailing time financing structure stedim biotech group exposed potential risk converted holding company area result pronounced dependence groupwide financing subsidiary financed system since errorfree operation primarily financing contract within group essential smooth functioning company business process reduce security risk shortterm liquidity procurement also employ continuously enhancing implementing security various measure addition credit line guideline policy rule measure accessed repaid short notice based requirement iso number bilateral credit line place smaller standard german federal office scale individual group company furthermore information security bsi standard furthermore use cash pooling agreement selected group company existing application system company primary tool manage liquidity checked potential risk regular external within group internal audit appropriate measure taken minimize risk identified continuous alignment strategy business strategy tracking regulatory risk new technical development use advanced hardware software minimize risk inherent role supplier biopharmaceutical operation system environment new erp industry health care provider mean system commissioned sartorius stedim biotech sartorius stedim biotech also affected goettingen group headquarters underlying development area possibility successively rolled group site around regulatory authority fda emea adopting world starting conducting project restrictive approach approval new continued focus controlling risk medication remains principal source risk involved maintaining precautionary context move would reduce number backup system implementation new system new pharmaceutical product marketed brings whole series opportunity especially would consequently downgrade future prospect relation efficiency gain standardization sartorius stedim biotech medium term harmonization business process worldwide believe low probability occurrence risk mentioned case environmental risk occurrence significant sartorius stedim biotech group whole sartorius stedim biotech established environmental management system encompasses integrated division cover whole series environmentally relevant regulation minimize environmental risk management system certified compliance iso company relatively large manufacturing site respective company organizational unit ensure particular site law regulation relating environmental protection management report opportunity risk report process risk legal dispute proceeding could substantial negative impact group result allowance made balance sheet cover cost potential proceeding insurance taken insurance policy cover wide range risk possible economically advisable insurance policy include coverage liability business interruption transport material pecuniary damage risk provide comprehensive coverage legal cost independent department working conjunction external insurance broker regularly review nature extent insurance protection make adjustment necessary assessment overall risk situation risk outlook expedient feasible adopted countermeasure arranged balance sheet measure reporting year cover discernible risk within sartorius stedim biotech group potential damage net worth financial situation profitability judge probability occurrence risk presented low case occurrence significant sartorius stedim biotech group whole individual group company thorough analysis entire risk situation according current review discernible risk present could jeopardize continued existence group similarly based current review discernible risk could jeopardize future existence group management report forecast report forecast report strong growth prospect moderate growth europe japan pharmaceutical industry growth european japanese pharmaceutical future global pharmaceutical industry market likely remain moderate driven large part constantly expanding next year continuing aging global population increasing access austerity measure impact respective healthcare healthcare emerging developing country system general increase prevalence lifestyle chronic disease new medication especially targeting condition currently difficult treat emerging country still driving growth also fuel significant growth expiry patent austerity measure cut healthcare spending expansion pharmerging market contrast particular industrialized country remain average around per hand tend slow future growth industry annum period rapid growth driven demographic trend market researcher ims health forecasting also notably rising level state investment overall growth global healthcare system increased private spending pharmaceutical industry period especially among fastexpanding middle class thus share global pharmaceutical market accounted pharmerging market u pharmaceutical market expected likely increase next five year post solid growth approximately u pharmaceutical market world largest expected register growth average period expansion driven principally continuous rollout state health insurance demographic change price increase management report forecast report pronounced longterm trend drive average growth biopharmaceutical industry global trend pharma market sector trend q aging population q average growth q patent expiry western country q increasing cost pressure eg q increasing population due healthcare reform improved access health care biopharma market developing economy q growing number chronic q average growth trend toward biotech civilization disease q continued market penetration approved indication technology trend singleuse technology q label expansion q higher yield efﬁciencies q doubledigit growth q personalized medicine cell cultivation q highest growth innovative q biosimilars q availability innovative segment eg bioreactors singleuse technology ﬂuid management q strong pipeline eg mabs q higher ﬂexibility change manufacturing system multipurpose source ims global use medicine outlook evaluate pharma world preview june bioplan th annual report april biotech sector still growing faster market whole expert forecast suggest biopharma segment expiry patent significant factor pharmaceutical market enjoying traditional market likely increasing particularly strong growth year continue effect growth biotechnology market noting outperform market whole going forward expiry whole series patent ims health proportion sale revenue accounted report sale come known medication vaccine manufactured using biotech biosimilars biobetters likely swell method expected rise today figure u billion around approximately period expert expect biotechnology market whole grow around average continued exceptional growth driven part biopharmaceuticals already gained approval increasing market penetration expanding range indication part segment persistently strong research development pipeline proportion new development based biological manufacturing process particularly high around management report forecast report biopharma growing market percentage worldwide rx otc pharmaceutical sale biotech v conventional technology biotech share within top product bn bn bn biotechnology conventional unclassified split biotech n avg bn conv n avg bn source evaluate pharma world preview outlook june publicsector research demand stabilizes future business development ongoing widespread reduction national budget outlook fiscal incorporates risk likely affect overall level demand opportunity outlined report supply public sector however according biopharmaceutical industry business development frost sullivan important u market likely generally driven stable longterm trend stabilize current year thus global demand therefore economic fluctuation play less role public sector may broadly flat example decision regulatory agency regarding drug approval use medication source ims global use medicine outlook ims searching terra firma biosimilars assuming trend toward biomanufacturing nonoriginal biologics market evaluate pharma preview pharmaceutical increasing utilization single june bioplan th annual report use technology continue expect sale april midyear report forecast analysis revenue grow considerably thus global market laboratory product forecast sale revenue rise constant currency compared strong prior year base management expects underlying ebitda margin rise without currency effect considered please refer definition underlying ebitda margin page glossary moreover plan invest sale revenue mainly expansion production capacity regard financial position forecast end ratio net debt underlying ebitda edge without taking potential portfolio change account management report financial statement parent company sartorius stedim biotech sa december financial statement parent company sartorius stedim biotech sa december financial statement parent company annual shareholder meeting acknowledges informed new tax regulation sartorius stedim biotech sa parent company dividend according finance law group reminder since january abolished right choose withholding tax company transformed mixt holding submitting dividend company company managing distribution progressive scale tax income investment group real estate application allowance french company retained without modification accordance article french general code sale revenue generated sartorius stedim biotech sa k relative k dividend paid april operating profit k versus k net financing income totalled k versus amount distributed january k eligible tax rebate follows net profit k compared income eligible tax rebate k income fiscal year ended dividend distributed dec appropriation net profit dec dec annual shareholder meeting asm suggest appropriate net profit reporting year director receive sartorius stedim biotech sa share capital director meeting attendance fee whose amount allocation established board director consideration limit set asm follows share capital december legal reserve total capital amount fifteen million three hundred fiftynine thousand two hundred thirtyeight balance resulting deduction legal reserve euro divided share worth one euro fully subscribed paid heading article bylaw following amount added balance yearearlier profit carried forward evolution share capital would yield distributable profit sartorius stedim biotech sa beginning fiscal year share total amount dividend disbursed capital company ten million three shareholder hundred ninety five thousand eight hundred six euro sixty six cent balance resulting disbursement year share capital company rose ten million three hundred ninety five remaining amount thousand eight hundred six euro sixty six carried next year cent ten million four hundred five thousand three hundred forty eight euro therefore considering company hold twenty eight cent treasury share net dividend paid stock option exercised reduced ii nine million every share par value three hundred sixtynine thousand one hundred thirtyfive euro eighteen cent management report financial statement parent company sartorius stedim biotech sa december rose iii fifteen million three hundred share purchased share buyback fiftynine thousand two hundred thirtyeight euro program allocated following following condition objective reduction share capital share representing approximately five per cent company share capital ex must kept mind extraordinary change payment within scope potential ex shareholder meeting held april ternal project term seventh resolution authorized share representing approximately five per board director trade share cent company share capital de share buyback program specified livered case exercise right attached maximum number share purchased security giving access mean immediate company authorisation could exceed ly future date share capital ten per cent total number share company comprising share capital maximum purchase price fortyfive euro per share board director report submitted ii share thus purchased allocated extraordinary shareholder meeting april following objective proposed said meeting reallocate share purchased share buyback program handle secondary market liquidity objective cancellation part share share company share capital reduction accordance deliver share case exercise right authorisation granted extraordinary attached security giving access company shareholder meeting april share capital allocate repurchased share bought extraordinary shareholder meeting held april company officer employee company authorized board director proceed andor company group within scope cancellation one several installment stock option plan free granting decision alone portion share acquired share company saving plan etc company context share repurchase retain company share programme limit ten per cent purchased order return exchange pay company share capital period twentyfour ment within scope potential external project month provided ten percent limit cancel repurchased share applied company share capital share capital reduction company necessary adjusted take account transaction pursue objective subsequently affecting share capital company occur permitted applicable law regulation subsequent shareholder meeting meeting held april board extraordinary shareholder meeting held director unanimously decided implement april authorized board director share buyback program pursuant condition set reduce company share capital accordingly forth extraordinary shareholder meeting held april extraordinary shareholder meeting held april granted board director course fiscal year company authorization period twentysix month acquired one million six thousand ninetyeight date extraordinary shareholder seven hundred ten share meeting held april representing approximately exceeding ten per cent share capital pursuant share buyback program authorized extraordinary shareholder meeting held april share acquired aggregate amount sixtyone million three hundred twentyseven thousand one hundred ninety euro seven cent corresponding average price thirtysix euro ten cent per share management report financial statement parent company sartorius stedim biotech sa december meeting july board operation done increase director light authorisation granted nominal unit value seventeen million fortytwo extraordinary shareholder meeting hold thousand three hundred six existing april reduced share capital nominal share sixtyone cent one euro amount one million thirtysix thousand two hundred thirteen euro ten cent said extraordinary shareholder meeting cancelling entirety authorized board director implement share acquired share buyback program decision increase share capital authorised extraordinary shareholder meeting consequently determine definitive nominal held april ie one million six hundred amount share capital increase based ninetyeight seven hundred ten share number share existing date specified amount share decision board director complete represents less ten per cent share share capital increase capital company date operation difference purchase price authorisation granted period five cancelled share nominal year date extraordinary value difference equal sixty shareholder meeting held april million two hundred ninety thousand nine hundred seventysix euro ninetyseven cent july board director using charged delegation power granted available premium thirtyseven million eight extraordinary shareholder meeting april hundred eightyeight thousand nine hundred twenty decides carry share capital increase nine euro eighteen cent capitalization five million nine hundred ninety balance twentytwo million four hundred two thousand one hundred two euro eightytwo thousand fortyseven euro seventynine cent cent drawn issue item retained earnings premium set forth annual account company financial period closed operation reduction share capital december approved extraordinary le share capital amounted nine million three shareholder meeting held april hundred sixtynine thousand one hundred thirtyfive euro eighteen cent divided share capital increase carried fifteen million three hundred fiftynine thousand increase thirtynine cent nominal two hundred thirtyeight share amount fifteen million three hundred fiftynine nominal unit value sixtyone cent thousand two hundred thirtyeight share comprising share capital company increase share capital nominal unit value went sixtyone cent one euro extraordinary shareholder meeting held april decided increase share capital sum cost relating share capital maximum nominal amount six million six hundred increase charged one several fortysix thousand four hundred ninetynine available reserve deduct amount euro thirtyfour cent calculated sum necessary increase legal reserve basis number share existing date aforementioned shareholder meeting end definite completion reduction carried proportional increase company share capital done capitalisation available sum drawn issue july company share capital premium amount fifteen million three hundred fifty nine thousand two hundred thirtyeight euro divided fifteen million three hundred fiftynine thousand two hundred thirty eight share nominal unit value one euro management report financial statement parent company sartorius stedim biotech sa december number share share capital share par share capital share number new date nature transaction value increase premium share transaction transaction exercise share st half subscription option exercise share nd half subscription option exercise share nd half subscription option exercise share ndhalf subscription option exercise share st half subscription option exercise share st half subscription option exercise share year subscription option exercise share year subscription option reduction capital cancellation treasury year share increase capital year nominal value change sartorius stedim biotech sa shareholding december situation sartorius stedim biotech sa shareholding shareholder share voting right sartorius ag sartorius ag less none none less none none management report financial statement parent company sartorius stedim biotech sa december past three year ownership sartorius stedim biotech share capital distributed follows december december december number share voting number share voting number share voting shareholder share capital right share capital right share capital right sartorius ag single voting right double voting right vl finance single voting right double voting right total sartorius group treasury share personnel shareholder general public single voting right double voting right total share belonging sartorius ag reverse merger sartorius stedim legal disclosure threshold crossed company vl finance said individually passed december following sale letter received august amf autorité sartorius stedim biotech share share de marché financier intended person buyback program share threshold following threshold occurred regularization voting right issued capital sartorius stedim biotech held individually simplified joint stock company vl finance date share sartorius stedim zone industrielle le paluds avenue de jouques biotech representing voting right aubagne said individually passed issued capital voting december following sale market right company share sartorius stedim biotech threshold voting right company sartorius ag said individually issued capital sartorius stedim biotech passed december following held individually date share allocation double voting right threshold sartorius stedim biotech representing voting right company sartorius voting right capital stedim biotech held individually date voting right company share sartorius stedim biotech representing voting right german company sartorius ag weender issued capital voting right landstrasse goettingen germany company said individually passed december following decrease total number company vl finance said individually company sartorius stedim biotech voting right passed december following threshold voting right increase total number voting right sartorius stedim biotech individually held company sartorius stedim biotech threshold date share sartorius stedim voting right company biotech representing many voting right ie sartorius stedim biotech held individually issued capital date share sartorius stedim voting right company biotech representing voting right management report financial statement parent company sartorius stedim biotech sa december issued capital voting voting right ie issued capital right company voting right company letter received july completed occasion company sartorius ag particular letter received august passed directly indirectly company vl company vl finance individually passed finance control threshold said july reduction issued held august share capital company sartorius stedim biotech sartorius stedim biotech representing threshold issued capital sartorius voting right ie issued capital stedim biotech held individually voting right company sartorius stedim biotech share representing follows share issued capital voting right voting right vl finance sartorius ag total sartorius ag letter following declaration intent hold agreement financial instrument made referred bi article l commercial code company vl finance say six month come provided article l entered temporary reverse commercial code vii agreement share voting right company sartorius stedim biotech threshold crossing passive nature without acquisition share result intend request appointment new cancellation treasury share held company member board director sartorius sartorius stedim biotech stedim biotech provided concert sartorius ag vl finance sa already represented consider additional acquisition board five total eight sartorius stedim biotech share director act agreement another shareholder controlled company sartorius ag controlled company sartorius ag towards sartorius stedim liability proceeding constituted mr c franken mr u baro mr k sartoriusherbst dealing property biotech company bequeathed mr horst sartorius administered independently executor mr arnold picot already control sartorius stedim based issued capital date share biotech company member concert representing voting right pursuant second sartorius ag vl finance sa holding date paragraph article general regulation based issued capital date share declaration issued capital representing voting right pursuant second voting right sartorius stedim paragraph article general regulation biotech based issued capital date share representing voting right pursuant second wish pursue strategy implemented paragraph article general regulation controlled company sartorius ag controlled company sartorius stedim biotech described liability proceeding constituted mr c franken mr u baro company reference document mr k sartoriusherbst dealing property company sartorius stedim biotech filed bequeathed mr horst sartorius administered amf february independently executor mr arnold picot see press publication company dated july basis issued capital composed consider transaction listed share representing voting right pursuant article general regulation second paragraph article general amf regulationcontrol company december management report financial statement parent company sartorius stedim biotech sa december control company december authority delegated annual shareholder meeting board director still valid sartorius ag hold directly indirectly share capital outstanding voting right multiple delegation granted board treasury share without voting right director combined shareholder meeting april staff shareholding able increase share capital company capitalizing everything portion exception stock subscription plan stock issue premium increasing nominal value option plan company run employee existing share currently amounting profitsharing scheme limit equal corresponding maximum nominal amount increase share capital delegation power granted treasury share held period year date shareholder sartorius stedim biotech sa meeting april july board director decided share capital following decision taken extraordinary increased capitalizing amount shareholder meeting april treasury deducted share premium account share held company cancelled contained year ended december see information page sartorius stedim biotech sa operation realized increasing nominal value share capital existing share amounting able reduce share capital unpaid capital cancellation share purchased share buyback program limit amount none adjusted capital account necessary transaction affecting share capital performed combined shareholder meeting april actual completion date capital reduction authorized unissued capital made board director authorization granted period month date none shareholder meeting april july board director decided share capital reduced nominal amount security representative share capital cancellation overall treasury share pursued share buyback none program amounting share representing less share capital time transaction difference value cancelled share nominal amount equal charged share premium account amounting retained earnings account amounting ability issue share andor security giving access share capital company andor security giving right allotment debt instrument preferential subscription right shareholder limit corresponding maximum nominal amount increase share capital maximal nominal amount debt instrument delegation authority granted period month date shareholder meeting april management report financial statement parent company sartorius stedim biotech sa december ability issue share andor security giving ability issue share andor security giving access share capital company andor access share capital company security giving right allotment debt consideration contribution kind consisting instrument without preferential subscription right company share andor security giving access shareholder public offering share capital maximum ten per cent limit deducted overall limit share capital outside public exchange offer increase share capital overall limit initiated company limit amount debt instrument delegation share capital deducted overall limit authority granted period month increase share capital date shareholder meeting overall limit debt instrument april delegation authority granted period month date shareholder meeting ability issue share andor security giving april access share capital company andor security giving right allotment debt ability issue share andor security giving access instrument without preferential subscription right share capital company consideration shareholder private placement security tendered public exchange offer set forth article l ii french monetary initiated company without preferential financial code limit deducted subscription right shareholder limit overall limit increase share deducted overall limit increase capital overall limit debt share capital overall limit instrument delegation authority granted debt instrument delegation authority period month date granted period month date shareholder meeting april shareholder meeting april ability event issuance share ability increase share capital andor security giving access share capital capitalization reserve earnings premium company public offering private sum upon capitalization would placement set forth article l ii permitted limit corresponding french monetary financial code without maximum nominal amount increase preferential subscription right shareholder share capital independent limit delegation set issuance price condition defined authority granted period month shareholder meeting maximum ten date shareholder meeting april per cent share capital per year limit amount share capital period month deducted overall limit security giving access increase share capital share capital overall limit debt instrument delegation authority granted period month date shareholder meeting stock option april ability increase number share andor share subscription plan security giving access share capital company issued event share capital stock option plan detailed table increase without preferential subscription authority delegated board director right shareholder limit amount setting new plan recently expired board initial issue share deducted overall director longer delegated limit increase share capital authority set new plan overall limit debt instrument delegation authority granted period month date shareholder meeting april management report financial statement parent company sartorius stedim biotech sa december number total number share number number date total option senior number sub subscribed option target number agm number granted executive initial scrip granted performance beneficiary authorized option senior bene bene tion jan based valid plan board meeting granted executive ficiaries ficiaries price dec exercisable option option june aug sept june june oct sept june june feb june july sept june june nov total agm annual general shareholder meeting change number stock option january december outstanding share january allocated period cancelled period exercised period lapsed period outstanding december share capital dilution option exercised fiscal year december total number share reported year option exercised capable issued basis performance ten significant accounted total based share subscription option potential option exercised share fully diluted share capital share subscription warrant share subscription option granted senior executive company option sartorius stedim biotech sa issued share exercised fiscal subscription warrant none pledging share share subscription option granted ten top sartorius stedim biotech sa share pledged nonsenior executive beneficiary option exercised fiscal year pledging asset none none management report financial statement parent company sartorius stedim biotech sa december dividend distribution policy company dividend distribution policy based net profit generated group level relevant fiscal year well group foreseeable growth profitability april annual shareholder meeting voted payment net dividend per share dividend available payment april dividend interim dividend unclaimed five year following payment date must paid state ie france article french civil code dividend per share fiscal year number share dividend corrected per share compared number share december senior executive membership committee director receives lumpsum amount per information sartorius stedim biotech sa senior full year membership addition executive list position hold attendance fee insofar hold held past five year included chair instead receive lumpsum corporate governance report amount per full year hold chairperson addition attendance fee remuneration activity committee director meeting attendance fee due together remuneration term previous subsection hereof director meeting attendance fee calculated annual basis method calculating fee valueadded tax reimbursed changed fiscal year corporation insofar member board entitled invoice corporation separately director receive director meeting attendance valueadded tax exercise right fee whose amount allocation established board director consideration limit resolution applied set asm director got executive top management activity group level context director receives fixed remuneration executive corporate officer receive per year paid annual remuneration membership financial statement adopted annual shareholder meeting fall due total paid director meeting payment annual shareholder meeting attendance fee chairman board receives twice amount furthermore member board receive attendance fee per meeting reimbursement expense addition annual remuneration management report financial statement parent company sartorius stedim biotech sa december compensation executive management team director meeting base fixed annual long term stock departure attendance salary incentive incentive option indemnity fee k k k k k k k total total joachim kreuzburg joachim kreuzburg volker niebel volker niebel oscarwerner reif oscarwerner reif reinhard vogt reinhard vogt detail please refer chapter corporate governance page independent auditor payment term trade payable independent auditor sartorius stedim december balance trade payable biotech sa totaled trade payable comprised following ernst young represented xavier senent alternate auditor auditex invoice paid day regarding invoice issue date deloitte associés represented christophe perrau alternate auditor beas invoice paid day regarding invoice issue date group decided settle recommendation green book european community date cumulative overdue trade approval financial statement payable amounted december annual shareholder meeting april propose nomination kpmg december balance trade payable replace ernst young audit totaled trade payable comprised following current regulated agreement invoice paid day regarding invoice issue date shareholder sartorius stedim biotech group requested approve agreement invoice paid day regarding covered article l french invoice issue date commercial code duly authorized board director form submitted date cumulative overdue trade payable amounted management report financial statement parent company sartorius stedim biotech sa december fiveyear financial result parent company sartorius stedim biotech sa k share capital end period share capital capital stock number share outstanding transaction financial performance sale revenue excl vat profit tax employee profit sharing plan amortization depreciation provision expense reversal income tax contribution employee profitsharing plan net profit dividend paid proposal dividend earnings per share eps tax employee profitsharing amortization depreciation provision expense eps tax employee profitsharing amortization depreciation provision expense dividend per share personnel workforce size personnel cost social security cost corporate governance corporate governance board director committee board director committee board director joachim kreuzburg board director composed eight member chairman chief executive officer two independent director appointed threeyear period date birth april nationality german organization work board composition must suited shareholding first appointment june structure size nature activity mandate renewed april sartorius stedim biotech sa particular appointed date annual general circumstance facing shareholder meeting approve financial statement fiscal year ending composition board director december december number sartorius stedim biotech share held historical reason due shareholding structure company composition current directorship position board director comittees reflected within group search reference shareholder long lasting chairman executive board vorstand balance director representing sartorius ag shareholder independant director vice chairman supervisory board executive sartorius stedim biotech gmbh managing director sartorius lab holding gmbh reference shareholder take responsibility member board director towards shareholder direct distinct sartorius stedim north america inc board director one take particular member board director care avoid possible conflict interest sartorius stedim filter inc transparency information provided member board director market fairly take interest account sartorius stedim japan kk member board director board director consider would sartorius stedim lab ltd desirable balance membership président vl finance sa committee stablished particular member board director representation woman men nationality sartorius japan kk diversity skill taking measure appropriate member board director guarantee shareholder market denver instrument beijing co ltd mission carried necessary member board director independence objectivity make public sartorius scientific instrument beijing co ltd reference document objective method member board director resuts politics subject sartorius hong kong ltd member board director sartorius north america inc président member executive committee sartorius stedim fmt sa past directorship held past five year within group vice chairman supervisory board sartorius weighing technology gmbh member board director sartorius stedim sus inc member board director sartorius biohit liquid handling oy corporate governance board director committee current directorship position volker niebel outside group member advisory board regionalbeirat executive member commerzbank ag germany executive vice president operation member advisory board beirat date birth august otto bock holding gmbh co kg germany nationality german member economic advisory board wirtschafts beirat norddeutsche landesbank germany first appointment june member supervisory board aufsichtsrat mandate renewed april carl zeiss ag germany appointed date annual general shareholder meeting approve past directorship held past five year financial statement fiscal year ending outside group december member advisory board beirat hameln group gmbh germany number sartorius stedim biotech share held educational professional background current directorship position diplommaschinenbauingenieur dr rer pol within group university degree mechanical engineering managing director geschäftsführer doctorate economics sartorius stedim biotech gmbh member board director research associate institute sartorius stedim north america inc solar energy research hamelin member board director germany sartorius north america inc research associate faculty member board economics management sartorius stedim filter inc university hanover germany member board director since sartorius ag goettingen germany sartorius stedim india pvt ltd may recent position member board director promotion executive board sartorius weighing india pvt ltd vice president finance member board director investor relation sartorius stedim lab ltd since member executive board member board director nov sartorius ag goettingen germany sartorius stedim aseptics sa may spokesman sprecher managing director nov executive board sartorius ag sartorius stedim bioprocess sarl goettingen germany managing director sartorius stedim biotech sarl since ceo executive board chairman managing director nov sartorius ag goettingen sartorius stedim integrated service sarl germany currently responsible managing director member operation corporate strategy executive committee sartorius stedim fmt sa legal affair compliance member board director corporate communication biohit biotech suzhou co ltd past directorship held past five year within group member board director sartorius stedim sus inc managing director sartorius stedim sus sarl managing director sartorius stedim dd sarl managing director sartorius stedim industry sarl member board director sartorius stedim system inc corporate governance board director committee educational professional background sartorius ag goettingen germany diplombetriebswirt university degree business recent position vice president administration economics rd technology sartorius stedim biotech gmbh recent position vice president schmidt clemens lindlar rd technology germany sale manager petro since managing director sartorius chemical industry usa stedim biotech gmbh goettingen gambro ab lund sweden germany skanska ab malmö sweden member executive management team poggenpohl reinhard vogt gmbh herford germany sartorius ag goettingen germany executive member recent position executive vice president marketing sale service senior vice president operation date birth august biotechnology division nationality german since managing director sartorius stedim biotech gmbh goettingen first appointment june germany mandate renewed april appointed date annual general shareholder meeting approve oscarwerner reif financial statement fiscal year ending december executive member executive vice president research development number sartorius stedim biotech share held date birth november nationality german current directorship position within group first appointment april member executive board sartorius ag appointed april managing director appointed date annual general sartorius stedim biotech gmbh shareholder meeting approve member board director financial statement fiscal year ending sartorius stedim north america inc december member board director sartorius north america inc number sartorius stedim biotech share held member board director sartorius stedim malaysia sdn bhd current directorship position within member board director group sartorius stedim australia pty ltd managing director sartorius stedim biotech gmbh member board director member board director sartorius stedim sartorius australia pty ltd switzerland ag member board director denver instrument beijing co ltd past directorship held past five year member board director none sartorius scientific instrument beijing co ltd member board director educational professional background sartorius shanghai trading co ltd diplomchemiker dr rer nat university degree member board director degree chemistry molecular biology doctorate sartorius stedim shanghai trading co ltd chemical engineering member board director sartorius hong kong ltd research associate institute member board director chemical engineering tap biosystems group ltd university hanover germany member board director sartorius stedim switzerland ag corporate governance board director committee member board director managing director l l conseil sarl sartorius japan kk management consulting service human resource member board director management sartorius stedim japan kk member board director educational professional background sartorius korea ltd phd organic chemistry mba past directorship held past five year master degree sanskrit within group member board director scientific employee charge sartorius stedim sus inc research french cnrs member board director national center scientific sartorius stedim india pvt ltd research later university member board director california berkeley california usa sartorius stedim biotech beijing co ltd psa automobile citroën managing director geschäftsführer head department charge sartorius weighing technology gmbh overall manufacturing planning managing director geschäftsführer programming sartorius lab holding gmbh renault automation robotics vice president strategic planning educational professional background ceo chairman board industriekaufmann vocational diploma industrial hightech startup company business administration specializing artificial intelligence cognitech sarstedt ag nuembrecht germany consultant human resource general manager sarstedt ab management company executive sweden especially multicultural sartorius ag goettingen germany environment recent position senior vice ceo stedim biosystems president sale marketing executive vice president biotechnology division sartorius stedim biotech since managing director sartorius since managing director l l conseil stedim biotech gmbh goettingen may sarl management consulting germany service management human since member executive board resource sartorius ag goettingen germany currently responsible marketing sale service bernard lemaître nonexecutive member liliane de lassus date birth december nationality french nonexecutive member date birth december first appointment june nationality french mandate renewed april appointed date annual general first appointment june shareholder meeting approve mandate renewed april financial statement fiscal year ending appointed date annual general december shareholder meeting approve financial statement fiscal year ending number sartorius stedim biotech share held december number sartorius stedim biotech share held current directorship position outside group current directorship position outside president financière de la seigneurie sa group member board director senova system inc corporate governance board director committee member board director educational professional background sycovest asset management paris bankkaufmann diplomkaufmann banker university member supervisory board degree business administration dr rer pol post azulis capital sa paris doctoral lecture qualification venia legendi betriebs member supervisory board wirtschaftslehre authorization teach business solon venture ltd london managerial economics university member supervisory board qualium investment sa paris research assistant assistant professor university munich past directorship held past five year university professor faculty outside group business administration university member supervisory board intrasense sa hanover germany director institute management educational professional background organization founder ceo chairman visiting scholar stanford university stedim sa california usa university professor faculty business administration technical arnold picot university munich director institute general industrial nonexecutive member business administration date birth december since university professor executive nationality german director institute information organization first appointment june management faculty economics mandate renewed april ludwig maximilian university appointed date annual general munich shareholder meeting approve konrad adenauer visiting professor financial statement fiscal year ending georgetown university washington december dc usa number sartorius stedim biotech share held henri riey current directorship position within group nonexecutive member chairman supervisory board independent member sartorius ag date birth november chairman supervisory board nationality monegasque sartorius stedim biotech gmbh first appointment june past directorship held past five year mandate renewed april within group appointed date annual general chairman supervisory board shareholder meeting approve sartorius weighing technology gmbh financial statement fiscal year ending december current directorship position outside group number sartorius stedim biotech share held member supervisory board takkt ag member supervisory board current directorship position outside wissenschaftliches institut für infrastruktur und group kommunikationsdienste gmbh und president aidea wikconsult gmbh president groupe hr sa director princess grace foundation monaco past directorship held past five year outside group past directorship held past five year none outside group none corporate governance board director committee educational professional background educationnal professional background diplôme institut supérieur de gestion france degree earned french higher institute graduated essec ecole supérieure de science business management institut supérieur de gestion economiques et commerciales fund manager paribas bank international distiller vinters fund manager responsible france product manager european equity fund management urgo laboratory adhesive team barclays bank france marketing manager head research barclays asset roc sa johnson johnson head management europe international marketing group executive vice president barclays sanofi pasteur msd france product asset management charge manager adult vaccine fund management business sanofi pasteur head range cfo hendyplan sa europe adult vaccine marketing director sanofi pasteur msd executive manager business management board director february sanofi pasteur msd vice president proposed annual shareholder meeting business management nominate independent member mr annemarie since managing director smag sàrl advice griffin mr susan dexter biotech medtech strategy professional background management annemarie graffin susan dexter nonexecutive member nonexecutive member independent director independant director date birth may date birth october nationality french nationality american number share sartorius stedim biotech held number sartorius stedim biotech share held mandate current function current directorship position member supervisory board valneva se biosense technology woburn massachusetts usa since march clinical diagnostic technology based cellular member supervisory board nanobiotix sa impedence since january managing director smag consulting sarl since september past directorship held past five year biosense technology woburn massachusetts usa active number mandate exercised achieved within kalon biotherapeutics college station last past five year texas usa retired cmo member board director themis bioscience gmbh july december member board director portugal sanofi degree certification pasteur msd march december member board director spain sanofi b immunology marketing double major pasteur msd march december honor american university washington dc usa member board director uk sanofi harvard university negotiation course lawyer pasteur msd march december harvard university cambridge massachusetts usa member board director ireland sanofi finance nonfinancial manager harvard pasteur msd march december university dow chemical company internal training program corporate governance board director committee work history shareholder meeting april nominate two new independent administrator order reach university massachusetts medical threshold school research mammalian cell culture animal toxicology study pursuant principle good corporate basic research governance independent member may collaborative research biotechnology principal shareholder employee former group sale emerging market employee supplier banker group major bioprocessing supplement raw customer may link likely material biomanufacuting impair judgment celltech biologics lonza biologics business developmentbioprocessing sartorius stedim biotech sa board director manufacturing biotechnology includes two independent director mr liliane de based biotherapeutics lassus mr henri riey collaborative bioalliance dow chemical company dow biotechnology contract criterion needed qualify independent manufacturing service vice president director following business develoment microbial fermentation service technology may employee senior executive implementation single use employee director parent company bioprocessing technology one consolidated company may xcellerex inc ge healthcare five previous year chief business officer cmo service may senior executive company using fully integrated singleuse company directly indirectly hold bioprocessing technology sale director position employee single use bioprocessing technology senior executive company either present latham biopharm group principal currently less five year consultant vp business development hold director position multiple cmos offering contract may significant client supplier business manufacturing service banker investment banker company biotechnology life science industry group company group strategic consulting singleuse represents significant part business disposable technology implementation may close family tie one project management highlevel senior executive business development marketing may auditor company advisor speak bioprocess five past year international may director company twelve year registered address balanced representation woman men regard social mandate member board director general manage term men woman representation ment domiciled company headquarters objective board reach maintains percentage least woman threeyear notice least woman sixyear notice independent director starting shareholder meeting board composed least ten member company controlled majority difference sixyear period shareholder portion independent administrator gender cant higher administrator board member least two december board director third board december composed woman respect board director sartorius stedim sa percentage mentioned order get composed independent member line proposed april shareholder independence criterion defined apefmedef meeting nominate two new woman administrator code order comply proposed order reach threshold corporate governance board director committee staggering mandate term company knowledge within last five year member board director according apef medef governance code listed company staggering term convicted fraud last five organized order avoid renewing group year subject official public mandate promote harmonious renewing investigation sanction statutory regulatory administrator mandate december authority afferent rule relating staggering term associated capacity manager respected given operation firm bankruptcy receivership liquidation closely related presence reference past five year shareholder purchasing company sartorius stedim disqualified court acting thereby nominated member capacity member administrative board time order get line management supervisory body issuer rule board director partially acting capacity management renewed seven member three executive conducting business issuer member past five year plurality mandate company knowledge family relationship accordance apef medef governance code exist among member company board listed company executive director cant director exercise two mandate director listed company outside group including foreign furthermore company knowledge company addition collect notice conflict interest duty member board accepting new director board director private interest mandate listed company duty director must inform board soon aware conflict interest moreover administrator cant exercise even possibility potential conflict must four mandate listed company outside refrain participation discussion group including foreign company relevant subject matter voting recommendation applied nomination associated resolution renewal administrator mandate company knowledge settlement information agreement reached shareholder client supplier others appoint member board board director met eight time director fiscal company knowledge service accordance bylaw sartorius stedim contract linking board member sartorius biotech sa company diretor owns personally stedim biotech group granting least one share company benefit director fulfill mentioned threshold knowledge company administrator regard number mandate listed linked sartorius stedim biotech service company contract conferring advantage executive director maximum two measure taken ensure control done mandate company belonging group abusive way following independent member board non executive director maximum four member board director mandated company belonging group independent member board member audit committee independent member board member remuneration committee corporate governance board director committee audit committee audit committee currently composed four member mr henri riey chairman committee since december mr arnold picot mr liliane de lassus mr bernard lemaître chairman audit committee mr de lassus independent chairman board director also ceo group permanent guest audit committee voting right audit committee met five time fiscal remuneration committee remuneration committee currently composed four member mr arnold picot chairman committee since june mr liliane de lassus mr henri riey mr bernard lemaître two four member remuneration committee independent remuneration committee met twice fiscal information organization function activity committee fiscal please refer chairman report pursuant article l french commercial code included publication following page corporate governance chairman report pursuant article l chairman report pursuant article l pursuant article l french corporate governance code commercial code chairman board director u report cover fiscal year since fiscal sartorius stedim biotech sa ended december present composition board director therefore decided adopt board director application afepmedef recommendation reference code principle balanced representation men corporate governance see wwwmedeffr woman condition preparation organization work board director afepmedef corporate governance code internal controlling control procedure code defines set regulation good implemented company within group responsible corporate governance follows comply explain principle implemented pursuant last paragraph article l country european union listed french commercial code company company comply recommendation independent auditor prepare report code must explain corporate concerning report chairman board governance report director internal control risk management procedure relative preparation processing accordance article corporate accounting financial information governance code listed company effect presented date code listed company referring code required precisely identify reference document application recommendation case nonapplication one provision company required provide comprehensible relevant circumstantial explanation according rule apply explain recommended amf recommendation n september company indicate specific table recommendation applied related explanation corporate governance chairman report pursuant article l specific table recommendation afep medef code governance listed company article provision code removed explanation disclosure option selected board director opted chairman function respect essential shareholder third meeting board committee chief executive party fully informed choice made officer order simplify company operational separation office chairman chief executive management increase effectiveness officer maintenance position single office organization take account presence controlling shareholder company share capital nonexecutive director meeting nonexecutives director meet without recommended nonexecutive director meet executive member tough open transparent periodically without executive inhouse director debate possible even presence executive internal rule operation board director must member provide meeting year time evaluation chairman chief executive officer deputy chief executive respective performance shall carried participant shall reflect future company executive management independent director within audit committee historical reason related company share option proportion independent director audit composition specialized committee reflecting committee excluding director representing employee research shareholder order reflect balance shareholder director representing employee director representing shareholder taken account least equal twothirds independent director committee include executive director composed independent director examination deadline account practical reason fact nonresident member audit committee board part committee audit committee verifies appointment extension term office account board director meeting member audit committee chairman proposed committee however access document appointmentsnominations committee specially information necessary function within reasonable reviewed board deadline allowing take notice verify satisfactory manner committee charge compensation independent director within compensation committee historical reason related company share option composition specialized committee reflecting research shareholder order reflect balance director representing shareholder independent director composed mainly independent director composed independent director chairman compensation committee sartorius stedim biotech group nonindependent also chairman compensation committee sartorius group ag management coherency reason director ethic attendance fee retained action director shareholder personally hold board director left freedom fairly significant number share received attendance director invest insignificantly company fee default hold share upon assuming executive member perceiving attendance fee function must use acquired attendance fee therefore stock option purchase obligation acquired responsibility board complete formulated otherwise list director basic obligation termination employment contract case appointment executive director termination employment contract case recommendation applied appointment executive director director employee appointed executive director volker niebel still employment contract sartorius recommended terminate employment contract stedim biotech gmbh put place started company company affiliated group work sartorius group according german law whether contractual termination resignation necessary change employment contract someone becomes managing director company work also considered sartorius stedim biotech group controlled german majority shareholder biggest group company german company therefore respect german rule regulation common whole group observed respective group level corporate governance chairman report pursuant article l article provision code removed explanation compensation executive director award applicable oscar werner reif volker niebel award option share executive director must joachim kreuzburg reinhard vogt representing conditional attainment performance target group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech performance action element detailed document reference within part company governance report internal control executive director may awarded stock option share joachim kreuzburg receive november performance share time departure subject performance criterion nevertheless accordance legal provision stock option give back share leaf performance share awarded employee sartorius ag november half share necessary provide another scheme involving leaf sartorius ag november share corporate performance incentive scheme profitsharing transferred incentive grow sartorius scheme mandatory scheme granting bonus group would participate increase share share etc price total amount stock option plan performance share must represent small fraction capital right balance must struck according benefit derived shareholder management level dilution must taken account furthermore necessary ensure awarded stock option performance share valued accordance ifrs standard represent disproportionate percentage aggregate compensation option share awarded executive director end board must systematically review award new stock option performance share view compensation item awarded executive director concerned board shall responsible determining percentage compensation accordance market standard exceeded said award award overly concentrated executive director according situation company size industry broad narrow scope award number officer etc board must define maximum percentage option performance share may awarded executive director compared aggregate award approved shareholder resolution authorizing award plan submitted vote meeting shareholder must mention maximum percentage form award subceiling executive director award made calendar period eg disclosure financial statement previous financial year probably year order limit windfall effect windfall effect associated bear market prohibited value awarded option performance share may markedly different company earlier practice unless material change scope business justifies revision scheme accordance term determined board announced upon award performance share awarded executive director conditional upon acquisition defined quantity share awarded share available price discount applied upon award stock option particular stock option awarded executive director executive director beneficiary stock option andor performance share must make formal commitment engage hedging transaction respect risk either option share resulting exercise option performance share end period determined board director holding share corporate governance chairman report pursuant article l article provision code removed explanation exercise exercise executive director option acquisition share must related serious demanding performance condition met period several consecutive year condition may internal andor external performance requirement ie related performance company benchmark sector etc possible relevant internal external performance requirement combined necessary determine period preceding disclosure annual interim financial statement exercise stock option possible board director supervisory board must determine period applicable determine procedure implemented executive director prior exercise stock option order ensure hold information likely prevent exercise termination payment severance payment joachim kreuzburg reinhard vogt acceptable executive director whose company oscarwerner reif capped maximum two failed personally failed may receive year remuneration reference made respect termination payment upon departure remuneration agreed service contract lined remuneration report approximately half remuneration fix remuneration half remuneration variable remuneration performance target variable remuneration taken account calculating severance payment case early termination service contract law give major role shareholder making predefined benefit paid termination office executive director subject procedure related party agreement imposes total transparency make termination payment conditional upon performance requirement performance requirement must assessed least two financial year performance requirement set board must demanding may allow indemnification executive director unless departure imposed regardless form departure linked change control strategy payment termination benefit executive director must excluded said executive director elect leave company order hold another position assigned another position within group able benefit near future pension right termination payment exceed applicable two year compensation fixed variable nocompetition clause additionally applied aggregate two benefit must exceed ceiling see hereafter artificial increase compensation period preceding departure prohibited group also communicates appendix applied recommendation order give overall idea practice concerning corporate governance corporate governance chairman report pursuant article l condition preparation organization board director shall examine corporate work board director consolidated account approve manage ment report section annual report dealing corporate governance setting internal rule regulation company policy respect remuneration stock option procedure governing organization functioning board director defined although modification social internal rule regulation board purpose board director must seize published website sartorius stedim shareholder meeting transaction concern biotech sa publication particular preponderant share asset activity report group internal rule modified board board director shall convene annual share director february order bring holder meeting propose change article line new provision afrp medef association governance code listed company mission mentioned summarize internal board director deal matter concerning bylaw board director proper operation company take decision subject concern activity report board director fiscal mission board director met eight time main mission board director fiscal year average attendance follows board reviewed approved corporate board director shall define company consolidated account strategic goal assess overall perspective least year proposed board director considered debated ceo ensure goal implemented following meeting shall also appoint corporate officer responsible managing company pursuit strategy strategic direction major group project review delegation authority annual halfyear quarterly financial statement board director shall review management budget presented executive management group monitor quality information information financial structure provided shareholder market cash flow item financial statement material event significant offbalance sheet commitment occur especially company shareholding risk indicator group internal organization project board director responsible approving stock market performance strategic investment project transaction selfassessment board member particular acquisition disposal likely element remuneration due attributed materially affect company result structure modification bylaw balance sheet risk profile operation capital project acquisition follow board director beforehand decide recent acquisition significant transaction outside scope situation statutory auditor announced strategy regard green book board director shall deliberate prior board member carried formal making change management structure assessment work board director company shall informed principal questionnaire sent board member organizational change summary result show positive overall assessment board performance selfassessment corporate governance chairman report pursuant article l show director consider well informed board committee executive management company belief ceo moderating properly audit committee remuneration discussion board director committee responsible studying making preparation board main deliberation evaluation three objective order improve board efficiency take stock modality performance circumstance committee relieve board board legal power decision verify important question properly allowed cause division within college prepared debated stay responsible accomplishment measure effective contribution adminis mission committee dont replace trator board work due competency emanation board director facilitating involvement debate work committee chairman submitted work report committee board may consult board discussion performance function main company executive member informed independent auditor invited two board chairman board director subject meeting reporting back board committee board may request external information provided director technical study relating matter within competence expense company board meeting director receive report informed chairman board agenda item require prior consideration director board director subject due time following notification reporting back board preliminary figure annual interim case making use external consultancy service statement generally sent director least example remuneration advice order obtain one week meeting audit committee information concerning system level always held day day remuneration force main market board meeting committee ensure objectivity concerned service addition board meeting chairman regularly informs director event development board meeting preceded meeting may material impact group operation least one two committee depending information previously communicated item agenda committee report board board work observation submit opinion proposal recommendation member board director receive copy press release published company procedure committee also defined director may time request internal rule regulation information chairman board shall assess relevance request member committee board chosen board director appointment renewal president audit committee mandate proposed remuneration committee subject specific review board director corporate governance chairman report pursuant article l duty audit committee audit committee duty area external controlling consist audit committee assist board director company accounting policy reporting submitting recommendation board treasury hedging instrument internal director concerning statutory auditor external controlling financial communication risk appointment reappointment annual management shareholder meeting end committee steer statutory auditor selection procedure member audit committee therefore submits recommendation board either financial accountant expertise director proposed shareholder meeting committee proposes board director proportion independent administrator selection procedure particularly tender audit committee lower two third might necessary supervises tender validates tender specification also approves committee include executive director choice consulted firm ensuring highest lowest bidder respect audit committee shall consult selected statutory auditor well financial accounting financial investment director shall analyzing issuing opinion definition possible interview take place scope timetable assignment fee committee requires without presence management company analyzing independence legal auditor committee ask external expert needed end committee informed year ensuring expertise independence statutory auditor audit committee duty field declaration independence accounting policy internal controlling consist mainly amount fee paid network statutory auditor company controlled review annual corporate consolidated firm entity hold accrued benefit account reviewing halfyearly annual directly linked mission corporation consolidated account including auditor note financial statement management report presented board information concerning benefit accomplished director annual general shareholder audit directly linked auditor mission meeting convened approve statement fiscal presenting observation committee examines statutory auditor recommendation board director risk threating independence protective review account committee consider measure made reduce risk also important operation conflict ensure amount fee paid interest could occurred company group portion represents revenue office ensuring suitability consistent application network likely impair statutory accounting method procedure chosen auditor independence context company guaranteeing correct accordance green book policy application role audit established european commission proposed next sartorius stedim review accounting treatment significant biotech sa shareholder meeting april transaction carried company nominate review scope consolidated company necessary reason certain company included corporate governance chairman report pursuant article l kpmg auditory auditor replacing ernst main subject audit committee review young audit following salustro reydel alternate auditor replacing examining corporate consolidated annual auditex account reviewing financial statement quar terly halfyearly annual corporate con audit committee duty field risk solidated account including implementation analysis prevention consist specific action related ifrs standard working hedging instrument defining internal audit plan group review internal audit work company obtaining report audit carried review quarterly risk management report defining necessary action plan approval auditor fee implementing new procedure respective june december audit company account auditor presented essential result audit option decided examining company exposure significant situation statutory auditor regard risk risk mapping committee review risk green book balance sheet commitment appreciates importance weakness received informs board appropriate duty remuneration committee verifying appropriate application internal control purpose remuneration committee help accounting financial reporting procedure company board director establish remuneration policy corporate officer audit committee duty area financial particular incentive mechanism granting communication consists reviewing company share subscription option share purchase option proposed financial communication respect free allotment share company may publication halfyearly annual corporate introduce account quarterly result remuneration committee must put board committee may also perform activity director best condition determine deemed necessary appropriate committee overall remuneration benefit executive board director director board director responsible decision otherwise committee must activity report audit committee fiscal informed remuneration policy non executive director occasion committee audit committee met five time fiscal associate executive director year average attendance remuneration committee also activity report audit committee ponsibility give recommendation regard board director help board fully informed new potential director committee member facilitating deliberation circumstantially considered element need taken account deliberation desirable balance membership board regard composition evolution shareholding company balance men woman within board identification evaluation potential candidate desirability extension term need particular organize procedure order select future independent administrator achieve study potential candidate taking measure regarding others corporate governance chairman report pursuant article l activity report remuneration committee within scope remuneration committee consulted board director proposal concerning remuneration committee met twice fiscal year average attendance total budget allotted director fee term allocation thereof taking account activity report board director help actual presence director board meeting board fully informed facilitating possibly committee meeting deliberation presentation report fixed remuneration corporate officer made remuneration committee necessary term variable remuneration board deliberate remuneration general policy granting share sub executive director without presence scription option share purchase option free allotment company share remuneration committee deliberated main policy director nomination renewal following topic target achievement limitation power chairman reviewing remuneration chief executive officer corporate officer reviewing payment director fee june board director voted structure board director evaluation combine function chairman chief implementation executive board executive officer without limitation power supervisory board included internal regulation number woman board director board director mainly strategic renewal term duty director investment project transaction especially acquisition disposal may lead material remuneration mr joachim kreuzburg profit loss impact procedure concern mr reinhard vogt discussed within operation one million euro corporate remuneration committee sartorius stedim biotech governance structure adopted overwhelming determined remuneration committee majory french company board sartorius ag director allows simplifying operational management company order increase efficiency taking account presence controlling shareholder company capital well continued application company best principle corporate governance remuneration senior executive senior nonexecutive board member mandataires sociaux total remuneration including benefit paid year senior executive chairman board director chief executive officer director including sharebased payment disclosed corporate governance report sartorius stedim biotech group remuneration committee set review remuneration board director executive member furthermore remuneration committee also responsible checking annual director fee paid director corporate governance chairman report pursuant article l dr joachim kreuzburgs reinhard vogts internal control procedure remuneration determined annually sartorius ag supervisory board remuneration consists fixed variable component introduction line respective area responsibility variable portion contains short mid longterm objective defined chairman component shortterm component paid internal control system sartorius stedim biotech every year mid term component paid every follows three year based average achieved target threeyear term long term prevent risk would endanger quality component comprised phantom stock plan asset sartorius stedim biotech even existence subject risk remuneration component ensure executive management activity depends development sartorius ag share transaction completed conduct price period least four formerly three employee comply guideline defined year year payable price exceeds executive management applicable law regula least formerly per year relative time tions fundamental value standard internal phantom stock assigned share price rule business ethical code outperformed tecdax comparative index convention healthcare industry amount paid capped maximum ensure accounting financial information time share price time phantom stock management data provided executive assigned based case actual annual management company accurately reflect tranche concerned use component operation sartorius stedim biotech designed longterm incentive effect prevent risk arising operation error fraud entail risk recommendation adopted especially accounting financial area german french corporate governance code date payment made dr kreuzburg reinhard vogt according phantom stock plan scope internal control part remuneration cross charged annually internal control system described cover parent sartorius stedim biotech group company affiliate remuneration oscarwerner reif volker niebel discussed within remuneration component internal control committee subsequently voted annual shareholder meeting sartorius stedim environment internal control biotech gmbh oscarwerner reif volker niebel employment contract core business people individual remuneration consists fixed variable attribute including integrity ethical value component line respective degree expertise environment operate responsibility engine drive organization foundation support company risk assessment process risk mapping company must aware deal risk face must set objective integrate sale production marketing financial activity organization operates concert must also establish mechanism identify analyze manage related risk corporate governance chairman report pursuant article l control activity risk management control activity undertaken every level sartorius stedim biotech group inevitably group ensure internal control exposed wide variety risk nature efficient checking accuracy completeness operation around world accordingly internal authorization validation recording transaction risk management system set help ensuring different people discharge different identify assess manage risk efficiently duty reduce risk error fraud within risk management system ad hoc committee comprised representative different information communication department regularly study current issue risk management enables committee provide availability accurate reliable complete executive management overview risk information essential achieve business company exposed enabling take objective enable proper reporting party appropriate action required concerned compliance applicable law regulation internal auditing department monitoring control management internal auditing department charge monitoring effectiveness suitability risk responsibility authority must defined management internal control system understood level company internal sartorius stedim biotech group company well control function effectively duty must compliance activity process internal assigned way person work always external rule standard provides checked approved different person independent auditing consulting service size local unit concerned permit focus primarily compliance relevant legal responsibility initiating authorizing recording provision improvement business process processing transaction must always assigned company ensure independence different individual internal auditor audit committee receives least year report internal auditing unit management responsible maintaining department work done according internal check internal control time audit plan established committee finding regard group affiliate internal controlling role finance controlling department executive management finance controlling department track monitor operation project optimize chairman chief executive officer group profitability cash flow providing responsible internal control system internal external stakeholder reliable management level also responsible information development operation monitoring management internal control controlling system two department define group accounting providing necessary assurance step rule method principle financial process implemented fiveyear business plan budget etc well reporting tool order monitor daytoday audit committee business audit committee responsible carrying necessary review evaluation internal controlling procedure including relating financial information also assist preparation group consolidated financial statement information audit committee see page corporate governance chairman report pursuant article l procedure preparing group executive management review effectiveness financial statement accounting internal controlling financial reporting regularly financial information particular verifies transaction recorded consistently accordance ifrs account affiliate prepared accordance international accounting standard applied group accounting policy data group set accounting reporting adjusted necessary produce company manual order ensure pertinence account comply applicable local legal transaction asset recognized within time set tax provision integrated consolidation software used management reporting purpose produce group financial statement internal control since group decided implement internal control perspective group hard close process november order focused following year anticipate improve annual audit accounting standard training code conduct anticorruption code consolidated financial statement prepared accordance ifrs accounting standard collaborator consult sartorius code currently adopted european union conduct sartorius anticorruption code consolidated financial statement comply initial training process closed transferred accounting rule method detailed note controlled operation consolidated financial statement role group finance controlling midterm prospect department group continue work internal control finance controlling department check issue strengthening approach risk mapping quality reporting package submitted risk management process based affiliate focusing primarily following element element amf internal control reference checking corporate data consolidated adjustment framework entered locally intercompany elimination accounting treatment nonrecurring transaction addition process defining mandatory reporting period verifying principal minimum standard internal control applying movement opening closing balance group company followed sheet prepare cash flow statement pursued finance department also verifies result procedure including currency translation intercompany elimination etc aubagne february key point review include preparation chairman validation statement change shareholder equity cash flow statement joachim kreuzburg financial information reporting group rule procedure relation financial reporting accounting set accounting reporting manual application compliance principle rule procedure direct responsibility finance director affiliate must ensure information provided via management information system complies fully applicable disclosure requirement corporate governance remuneration executive nonexecutive member board remuneration executive nonexecutive member board information remuneration sartorius ag executive board member also executive board member executive member board sartorius stedim biotech however component remuneration element parameter remuneration member described refer parameter executive board member differ financial key figure sartorius group total member time member executive board major shareholder sartorius ag variable remuneration member mem bers sartorius ag executive board receive variable portion remuneration contains fixed variable remuneration sartorius ag component paid annually component portion fixed remuneration charged determined multiyear performance assessment sartorius stedim biotech sa reflecting role category component general making director company portion defined one half target achievement possible scheme director meeting attendance fee part bylaw company annually paid variable remuneration portion total remuneration charged ssb group management service portion variable remuneration paid detail please refer section related party annually linked weighted target achievement financial statement note page following financial key figure sale reve nue order intake underlying ebitda ratio net debt underlying ebitda component remuneration executive member minimum target achievement required maxi board member executive mum payout ratio defined amount paid board major shareholder sartorius ag depends degree respective financial joachim kreuzburg reinhard vogt target achieved financial target mentioned line budget approved annually general fixed remuneration supervisory board sartorius ag total amount remuneration executive b longterm incentive board member sartorius ag reflects scope responsibility executive member con component determined multiyear assessment cerned executive member personal performance depend degree respective target company economic situation sustainable achieved progress addition amount benchmarked peer company vertical remu consolidated net profit neration structure within company well peer company remuneration comprised subordinate target basis assessment fixed variable component reviewed consolidated net profit minority interest ex annually supervisory board sartorius ag cluding amortization impairment value intan ensure remains appropriate case gible asset due business combination pursuant target achievement variable remuneration ifrs target achievement component component represent approximately half total based threeyear average consolidated net remuneration excluding pension commitment profit achieved compared average annual fringe benefit target set variable remu budget three year smooth neration refer financial key figure sartorius amount paid partial payment amounting group sartorius stedim biotech group target achievement first fiscal fully consolidated specifically sartorius stedim year effected overpayment result biotech represents approx business partial payment offset final asset sartorius group therefore develop calculation target achievement third ment sartorius stedim biotech significant year remuneration component fixed influence financial result sartorius variable minimum target achievement cap group thus variable remuneration applied component well corporate governance remuneration executive nonexecutive member board phantom stock plan pension commitment joachim kreuzburg reinhard vogt according company remuneration policy eligible participate phantom stock plan executive board member sartorius ag receive responsibility sartorius ag level performancerelated benefit commitment defined benefit plan reappointed first issue shadow share called phantom time addition including basic pension stock executive board member member commitment provide executive board member treated owner certain number make contribution variable earn share sartorius ag without however entitled ings company match contribution receive dividend development value bonus amount executive board member may phantom stock linked development choose receive defined benefit form sartorius share increase decrease monthly retirement pension old age one share price taken account later phantom time payment cover member retirement pen stock valuated based share price time sion old age invalidity well form equivalent paid provided associ survivor benefit surviving spouse chil ated condition met phantom stock cannot trad dren decedent ed entail share subscription right beyond commitment joachim kreuzburg according sartorius phantom stock plan additionally entitled former company pension executive board member credited beginning scheme receive performancebased retirement bene every year phantom stock unit valued fit based salary german federal civil servant agreed monetary sum value phantom stock classified grade salary class b ministry offi paid entire annual tranche cials according federal civil service remunera payment requested earliest tion act bundesbesoldungsgesetz benefit period four year later eight year paid form retirement pension old age invalidity well form survivor benefit executive board member entitled receive surviving spouse child decedent payment phantom stock unit share price time payment request appreciat member turned shall considered ed least per year relative time phan regular age limit member shall auto tom stock assigned share price matically entitled receive benefit outperformed tecdax comparative index phantom stock plan rule subsequent change remuneration component parameter used comparative stock valuation amount paid capped maximum remuneration system provides supervisory time share price time phantom stock board sartorius ag discretion may grant assigned based case actual annual executive board member special compensation based tranche concerned member exceptional performance assignment phantom stock payment severance cap monetary equivalent depend mean value calculat ed average price class sartorius ag service contract include severance pay cap share closing auction xetra trading frank maximum two annual salary cover case furt stock exchange last day trading sartorius ag executive board membership previous year last day trading terminated prematurely prior submission payment request serf compensate shortterm fluctuation noncompetition clause share price executive board member sartorius ag payment phantom stock blocked four week postcontractual noncompetition obligation preceding scheduled publication date quarterly accordance german law obligation last preliminary yearend result day trad two year executive board member left ing stock exchange following actual publica group time noncompetition tion quarterly preliminary yearend result clause waived terminated executive board blackout period intended prevent executive board member may claim half recent annual member profiting insider knowledge remuneration received company corporate governance remuneration executive nonexecutive member board fringe benefit grant date amount k considering agreed condition amount resulting decem member executive board sartorius ag ber spread employee benefit entitled use company car reclaim ex expense account sartorius ag recog penses incurred business travel covered nized full vesting period account accident insurance insurance fringe sartorius stedim biotech affected benefit addition receiving remuneration fiscal component mentioned insurance provides application deductible excess amount required law remuneration executive member board part sartorius sharebased payment stedim biotech group oscarwerner reif volker niebel remuneration policy executive board member sartorius ag provide transfer general fixed remuneration sartorius ag share compensation member exception made december total amount remuneration executive joachim kreuzburg granted entitlement member reflects role director company receive sharebased remuneration due third scope responsibility executive reappointment member executive board member concerned executive member personal chairman ceo sartorius ag performance company economic situation sustainable progress addition amount third term joachim kreuzburg member benchmarked peer company executive board chairman ceo sartorius ag vertical remuneration structure within compa expire november resolution ny well peer company remuneration supervisory board sartorius ag december comprised fixed variable component joachim kreuzburg reappointed member reviewed annually ensure remains appro executive board chairman ceo priate case target achievement term november november variable remuneration component represent approxi due joachim kreuzburgs excellent perfor mately half total remuneration excluding fringe mance developing company since start benefit portion fixed component allocated tenure executive board company role director company portion wished continue successful cooperation defined scheme director meeting attendance despite alternative offer made fee part bylaw company reason new remuneration contract pro vides supplementary remuneration component variable remuneration transfer ordinary share preference share sartorius ag joachim kreuzburg fol variable portion remuneration contains lowing basic structure agreed upon component paid annually component transfer share granted shall effected determined multiyear assessment time determined joachim kreuzburg earlier november however share annually paid variable remuneration granted shall subject holding period end november joachim kreuzburg portion variable remuneration paid leave company prior november annually linked weighted target achievement request entitlement granted said share following financial key figure sale transfer shall lapse entirety joa revenue order intake underlying ebitda ratio chim kreuzburg leaf company november net debt underlying ebitda november component minimum target achievement request half entitlement granted said quired maximum payout ratio defined share shall lapse share already transferred amount paid depends degree entitlement lapsed shall returned respective financial target achieved company remuneration component financial target mentioned line included total remuneration fair value budget approved annually time granted share respective fair value derived number share granted price class share corporate governance remuneration executive nonexecutive member board b longterm incentive table summarizing remuneration option share granted longterm component multiyear assessment executive board member determines degree target achieved joachim kreuzburg consolidated net profit chairman board chief executive officer subordinate target basis assessment k year year consolidated net profit minority interest ex remuneration due cluding amortization impairment value intan valuation option granted gible asset due business combination pursuant reporting period ifrs target achievement component valuation performance based threeyear average achieved compared share granted previous year threeyear average annual budget total smooth amount paid partial payment amounting target achievement first fiscal year effected overpayment amount crosscharged company result partial payment offset sartorius ag sartorius stedim biotech group final calculation target achievement concerning joachim kreuzburg submitted third year remuneration component vote annual shareholder meeting fixed variable minimum target achievement accordance afepmedef code amounted cap applied component well k severance cap volker niebel executive vice president operation oscarwerner reif limited service agreement sartorius stedim biotech gmbh place case k year year severance would receive payment amount remuneration due reflecting remaining duration contract valuation option granted capped two year given contract expire reporting period april severance payment would reflect valuation performance remaining duration volker niebel employed share granted previous year sartorius stedim biotech according german labor total contract case termination german labor law would apply potential severance due amounting half monthly salary based oscarwerner reif total package per year employment minimum executive vice president research development noncompetition clause k year year remuneration due executive director postcontractual non valuation option granted competition obligation accordance reporting period german law sartorius stedim biotech sa valuation performance controlled german company obligation share granted previous year last two year director left group total time noncompetition clause waived terminated director may claim half recent annual remuneration received company fringe benefit executive member entitled use company car reclaim expense incurred business travel covered accident insurance insurance fringe benefit addition receiving remuneration component mentioned corporate governance remuneration executive nonexecutive member board reinhard vogt summary remuneration executive vice president marketing sale service executive board member k year year joachim kreuzburg chairman board chief executive officer remuneration due valuation option granted reporting period year year valuation performance amount amount amount amount share granted previous year k due paid due paid total fixed remuneration variable remuneration amount crosscharged company annually paid sartorius ag sartorius stedim biotech group longterm concerning reinhard vogt submitted vote incentive annual shareholder meeting accordance exceptional afepmedef code amounted k remuneration director attendance fee benefit kind total joachim kreuzburg receives salary sartorius ag duty performed entire sartorius group remuneration determined annually supervisory board sartorius ag company car volker niebel executive vice president operation year year amount amount amount amount k due paid due paid fixed remuneration variable remuneration annually paid longterm incentive exceptional remuneration director attendance fee benefit kind total volker niebel receives salary sartorius stedim biotech gmbh duty performed sartorius stedim biotech group company car corporate governance remuneration executive nonexecutive member board oscarwerner reif information remuneration executive vice president research development nonexecutive board member year year remuneration nonexecutive board member amount amount amount amount defined bylaw sartorius stedim biotech sa k due paid due paid comprises fixed remuneration meeting attendance fixed fee reimbursement outofpocket expense remuneration member also serving member committee variable board receive higher fixed remuneration remuneration annually paid longterm incentive table director meeting attendance fee exceptional remuneration received remuneration nonexecutive board member director attendance fee k year year benefit kind liliane de lassus total director attendance fee remuneration oscarwerner reif receives salary sartorius bernard lemaître stedim biotech gmbh duty performed director attendance fee sartorius stedim biotech group remuneration company car arnold picot director attendance fee remuneration reinhard vogt henri riey executive vice president marketing sale service director attendance fee remuneration year year total amount amount amount amount k due paid due paid fixed remuneration performance share available variable board member remuneration annually paid number share longterm performance share available incentive available date reporting acquisition exceptional corporate officer plan period condition remuneration joachim kreuzburg applicable director volker niebel applicable attendance fee oscarwerner reif applicable benefit kind reinhard vogt applicable total liliane de lassus applicable bernard lemaître applicable reinhard vogt receives salary sartorius ag arnold picot applicable duty performed entire sartorius henri riey applicable group remuneration determined annually total supervisory board sartorius ag company car performance share bonus share allocated board member within framework l article following commercial law subjected additional requirement laid recommendation afepmedef october corporate governance remuneration executive nonexecutive member board performance share granted board member performance share program place board member sartorius stedim biotech sa information provided table refers phantom stock plan sartorius ag described page plan relates joachim kreuzburg reinhard vogt executive board member sartorius ag valuation share performance share granted according agm reporting period corporate officer number consolidated issuer date share granted account date date performance company group plan year methodology acquisition availability conditions joachim kreuzburg jan jan volker niebel oscarwerner reif reinhard vogt jan jan liliane de lassus bernard lemaître arnold picot henri riey total stock option granted reporting stock option granted historical information period board member issuer company group applicable applicable stock option granted top ten noncorporate officer exercised stock option exercised reporting period board member applicable applicable corporate governance remuneration executive nonexecutive member board additional information executive board member indemnity compensation due employment additional regard termination noncompetition corporate officer contract pension plan contract position clause indemnity yes yes yes yes joachim kreuzburg ceo chairman volker niebel none oscarwerner reif none reinhard vogt joachim kreuzburg reinhard vogt service contract without social security component sartorius ag duty performed member executive board major shareholder sartorius ag standard practice germany oscarwerner reif volker niebel service contract employment contract respectively sartorius stedim biotech gmbh duty performed managing director company standard practice germany general pension plan place sartorius ag level joachim kreuzburg reinhard vogt level entitlement benefit paid company pension plan depends respective tenure corporate governance statutory auditor report prepared accordance article l statutory auditor report prepared accordance article l statutory auditor report prepared accordance information internal control risk article l french commercial code code management procedure relating de commerce report prepared chairman preparation processing accounting board director sartorius stedim biotech financial information free translation english report issued professional standard require perform french provided solely convenience necessary procedure assess fairness englishspeaking user report read information provided chairman report conjunction construed accordance respect internal control risk management french law professional standard applicable france procedure relating preparation processing accounting financial information year ended december procedure consist mainly shaeholders obtaining understanding internal control risk management procedure relating capacity statutory auditor sartorius preparation processing accounting stedim biotech accordance article l financial information information french commercial code code de presented chairman report based commerce hereby report report prepared existing documentation chairman company accordance article l french commercial code code obtaining understanding work involved de commerce year ended december preparation information existing documentation chairman responsibility prepare submit board director approval report determining material weakness internal control risk management procedure internal control procedure relating implemented company provide preparation processing accounting information required article l financial information would noted french commercial code code de commerce relating course work properly disclosed matter corporate governance chairman report role basis work matter report information relating company internal control report matter information risk management procedure relating pre contained chairman report respect paration processing accounting financial internal control risk management procedure information contained report prepared relating preparation processing chairman board director article l accounting financial information french commercial code code de commerce confirm report also includes information information required article l french commercial code code de commerce confirm report prepared chairman noted role verify board director also contains fairness information information required article l french commercial code code de commerce conducted work accordance professional standard applicable france marseille february french original signed statutory auditor ernst young audit deloitte associés xavier senent christophe perrau corporate governance independent auditor fee independent auditor fee principal independent auditor ernst young audit deloitte et associés avenue du prado bp marseille place de la joliette le dock atrium cedex france bp marseille cedex france represented xavier senent represented christophe perrau first commissioned combined general first commissioned annual general share shareholder meeting june date holder meeting may date commission commission expires annual general shareholder expires annual general shareholder meeting meeting approve financial statement approve financial statement member compagnie régionale de versailles member compagnie régionale de versailles independent auditor fee ernst young deloitte k audit independent audit certification parent company consolidated financial statement parent company subsidiary service directly related audit service parent company subsidiary subtotal service legal tax corporate information technology subtotal total corporate governance independent auditor fee substitute independent auditor auditex beas tour ernst young faubourg de larche villa houssay neuilly sur seine france parisla défense cedex france first commissioned annual general share represented alain pons holder meeting april date commission commissioned annual general shareholder expires annual general shareholder meeting meeting may date commission expires approve financial statement annual general shareholder meeting approve financial statement member compagnie régionale de versailles member compagnie régionale de versailles total consolidated financial statement note consolidated financial statement note statement profit loss comprehensive income statement profit loss comprehensive income note month month k k sale revenue cost sale gross profit sale selling distribution cost research development cost general administrative expense operating income expense earnings interest tax ebit financial income financial expense financial result profit tax income tax net profit period attributable equity holder sartorius stedim biotech noncontrolling interest earnings per share diluted earnings per share statement comprehensive income month month k k net profit period cash flow hedge income tax cash flow hedge net investment foreign operation income tax net investment foreign operation currency translation difference item probably reclassified profit loss net tax actuarial gain loss defined benefit obligation income tax actuarial gain loss item reclassified profit loss net tax total comprehensive income attributable equity holder sartorius stedim biotech noncontrolling interest note consolidated financial statement integral part statement consolidated financial statement note statement financial position statement financial position dec dec note k k noncurrent asset goodwill intangible asset property plant equipment financial asset asset deferred tax asset current asset inventory trade receivables financial asset current tax asset asset cash cash equivalent total asset equity equity attributable ssb sa shareholder issued capital capital reserve retained earnings including net profit noncontrolling interest noncurrent liability pension provision provision loan borrowing finance lease liability financial liability deferred tax liability current liability provision trade payable loan borrowing finance lease liability financial liability current tax liability liability total equity liability figure adjusted final purchase price allocation tap biosystems detailed note consolidated financial statement note statement cash flow statement cash flow month month k k profit tax financial result earnings interest tax ebit depreciation amortization fixed asset increase decrease provision income tax paid gross cash flow operating activity increase decrease receivables increase decrease inventory increase decrease liability net cash flow operating activity capital expenditure proceeds disposal fixed asset payment net cash flow investing activity payment acquisition consolidated subsidiary business operation net cash acquired proceeds disposal consolidated subsidiary business operation net cash flow investing activity acquisition change capital interest received interest paid financial charge dividend paid shareholder sartorius stedim biotech sa noncontrolling interest gross cash flow financing activity loan borrowing raised loan borrowing repaid net cash flow financing activity net increase decrease cash cash equivalent cash cash equivalent beginning period net effect currency translation cash cash equivalent cash cash equivalent end period consolidated financial statement note statement change equity statement change equity foreign cash flow currency non issued capital hedging pension retained translation group controlling total k capital reserve reserve reserve earnings reserve equity interest equity balance jan net profit period comprehensive income period total comprehensive income stock option dividend change balance dec jan net profit period comprehensive income period total comprehensive income stock option dividend purchase price liability forward non controlling interest change non controlling interest change capital change balance december amount k shown retained earnings refers acquisition allpure technology llc please refer note change capital include cancellation treasury share capital increase change nominal value share detail please refer note consolidated financial statement note note financial statement note financial statement general information effect new financial reporting standard sartorius stedim biotech leading provider cuttingedge equipment service compared yearearlier consolidated financial development quality assurance production statement following new amended standard process biopharmaceutical industry obligatorily applied first time integrated solution covering fermentation filtration purification fluid management cell culture medium ifrs consolidated financial statement supporting biopharmaceutical industry around world develop produce drug safely timely ifrs joint arrangement economically nextgeneration process sartorius stedim biotech focus singleuse ifrs disclosure interest entity technology addedvalue service meet rapidly changing technology requirement amendment ia separate financial industry serf strongly rooted scientific statement community closely allied customer technology partner company dedicated amendment ia investment associate philosophy turning science solution joint venture headquartered aubagne france sartorius stedim ifrs revise definition control biotech sa listed euronext paris isin code basis determination scope fr consolidated entity ifrs stipulates accounting joint arrangement ifrs compliance european regulation combine disclosure requirement interest july requiring listed company subsidiary joint arrangement associate non use international accounting standard consolidated structure entity consolidated financial statement sartorius stedim biotech group year ended december initial application ifrs lead compliant standard significant sartorius stedim biotech group interpretation ifrs ifric iasb adopted special purpose entity associate jointly european union available controlled entity existing ifrs lead following site additional disclosure consolidated financial statement see note httpeceuropaeuinternal_marketaccountingiasind ex_enhtm furthermore following standard interpretation applied initially consolidated financial statement prepared euro unless otherwise specified amount amendment ia financial instrument disclosed thousand euro abbreviated k presentation offsetting financial asset case sum figure given financial liability report may precisely equal stated total percentage may exact due rounding amendment ifrs transition guidance consolidated financial statement approved board director february amendment ifrs ia investment submitted approval shareholder entity meeting april amendment ia recoverable amount disclosure nonfinancial asset amendment ia novation derivative continuation hedge accounting consolidated financial statement note note financial statement amendment mentioned necessarily applicable group firsttime application result material impact group financial statement sartorius stedim biotech following standard interpretation revision amendment yet applied consolidated financial statement reporting year yet adopted eu application obligatory applicable endorsement financial standard interpretation title year eu commission standard amendment ia employee contribution july yes annual improvement ifrss cycle issued dec various july yes annual improvement ifrss cycle issued dec various january yes amendment ifrs ifrs ia investment entity applying consolidation exception january amendment ifrs sale contribution asset investor associate ia joint venture january amendment ifrs accounting acquisition interest joint operation january ifrs regulatory deferral account january amendment ia disclosure initiative january amendment ia ia agriculture bearer plant january amendment ia clarification acceptable method depreciation ia amortization january amendment ia equity method separate financial statement january annual improvement ifrss cycle issued sep various january ifrs revenue contract customer january ifrs financial instrument january interpretation ifric levy june yes required applied endorsed eu commission standard may provide earlier mandatory application process measuring potential impact standard interpretation consolidated financial statement sartorius stedim biotech group progress group anticipate stage analysis significant impact consolidated account presently firsttime application planned reporting period standard interpretation amendment enter force consolidated financial statement note note financial statement significant accounting policy foreign currency translation consolidated financial statement sartorius basis preparation stedim biotech group prepared thousand euro annual financial statement consolidated financial statement group individual company foreign currency transaction based principle historical cost translated exchange rate applicable acquisition construction production time transaction monetary asset debt exception item reflected fair value whose value given foreign currency financial asset held trading available sale translated exchange rate balance sheet derivative date rate gain loss recognized profit loss period consolidation subsidiary annual financial statement prepared foreign currency translated pursuant consolidated financial statement sartorius ia effect change foreign exchange stedim biotech group include annual financial rate accordance concept functional statement company controlled currency foreign subsidiary regarded directly indirectly sartorius stedim biotech sa independent subdivision sartorius stedim term ifrs consolidated financial statement biotech group balance sheet item accounting investment subsidiary translated exchange rate balance sheet controlling interest exists sartorius stedim date income expense item converted biotech sa subsidiary power govern average rate translation difference financial operating policy enterprise resulting use different exchange rate obtain economic benefit activity balance sheet item statement profit loss enterprise included consolidated financial recognized comprehensive statement time sartorius stedim income shareholder equity biotech sa subsidiary acquired control longer included time control certain defined loan granted longterm basis transferred entity outside group group applies principle net investment foreign operation foreign currency translation subsidiary included basis difference resulting loan recognized annual financial statement reporting comprehensive income according ia period parent company using uniform group recognition measurement method intragroup asset liability equity income expense cash flow relating transaction tween member group eliminated full consolidation business combination business combination measured according acquisition method identifiable acquired asset assumed liability potential liability recorded fair value date combination significant acquisition purchase price allocation carried assistance independent thirdparty valuation specialist valuation based information available acquisition date expense directly related business combination reported profit loss period consolidated financial statement note note financial statement exchange rate major currency item general administrative expense includes euro considered follows mainly employee benefit expense cost material general administrative area yearend exchange rate average exchange rate profit loss item cannot allocated one mentioned functional area recognized usd income expense includes essentially gbp effect currency translation sale fixed asset jpy allowance trade receivables reorganization inr extraordinary expense income grant cny related income recognized income reasonable assurance condition attached grant complied sale revenue grant received recognized period necessary match systematic basis revenue derived selling product cost intended compensated rendering service recognized sale revenue operational revenue recognized operating income sale recognized borrowing cost statement profit loss significant risk reward ownership good borrowing cost expensed incurred unless transferred customer company retains directly attributable acquisition neither continuing managerial effective control construction production qualifying asset good sold amount revenue cost therefore part cost asset incurred incurred measured reliably qualifying asset defined asset take sufficiently probable economic period least twelve month get ready benefit associated transaction flow intended use company income tax functional cost current income tax determined based general operating expense type assigned respective local taxable income period local function following functional area tax rule addition current income tax include corresponding profit cost center expense adjustment uncertain tax payment tax refund relating crossfunctional initiative project period yet assessed change deferred tax assigned respective functional cost based asset liability included income tax ex appropriate allocation principle cept change recognized comprehensive income directly equity item cost sale report cost product sold acquisition cost merchandise sold deferred tax asset liability determined based besides directly imputable expense raw temporary difference carrying material supply employee benefit expense amount tax basis asset liability energy expense cost sale also includes including difference consolidation loss carry overhead allocated manufacturing forward tax credit measurement based area corresponding depreciation tax rate expected effective period amortization asset realized liability settled selling distribution cost pertain particular purpose tax rate tax rule used cost sale marketing organization enacted substantively enacted distribution advertising market research reporting date deferred tax asset recognized extent probable taxable profit research development cost comprise cost level relevant tax authority available research product process development unless utilization deductible temporary recognized asset amortization capitalized difference loss carried forward development cost also indicated item consolidated financial statement note note financial statement goodwill capitalized development cost essentially cover cost allocated staff involved rd goodwill represents future economic benefit raw material supply outside service arising asset acquired business directly attributable overhead intangible asset combination individually identified generated internally amortized straight line separately recognized basis useful life generally exceed four year according ia goodwill acquired business combination may amortized rather must internally generated intangible asset may tested annually impairment soon recognized development cost included indication asset impairment period incurred cost research activity reported expense period purpose impairment testing goodwill must incurred allocated acquirer cashgenerating unit cgus expected benefit amortization intangible asset based synergy combination cashgenerating unit following period useful life cgu represents lowest level within entity goodwill monitored internal management software year purpose may larger segment capitalized development cost year customer relation technology year brand name na intangible asset intangible asset acquired stated cost less accumulated regular amortization calculated according straightline method useful life intangible asset period asset expected contribute directly indirectly cash flow entity cost incurred within scope development new product method capitalized internally generated intangible asset following criterion met technical feasibility completing intangible asset available use sale intention complete intangible asset use sell ability use sell intangible asset demonstration intangible asset generate probable future economic benefit availability adequate technical financial resource complete development use sell intangible asset ability measure reliably expenditure attributable intangible asset development consolidated financial statement note note financial statement property plant equipment group lessee finance lease amount equal fair value leased property property plant equipment item reported lower present value minimum lease cost subject depreciation depreciated payment recognized asset balance scheduled straightline method applied sheet simultaneously recognized financial depreciation reported consolidated financial liability minimum lease payment essentially statement consist finance charge reduction outstanding liability measured according depreciation fixed asset based following effective interest method leased asset period useful life depreciated straightline basis period expected useful life shorter lease term building year machinery year group lessor finance lease sale revenue factory office equipment year equal net investment lease recognized well lease receivable leasing rate receives also apportioned finance charge reduction liability according impairment intangible tangible asset effective interest method book value carrying amount property plant operating lease lease rate paid equipment intangible asset examined lessee recognized expense lease whether indication asset might rate received lessor recognized income impaired pursuant ia impairment asset respectively leased asset continues asset impaired recoverable amount recognized lessor balance sheet property asset estimated recoverable amount asset plant equipment cashgenerating unit higher fair value less cost sell asset cgu value use event individual asset recoverable inventory amount cannot estimated recoverable amount asset cashgenerating unit cgu estimated raw material supply including merchandise reported inventory average cost estimated recoverable amount asset principle finished good work progress cgu go book value carrying amount reported cost conversion cost includes carrying amount reduced recoverable amount direct cost allocated material appropriate portion production cause asset impairment removed material handling overhead general administrative book value asset cgu credited expense fixed asset normal depreciation newly estimated recoverable amount however amortization rate provided book value increase limited value asset expense caused production cgu would asset impairment loss would assessed previous financial year inventory must evaluated lower amount cost net realizable value net realizable value represents estimated selling price lease ordinary course business less estimated cost completion estimated cost necessary lease considered agreement whereby lessor marketing sale distribution inventory conveys lessee return payment series risk exist risk reduced shelf life payment right use asset agreed result storage period limited usability period time according ia lease classified inventory marked accordingly either operating finance lease finance lease lease transfer substantially risk reward incidental ownership asset lease designated operating lease consolidated financial statement note note financial statement trade receivables provision trade receivables reported provision recognized liability third discernible risk covered book value trade party incurred outflow resource receivables receivables representative probable amount obligation fair value considering maturity date reasonably estimated amount recognized credit risk determining recoverability trade provision represents best estimate receivables group considers change obligation balance sheet date provision credit quality date credit originally original maturity one year granted discounted present value expenditure expected settle obligation end reporting period construction contract provision regularly reviewed adjusted construction contract contract specifically information becomes available circum negotiated construction asset stance change provision warranty cost combination asset closely interrelated based historical experience interdependent term design technology function ultimate purpose use restructuring provision set connection outcome construction contract program materially change scope business estimated reliably revenue constructiontype performed segment business unit manner project generally recognized business conducted case percentageofcompletion method based restructuring expense include termination benefit percentage cost date compared total compensation payment due termination estimated contract cost expected loss agreement supplier dealer including leasing construction contract recognized expense contract restructuring provision recognized immediately group detailed formal plan either commenced implementation announced contract disclosed receivables liability percentage completion cumulative work contract cost contract result exceeds financial instrument advance payment received construction contract recognized receivables amount due financial instrument contract give rise customer balance deduction advance financial asset one entity financial payment received negative obligation liability equity instrument another entity construction contract recognized liability financial asset mainly include cash cash amount due customer equivalent availableforsale financial asset trade loan receivables derivative financial instrument positive fair value pension obligation financial liability group mainly comprise pension provision similar obligation loan bank trade payable finance lease recognized consolidated financial statement payable derivative financial instrument sartorius stedim biotech group accordance negative fair value actuarial principle ia employee benefit stipulates projected unit credit method initially financial instrument recognized method measurement addition known fair value transaction cost directly attributable pension life expectancy expected cash acquisition issue financial instrument value method take account future salary recognized determining carrying amount pension increase financial instrument measured fair value profit loss subsequently financial actuarial gain loss recognized asset liability measured according comprehensive income directly equity pension category cash cash equivalent availablefor reserve according standard ia r sale financial asset loan receivables financial liability measured amortized cost financial asset liability classified held trading assigned consolidated financial statement note note financial statement cash cash equivalent cash flow hedge group considers highly liquid investment effective portion change fair value less three month maturity date derivative instrument designated cash flow hedge acquisition cash equivalent mainly includes recognized comprehensive income check cash hand deposit bank cash ineffective portion recognized immediately net cash equivalent measured cost income financial result amount accumulated equity reclassified net income period hedged item affect net income investment investment nonconsolidated subsidiary statement cash flow associate security measured cost active market exists share security statement cash flow cash flow present fair value asset cannot reliably ed according allocation operating activity measured investing activity financing activity instance cash flow operating activity loan receivables determined using indirect method ie expense without effect payment added financial asset classified loan receivables profit tax income without effect measured amortized cost using effective payment subtracted cash flow interest method less impairment loss financing activity composed primarily change impairment loss trade receivables equity addition repayment loan recognized using separate allowance account critical accounting judgment key financial liability source estimation uncertainty financial liability measured except derivative preparation consolidated financial financial instrument amortized cost using statement management u estimate effective interest method assumption based best knowledge current future situation period however actual result may differ estimate derivative financial instrument estimate assumption revised regular basis impact change immediately derivative financial instrument foreign recognized income expense period currency exchange contract interest rate swap contract measured fair value derivative addition group management exercise judgment financial instrument classified held trading defining accounting treatment specific trans unless designated hedging instrument action existing standard inter hedge accounting applied change pretations specifically treat accounting fair value derivative financial instrument problem concerned recognized either net income case hedge comprehensive income assumption estimate primarily concern following topic consolidated financial statement note note financial statement business combination trade receivables accounting business combination requires allowance doubtful account involves asset acquired liability assumed significant management judgment review recorded respective fair value date individual receivables based individual customer group obtains control application creditworthiness current economic trend well acquisition method requires certain estimate analysis historical bad debt portfolio assumption made especially concerning fair basis value acquired intangible asset property plant equipment liability assumed acquisition date useful life acquired employee benefit pension provision intangible asset property plant equipment obligation pension postemployment measurement based large extent benefit determined accordance actuarial anticipated cash flow actual cash flow vary valuation valuation rely key assumption used calculating fair value may including discount rate expected salary increase materially affect group future result mortality rate discount rate assumption operation determined reference yield highquality corporate bond appropriate duration currency end reporting period impairment asset due changing market economic condition impairment test conducted certain event lead underlying key assumption may differ actual assumption asset might impaired development may lead significant change case carrying amount asset pension postemployment benefit obligation compared recoverable amount higher net realizable value value use difference recognized full directly calculation value use generally based equity period occur without discounted cash flow method using cash affecting profit loss sensitivity analysis see flow projection five year projection note pension employee benefit provision take account past experience represent management best estimate future sale revenue cost development cash flow provision contingent liability planning period extrapolated using individual contingent asset growth rate key assumption management based determination value use include provision recognized legal constructive estimated growth rate weighted average cost obligation exist balance sheet date capital tax rate estimate determine amount obligation certain material impact respective value estimate assumption applied ultimately amount impairment including evaluation probability carrying amount exceeds recoverable amount amount cost incurred typically significant impairment loss recorded estimate involved determination provision related onerous contract warranty cost asset retirement obligation legal proceeding intangible asset capitalization selfconstructed intangible asset also includes certain level estimation assumption eg evaluation feasibility development project expected market prospect determination useful life consolidated financial statement note note financial statement income tax segment business activity may result revenue expense operating result group operates various tax jurisdiction regularly reviewed entity chief operating therefore determine tax position decision maker executive member board respective local tax law tax authority view director discrete financial information complex subject different available internal reporting internal control interpretation taxpayer local tax authority reporting within sartorius stedim biotech based deferred tax asset recognized approach operating total solution deductible temporary difference unused tax provider customer accordingly loss extent probable future identification sartorius stedim biotech reportable taxable profit available operating segment biopharm deductible temporary difference unused tax loss utilized future development key performance indicator operating uncertain partly beyond management control segment sartorius stedim biotech group assumption necessary estimate future taxable socalled underlying ebitda ebitda corresponds profit well period deferred tax earnings interest tax depreciation asset recover amortization underlying ebitda mean ebitda adjusted extraordinary item connection estimate revised period extraordinary item expense income sufficient evidence revise assumption exceptional onetime nature management considers probable portion accordingly distort sustainable profitability deferred tax asset cannot realized segment material impact net worth corresponding valuation allowance taken financial position earnings group example account item restructuring expense large group project well proceeds loss disposal sale transfer financial asset property operating segment plant equipment provided recurrent nature according ifrs operating segment identification reportable operating segment segment asset segment liability based management approach ie reported regular basis chief operating segment defined analogously internal decision maker therefore part control reporting structure entity therefore segment report area activity considered operating biopharm group k change change sale revenue underlying ebitda sale revenue ebit sale revenue capital expenditure consolidated financial statement note note financial statement reconciliation segment profit loss key figure geographical area refer company location except sale revenue k reported according customer location underlying ebitda segment noncurrent asset correspond property plant depreciation equipment well intangible asset amortization group affiliate allocated extraordinary effect various region goodwill resulting reverse ebit acquisition stedim associated financial result intangible asset presented noncurrent asset profit tax europe european region following country account material noncurrent asset germany million million supplementary information region france million million provide additional information required ifrs amount sale revenue single customer table present supplementary exceed consolidated sale revenue information geographical region european region includes market western eastern europe north american region comprised u marketplace canadian market japan china australia south korea india well country allocated asia pacific region market segment primarily consists latin america africa sale revenue noncurrent asset k europe north america asia pacific market group scope consolidation financial statement following subsidiary sartorius stedim hungary sartorius icr russia tap biosystems phc ltd uk tap biosystems ltd uk sartorius stedim financiére sa france sartorius stedim integrated service sarl tunisia sartorius stedim biotech sarl tunisia included scope consolidation figure minor importance assessing financial position group sale revenue total asset non consolidated company group figure consolidated financial statement note note financial statement financial statement following company included group financial statement ownership europe parent sartorius stedim biotech sa aubagne france company sartorius stedim belgium nv vilvoorde belgium sartorius stedim nordic taastrup denmark sartorius stedim biotech gmbh goettingen germany sartorius stedim plastic gmbh goettingen germany sartorius stedim system gmbh guxhagen germany sartorius stedim uk ltd epsom uk sartorius stedim lab ltd louth uk tap biosystems group ltd royston uk tap esop management ltd royston uk automation partnership cambridge ltd royston uk sartorius stedim fmt sa aubagne france sartorius stedim france sa aubagne france sartorius stedim aseptics sa lourdes france sartorius stedim ireland ltd dublin ireland sartorius stedim italy spa florence italy sartorius stedim netherlands bv rotterdam netherlands sartorius stedim austria gmbh vienna austria sartorius stedim poland sp zoo kostrzyn poland sartorius stedim switzerland ag tagelswangen switzerland sartorius stedim spain sa madrid spain north america sartorius stedim filter inc yauco puerto rico sartorius stedim north america inc bohemia new york usa automation partnership inc greenville usa allpure technology llc new oxford usa asia pacific sartorius stedim australia pty ltd dandenong south victoria australia sartorius stedim biotech beijing co ltd beijing china sartorius stedim shanghai trading co ltd shanghai china sartorius stedim india pvt ltd bangalore india sartorius stedim japan kk tokyo japan sartorius korea biotech co ltd seoul south korea sartorius stedim malaysia sdn bhd kuala lumpur malaysia sartorius stedim singapore pte ltd singapore market sartorius stedim bioprocess sarl mhamdia tunisia associate joint venture included scope consolidation company consolidated full ownership rate equal share voting right company sartorius stedim poland sp zoo included scope consolidation first time far company included due minor importance company initial consolidation lead material effect group figure company sartorius korea biotech co ltdis included scope consolidation based contractual agreement group hold exercisable call option remaining interest company see note consolidated financial statement note note financial statement statement cash flow preliminary fair fair value value date acquisition date acquisition statement cash flow show impact cash k k inflow outflow cash cash equivalent intangible asset group cash flow classified property plant operating investing financing activity according equipment ia statement cash flow inventory trade receivables context cash equivalent asset asset converted cash within short maturity generally cash cash equivalent less three month amount considered deferred tax net statement cash flow includes mainly cash hand provision bank balance similar item equal loan borrowing amount statement financial position liability net asset acquired group received grant related asset connection purchase construction purchase price production facility puerto rico amount goodwill million cash inflow reported cash flow investing activity payment comparative column statement financial position retreated impact following noncash transaction concluded reflected statement cash flow purchase price paid cash acquisition capital expenditure finance lease amounted related cost amounting k million million recognized expense statement profit loss business combination acquisition pure technology llc acquisition tap biosystems group plc april sartorius stedim biotech acquired u startup pure technology llc december sartorius stedim biotech amount million u dollar cash payment acquired share british tap biosystems latter company based new oxford pennsylvania usa group plc company primarily specializes operating market four year design development small scale multi earned sale revenue around million parallel fermentation system particularly u dollar employee pure specializes biopharmaceutical application addition singleuse component solution biopharmaceutical company array product cover automated cell application provides product culture system bioprocessing bench top complementary group portfolio equipment biotech application bioprocess solution segment acquisition sartorius stedim biotech extends share pure remaining former current portfolio fermentation business owner also transferred sartorius stedim multiparallel small scale bioreactors range biotech latest exact time milliliter milliliter tap portfolio acquisition well purchase price depend stand gain substantial market penetration based future business performance entity sartorius stedim biotech greater sale strength purchased respective liability recognized global reach well benefit present value expected future payment synergy related product fluid disclosed financial liability amount management cell culture medium business million counterpart financial liability recognized equity according present preliminary purchase price allocation determined access method change fair value finalized follows liability posted within financial result within profit loss year consolidated financial statement note note financial statement preliminary purchase price allocation follows preliminary fair value acquisition date k intangible tangible asset inventory trade receivables asset cash cash equivalent provision liability net asset acquired purchase price goodwill noncontrolling interest goodwill recognized represents asset separately identified recognized also generate economic benefit group especially expansion group portfolio strengthened position relevant biopharmaceutical market well synergy resulting combination named sartorius stedim biotech group chosen recognize amount noncontrolling interest level prorated share net identifiable asset without goodwill partial goodwill method deferred tax recognized upon initial consolidation due structure transaction future period deferred tax liability recognized arising taxable temporary difference full amount goodwill deductible local tax purpose inclusion company scope consolidation january would significant impact group figure due low business volume activity since acquisition date acquired company contributed materially group result either transaction cost million recognized expense consolidated financial statement note note statement profit loss note statement profit loss sale revenue employee benefit expense sale revenue broken geographical item broken follows area consists following month month month month k k k k wage salary france social security germany expense retirement country benefit pension total total amount k earned operating income expense subsidiary sartorius group k month month k k turnover broken product sale amounting million service amounting currency translation gain million corresponds providing service income decrease allowance bad debt respectively million million income release use provision liability income grant functional cost income operating income statement profit loss built according cost sale format ie expense currency translation loss allocated relevant function extraordinary expense production sale marketing research allowance bad debt development general administration expense operating expense operating expense nature reconciled total operating profit loss statement nature note income expense material expense employee benefit expense follows item reported income grant discloses grant expense essentially related research development project recognized raw material supply income soon sufficiently reliable indication necessary prerequisite met item consists following income includes income acquired cell culture medium business month month k k extraordinary item amounted million purchase consumed previous year million essentially cover cost purchased service onetime expense strategic group project total integration acquisition related item consolidated financial statement note note statement profit loss financial result considering french german average tax rate impact tax legislation expected tax rate sartorius stedim biotech group month month roughly following table describes k k difference tax expense expected interest similar income income tax expense reported affiliated particular financial year company income derivative financial instrument month month financial income k k financial income expected tax expense interest similar expense difference group average income tax rate affiliated company permanent difference expense derivative financial taxfree income instrument tax exemption interest expense pension financial expense total financial expense total effective tax rate financial income includes mainly fair item contains mainly withholding tax value change liability connection tax previous year impact purchase noncontrolling interest pure french valueadded tax cotisation sur la valeur see note ajoutée de entreprises cvae expense derivative contain effect cancellation hedging relationship profit loss statement nature interest rate swap upon refinancing group financial expense include currency effect month month financial liability k k sale revenue purchase consumed income tax cost purchased service personnel cost amortization month month depreciation k k operating cost current income tax subtotal deferred tax operating profit ebit total financial income expense income tax noncontrolling interest matter principle income tax france group net profit calculated estimated taxable profit year germany rate applied taxable income income generated outside france germany taxed particular rate valid corresponding country consolidated financial statement note note statement profit loss earnings per share according ia earnings per share earnings per share class share must determined separately basic earnings per share basic eps calculated basis weighted average number ordinary share period diluted earnings per share measured taking account share subscription option outstanding end period certain group employee acquired entitlement subscribe total share december therefore diluted net earnings per share calculated basis financial year item including number existing potential future share including optional share treasury share included calculation earnings per share net profit tax k group net profit tax k earnings per share diluted earnings per share number share statutory level treasury share share buyback program dilution stock option exercised number share used earnings per share calculation future option potential option number share used diluted earnings per share calculation consolidated financial statement note note individual balance sheet item note individual balance sheet item goodwill intangible asset goodwill monitored internal management purpose may larger segment combination former sartorius biotechnology goodwill division former stedim group newly founded sartorius stedim biotech group follows goodwill strategy total solution provider customer k various interdependency within gross book value jan business lowest level goodwill currency translation monitored biopharm segment therefore change scope consolidation acquired goodwill allocated cgu acquisition gross book value dec impairment test conducted amortization impairment loss measure recoverable amount basis jan value use particular cashgenerating unit currency translation biopharm segment cash flow forecast consider amortization impairment loss previous experience generally based amortization impairment loss group management forecast period three dec five year calculation based terminal net book value dec year growth rate year rate derived market expectation goodwill forecast significant growth rate targeted k biopharmaceutical market major growth driver gross book value jan sartorius stedim biotech group aging currency translation people increase population improved change scope consolidation access drug emerging market well acquisition ongoing paradigm shift reusable product gross book value dec singleuse product utilized bio manufacturing amortization impairment loss jan biopharmaceutical industry currency translation amortization impairment loss discount rate applied correspond weighted amortization impairment loss capital cost rate recognized follows dec net book value dec tax tax tax tax item reported goodwill amount biopharm k capitalized difference asset segment resulting business combination according ia goodwill acquired business combination may amortized rather must tested impairment test result annually impairment soon recognition impairment loss context indication asset impairment various sensitivity analysis based realistic variation assumption disclosed result increase recorded concern acquisition impairment either following variation would tap biosystems acquisition refers theoretically represent breakeven point pure see note purpose impairment testing goodwill must discount rate allocated acquirer cashgenerating terminal growth rate unit cgus expected benefit cash flow synergy combination cashgenerating unit cgu represents lowest level within entity consolidated financial statement note note individual balance sheet item intangible asset patent capitalized license customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan currency translation change scope consolidation acquisition capital expenditure disposal transfer gross book value dec amortization impairment loss jan currency translation amortization impairment loss disposal transfer amortization impairment loss dec net book value dec patent capitalized license customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan currency translation change scope consolidation acquisition capital expenditure disposal transfer gross book value dec amortization impairment loss jan currency translation amortization impairment loss disposal transfer amortization impairment loss dec net book value dec consolidated financial statement note note individual balance sheet item stedim brand name acquired considered development cost k indefinite useful life therefore recognized asset k amortized foreseeable limit period capitalized development cost essentially covered brand name expected generate cost allocated staff involved rd net cash inflow group brand name raw material supply outside service tested annually impairment soon directly attributable overhead internally generated indication asset impairment intangible asset amortized according straightline method useful life integration stedim brand usually exceed five year sartorius stedim biotech brand separate measurement relevant cash flow longer amortization intangible asset allocated possible therefore separate impairment test corresponding function statement profit carried recoverability brand loss capitalized development cost amortization name considered level biopharm disclosed research development cost segment cashgenerating unit cgu customer relationship obtained part reverse acquisition stedim constitute material intangible asset book value customer relationship amounted million million year ended december remaining period useful life eight year property plant equipment factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan currency translation change scope consolidation acquisition capital expenditure disposal transfer gross book value dec depreciation jan currency translation depreciation disposal transfer depreciation dec net book value dec consolidated financial statement note note individual balance sheet item factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan currency translation change scope consolidation acquisition grant related asset capital expenditure disposal transfer gross book value dec depreciation jan currency translation depreciation disposal transfer depreciation dec net book value dec depreciation included statement profit capitalized property plant equipment include loss according use asset cost asset held finance lease amounting sale selling distribution cost research k k cost acquisition development cost general administrative expense asset total k operating expense rental payment amounting million fiscal significant million made asset leased impairment loss recognize intangible asset operating lease property plant equipment deferred tax deferred tax asset deferred tax liability dec dec dec dec k k k k intangible asset tangible asset inventory receivables current asset provision liability gross amount carry forward taxable loss offset net amount change thereof recognized profit loss consolidated financial statement note note individual balance sheet item deferred tax asset k cash flow hedge balance sheet date group unused tax actuarial gain loss loss amount carried forward million defined benefit obligation deducted future taxable profit million net investment foreign deferred tax amount reported approx operation million loss million total concerning remaining loss carried forward deferred tax amount recognized lack visibility future taxable profit inventory like deferred tax asset dec dec relation company reported loss year k k review earlier reporting year raw material supply work progress finished good deferred tax liability merchandise payment account deferred tax liability connection total intangible asset refer asset acquired business combination consequently mainly linked customer relationship dec dec k k addition group recorded deferred tax liability gross amount inventory tax amount million approx writedowns million cumulative undistributed earnings net amount inventory subsidiary million effect group considers cumulative undistributed earnings intended systematically reinvested current trade receivables subsidiary rather might used pay dividend france germany dec dec k k group recognize deferred tax liability trade receivables third remaining retained earnings subsidiary party earnings intended reinvested amount due operation dividend paid customer contract work amount dividend taxed receivables subsidiary french german taxation rule sartorius ag group applicable withholding tax furthermore trade receivables additional income tax consequence could arise case intermediate holding company therefore possible estimate amount taxable receivables subsidiary sartorius ag temporary difference undistributed earnings group item refers company sartorius group fiscal previous year tax effect hedging instrument deferred tax asset group transferred million recognition actuarial gain loss trade receivables item unrelated entity pension reserve recognized directly million factoring program consolidated equity likewise amount current group provided transferee credit income tax incurred net investment foreign guarantee part expected loss operation recognized comprehensive receivables transfer qualify income deferred current income tax derecognition ia accordingly group recognized comprehensive income continues recognize full carrying amount disclosed follows table receivables recognized cash received transfer secured borrowing consolidated financial statement note note individual balance sheet item group business area group aging trade receivables past due impaired carry longterm construction contract customerspecific contract recognized dec dec application ia construction contract based k k percentage completion method day day item amount due customer contract day work represents net amount cost incurred plus day recognized profit less recognized loss progress day billing connection construction contract total aggregate amount cost incurred recognized profit loss project progress reporting date k k project trade receivables k k advance payment k k past due reporting date valuation recorded year contract revenue allowance made material project progress k k change creditworthiness debtor could expected would pay amount trade receivables reported outstanding trade receivables yet due discernible risk covered book value trade financial asset written receivables receivables representative indication impairment fair value considering maturity date credit risk determining recoverability trade receivables group considers change financial asset credit quality date credit originally granted significant concentration dec dec credit risk due large base unrelated customer k k accordingly necessary make derivative financial provision cover risk beyond allowance already instrument considered financial asset current financial asset development trade allowance dec dec k k issued capital valuation allowance beginning year beginning fiscal year share increase year capital company ten million three derecognition hundred ninety five thousand eight hundred consumption six euro sixty six cent recovery amount previously impaired year share capital company rose foreign currency translation ten million three hundred ninety five difference thousand eight hundred six euro sixty six valuation allowance end year cent fifteen million three hundred fiftynine thousand two hundred thirty eight euro following condition meeting july board director light authorization granted extraordinary shareholder meeting hold april reduced share capital nominal amount one million thirtysix thousand two hundred thirteen euro ten cent cancelling entirety share acquired share buyback program authorized extraordinary shareholder consolidated financial statement note note individual balance sheet item meeting held april ie one million six july board director using hundred ninetyeight seven hundred ten delegation power granted share extraordinary shareholder meeting april decides carry share capital increase difference purchase price capitalization five million nine cancelled share nominal hundred ninety thousand one hundred two value difference equal sixty euro eightytwo cent million two hundred ninety thousand nine drawn issue premium set forth hundred seventysix euro ninetyseven annual account company financial cent charged period closed december approved available premium thirtyseven million extraordinary shareholder meeting held eight hundred eightyeight thousand nine hundred april twentynine euro eighteen cent balance twentytwo share capital increase carried million four hundred two thousand fortyseven increase thirtynine cent nominal euro seventynine cent amount fifteen million three hundred fifty item retained earnings nine thousand two hundred thirtyeight share comprising share capital company operation reduction share capital nominal unit value went sixtyone cent share capital amounted nine million three one euro hundred sixtynine thousand one hundred thirtyfive euro eighteen cent divided december december fifteen million three hundred fiftynine dilutive instrument share thousand two hundred thirtyeight subscription option plan share registered share nominal unit value sixtyone cent name owner least four year benefit double voting right consolidated financial statement note note individual balance sheet item dividend key figure board director submit proposal dec dec annual general shareholder meeting payment k k dividend year ended december sartorius korea biotech co ltd follows payment net dividend per sale revenue share ie total disbursement net result total asset attributed profit loss dec dec allpure technology llc number share sale revenue beginning period net result stock option exercised total asset cancellation treasury attributed profit loss share number share end period significant restriction group nominal value per share ability access use asset settle issued capital amount k liability mentioned entity noncontrolling interest pension employee benefit provision noncontrolling interest recognized statement financial position amounting k defined contribution plan refer subsidiary sartorius korea biotech pure technology llc interest sartorius sartorius stedim biotech group company korea biotech remaining subject make payment defined contribution plan exercisable call option therefore assumed primarily relating governmentrun pension plan sartorius stedim biotech control entity country percentage company pay interest pure technology social security contribution national insurance remaining share purchased sartorius contribution oldage retirement benefit cannot stedim biotech latest end reliably determined total expense recognized remaining company amounted purchase price noncontrolling interest k k entity variable depending future performance activity noncontrolling interest allocated follows respective entity dec dec k k sartorius korea biotech co ltd allpure technology llc total consolidated financial statement note note individual balance sheet item defined benefit plan measurement postemployment benefit obligation based following actuarial pension provision similar obligation assumption recognized consolidated financial statement sartorius stedim biotech group accordance actuarial principle actuarial gain loss germany shown directly comprehensive income according standard ia r actuarial loss dec dec transferred pension reserve discount rate essentially resulted change discount rate future salary increase totaled k actuarial gain k future pension increase amount k relates particular pension provision retirement pension plan france germany provision totaled k primarily relate direct commitment dec dec defined benefit pension plan discount rate commitment employee earn benefit future salary increase year service rendered company benefit future pension increase earned depend salary level age respective employee pension benefit generally funded asset amount reported statement profit assumed discount factor reflect interest rate loss comprehensive income consist paid reporting date prime following corporate industrial bond matching maturity denominated relevant currency corporate bond available matching k k longterm maturity insufficiently available current service cost matching interest rate determined past service cost extrapolation net interest expense component defined benefit cost recognized profit loss return plan asset excl interest actuarial gain loss component defined benefit cost recognized comprehensive income total consolidated financial statement note note individual balance sheet item statement profit loss current service plan asset cost disclosed according assignment employee respective function k k amount included consolidated statement plan asset jan financial position arising group obligation interest income respect defined benefit plan follows return plan asset excl interest dec dec actuarial gain loss k k group contribution payment present value obligation currency translation difference fair value plan asset employee contribution net liability employer contribution contribution plan participant change scope present value defined benefit obligation consolidation developed follows change plan asset dec k k present value obligation jan composition plan asset current service cost past service cost plan asset primarily refer insurance interest cost contract germany switzerland major equity debt investment included actuarial gain loss subsidiary south korea deposited amount currency translation difference million million local bank retirement benefit paid cash cash equivalent reporting year employee contribution contribution plan participant change present value obligation dec actuarial gain loss defined benefit obligation allocated follows k k experience adjustment change demographic assumption change financial assumption total consolidated financial statement note note individual balance sheet item sensitivity analysis sensitivity analysis presented may representative actual change defined increase decrease actuarial assumption benefit obligation unlikely change would following impact defined assumption would occur isolation one another benefit obligation furthermore present value defined benefit obligation calculated using method applied calculating defined benefit obligation liability recognized statement k financial position projected unit credit method demographic assumption life expectancy year year maturity analysis effect financial assumption undiscounted cash flow defined benefit discount rate bps bps obligation allocated maturity follows effect future salary increase bps bps dec dec effect k k future pension increase bps bps year effect year year year total k demographic assumption weighted average duration defined benefit life expectancy year year obligation year year effect financial assumption discount rate bps bps effect future salary increase bps bps effect future pension increase bps bps effect noncurrent provision payment employee early retirement plan total k k k balance jan currency translation consumption reversal addition reclassification balance dec consolidated financial statement note note individual balance sheet item payment employee early retirement plan total k k k balance jan currency translation consumption reversal addition reclassification balance dec noncurrent provision comprise mainly provision noncurrent provision reported present partial retirement employee anniversary value reporting date discount rate bonus included item employee early retirement plan obligation arise mainly german group company partial retirement plan allow employee work parttime year actual retirement provision employee beneficiary early retirement plan partial retirement maximum according ia r treatment severance period five year actuarial gain loss payment earned future period must well past service cost obligation recognized profit loss respective period recognized income expense service noncurrent liability loan borrowing balance current balance current dec dec dec dec k k k k liability bank loan sartorius ag total loan borrowing december sartorius group refinanced syndicated loan facility led bnp paribas commerzbank ag lbbw single million loan facility according loan agreement future financing group channeled parent company sartorius ag time sartorius ag signed loan agreement sartorius stedim biotech gmbh secures financing sartorius stedim biotech group long term credit volume agreement million euro interest rate variable credit margin based armslength principle see also note parallel sartorius stedim biotech group reimbursed longterm syndicated loan million euro negotiated september consolidated financial statement note note individual balance sheet item noncurrent liability noncurrent liability include liability remaining purchase price cell culture dec dec medium business company lonza amount k k k currently expected liability derivative financial paid two tranche instrument liability furthermore item includes forward liability total acquisition noncontrolling interest company pure see chapter amount k owner remaining share derivative financial instrument represent fair sell share company sartorius stedim value interest rate swap agreement context biotech group latest purchase price refinancing described designation depending performance activity interest rate swap agreement cancelled amount recognized compre hensive income posted profit loss period current provision financial current provision developed follows warranty total k k k balance jan currency translation consumption release addition change scope consolidation change balance dec warranty total k k k balance jan currency translation change scope consolidation consumption release addition change balance dec consolidated financial statement note note individual balance sheet item measuring provision recognizable financial obligation contingent obligation based past business asset liability transaction past event probably resulting cash payment resource representative like previous year significant economic benefit whose amount contingent liability contingent asset reliably estimated reported provision reported group major financial obligation refer operate lease follows provision considered result legal constructive obligation respect third dec dec party k k operate lease due within one year current liability due within year due thereafter trade payable dec dec financial instrument financial risk k k payment received account order general information trade payable third party section give overview impact payable participation financial instrument financial statement payable subsidiary sartorius ag group sartorius stedim biotech group provides total additional information balance sheet item contain financial instrument derivative measured fair value determined according marktomarket method financial liability recognized mathematical method used fair value based market data available dec dec k k time value derivative calculated reflect estimate market condition derivative financial instrument end year personnelrelated liability liability total derivative financial instrument refer fair value interest rate swap agreement foreign currency hedging transaction like forward contract mainly related u consolidated financial statement note note individual balance sheet item b class financial instrument following table compare carrying amount fair value category financial instrument reconcile balance sheet item carrying carrying amount fair value amount fair value dec dec dec dec category acc ia k k k k financial asset available sale trade receivables loan receivables financial asset loan receivables derivative financial instrument held trading derivative financial instrument hedging instrument financial asset cash cash equivalent loan receivables loan borrowing financial liability cost finance lease liability ifrs trade payable financial liability cost trade payable ifrs trade payable derivative financial instrument held trading derivative financial instrument hedging instrument financial liability financial liability cost financial liability ifrs financial liability carrying amount financial instrument category shown following table dec dec k k available sale asset loan receivables held trading asset asset held hedging instrument financial liability cost held trading liability liability held hedging instrument fair value financial instrument market price similar instrument level financial determined basis market information instrument calculated basis input factor available balance sheet date allocated derivable observable market data one three level fair value hierarchy accordance ifrs equity investment measured acquisition cost mainly investment nonconsolidated subsidiary level financial instrument calculated basis possible determine fair value reliably due price quoted active market identical asset absence active market applies mainly liability level financial instrument share nonconsolidated subsidiary assumed calculated basis input factor carrying amount correspond fair value derivable observable market data basis balance sheet date consolidated financial statement note note individual balance sheet item financial instrument carried fair value net result financial asset liability held balance sheet date derivative form trading predominantly comprises change forward contract interest rate swap agreement fair value derivative financial instrument well valuation done based quoted foreign interest income interest expense exchange rate available interest rate curve financial instrument taking consideration counterparty risk level net result liability measured amortized calculation fair value financial cost mainly comprises effect foreign currency liability amortized cost especially loan bank translation fair value change finance lease liability done level calculation based market interest rate curve total interest income expense financial asset following zerocoupon method consideration liability measured fair value without expected indicative credit spread recognition profit loss follows pure liability required disclosed amount present value expected purchase month month k k price payment noncontrolling interest company present value derived interest income expected pure sale revenue exercise interest expense date riskadjusted discount rate presented c capital risk management fair value remaining financial asset liability approximate carrying amount sartorius stedim biotech group capital account predominantly shortterm maturity managed order maximize earnings participating company optimizing ratio equity liability furthermore ensure net gain loss financial instrument group company operate premise goingconcern principle net gain loss various category financial instrument presented following financial liability detailed regarded table managed capital furthermore cash cash equivalent well equity capital month month k k goal financial risk management available sale asset loan receivables treasury department sartorius stedim financial asset biotech group centrally focused sartorius liability held trading corporate administration gmbh subsidiary financial liability cost sartorius ag centralized treasury department performs service company sartorius group including sartorius stedim biotech group net result financial asset available sale coordinate access national international mainly comprises gain loss equity investment financial market addition treasury dividend gain disposal share department monitor control financial risk internal risk reporting analyzes risk according net result loan receivables mainly degree scope essentially risk entail includes effect currency translation currency interest rate liquidity risk change allowance consolidated financial statement note note individual balance sheet item sartorius stedim biotech group strives previously established exchange rate minimize impact currency interest rate risk generally measured income expense using derivative financial instrument hedging statement profit loss transaction controlling carried different staff member moreover group addition target profit forward internal auditing department regularly monitor concluded optimize hedging transaction use financial instrument trading transaction secure right create obligation derivative financial instrument done hedging swap agreed amount foreign currency purpose corresponding euro amount fixed exchange rate several target date long profit resulting exchange transaction e management exchange rate risk exceed contractually defined limit group exposed currency risk group strategy provides hedging one third sale revenue generated u dollar one half year also hedging measure currency linked u dollar lesser reviewed regular interval order adapt extent foreign currency therefore currency fluctuation derivative financial instrument used hedge net currency exposure resulting currency balance sheet date forward contract translation sale revenue currency hedging carried amount million foreign currency option forward contract million hedge risk fluctuation used limited extent structured hedge eur usd exchange rate amount cover transaction roughly one third expected net exposure u dollar within period year furthermore forward contract secure right simultaneously japanese yen amount jpy million create obligation sell established foreign hedged jpy million currency amount exercise date specific exchange rate euro independently following table show forward transaction exchange rate actually valid date profit well target profit forward contract loss resulting difference current balance sheet date fair value dec currency volume maturity k forward contract usd q usd q usd q usd q usd forward contract jpy q jpy q jpy q jpy q jpy consolidated financial statement note note individual balance sheet item fair value dec currency volume maturity k forward contract usd q usd q usd q usd q usd q usd forward contract jpy q jpy q jpy target profit forward jpy q jpy derivative financial instrument measured variation swiss franc chf euro time acquisition cost fair value would primarily impact valuation subsequent balance sheet date change value liability connection acquisition derivative financial instrument recognized cell culture medium business lonza statement profit loss balance sheet denominated chf described note date derivative financial instrument serve increase decrease chf euro hedge cash flow risk qualified hedging would lead impact amounting million relationship exists based criterion ia increase million decrease treasury hedging valuation adjustment recognized directly equity amount recognized equity included profit loss period f interest risk management hedged transaction affect result explained note sartorius stedim biotech negative amount k paid syndicated loan raised positive impact k recognized mainly financed parent company comprehensive income cash flow hedging reserve sartorius ag major loan taken variable effective hedging relationship interest rate therefore group continues ineffective portion k posted profit exposed interest rate risk control interest loss period amount k risk appropriate ratio fixed variable transferred comprehensive income loan maintained furthermore group concluded profit loss period k interest rate hedge form interest swap cover majority loan outstanding u dollar would depreciated variable interest rate result group receives euro equity would increased particular variable interest rate valid million million result would market pay fixed interest rate increased million million following table provides overview interest hedging contract available reporting vice versa u dollar would appreciated date euro resulting impact financial result would million million comprehensive income million million consolidated financial statement note note individual balance sheet item hedging hedging fair value fair value volume volume dec dec hedged dec dec instrument k k end term interest rate k k march swap march forward swap total group hedging strategy secure roughly variable interest rate amount approx million risk exposure period hedged volume million five year dec raised loan million next five year g liquidity risk management maturity financial liability excluding derivative financial instrument show following pattern carrying amount cash flow dec dec year year year k k k k k loan borrowing finance lease trade payable liability excluding derivative financial liability carrying amount cash flow dec dec year year year k k k k k loan borrowing finance lease trade payable liability excluding derivative financial liability cash flow shown table include undiscounted expected payment connection respective financial liability including associated interest payment loan borrowing include loan raised parent company sartorius ag see note liability arising sale trade receivables factoring program initiated liability include liability acquisition cell culture medium business company lonza forward liability acquisition remaining share pure following table illustrate liquidity analysis derivative financial instrument based undiscounted cash flow consolidated financial statement note note individual balance sheet item carrying amount cash flow dec dec year year year k k k k k interest rate swap derivative carrying amount cash flow dec dec year year year k k k k k gross fulfilment forward contract payment obligation payment claim net fulfilment interest rate swap derivative group control liquidity risk maintaining credit line additional facility bank continuously tracking forecasted actual cash flow managing maturity profile financial asset liability table provides overview credit line available reporting date credit line used credit line credit line year year year interest rate unused dec k k k dec dec syndicated loan variable bilateral credit variable line fixed total credit line credit line credit line year year year interest rate used unused dec k k k dec dec loan sartorius ag variable bilateral credit variable line fixed total market interest rate percentage overall impact profit loss point higher interest expense statement tax would million derivative hedging profit loss would million instrument classified held trading million higher effect would would impact comprehensive compensated increase fair value income million interest rate swap amount million consolidated financial statement note note individual balance sheet item regard decrease interest rate base dec dec interest rate considered resulting number number option option impact financial result would million million caused outstanding beginning period valuation interest rate swap allocated period cancelled period explained note december group exercised period replaced syndicated loan agreement lapsed period intercompany loan ultimate parent company outstanding end sartorius ag credit line volume million period exercisable end period h risk associated financial instrument reporting date sartorius stedim biotech group exposed risk volatility share price sharebased payment sharebased payment relate stock option plan allocated group personnel various stock option plan outstanding december december summarized follows number number option share number number subject date initial sub number share option target total general date number scribed director number subscribed granted per number meeting board share director initial subscrip exercisable formance beneficiary authorizing granted executive bene tion fiscal year dec dec valid plan approval subscribed executive concerned ficiaries price option june july june sept june nov total number number number share number option option date initial sub number share granted subject total general date number scribed director number subscribed target per number meeting board share director initial subscrip exercisable formance beneficiary authorizing granted executive bene tion fiscal year dec dec valid plan approval subscribed executive concerned ficiaries price option june july june sept june nov total consolidated financial statement note note individual balance sheet item cost fiscal k new additional corresponding item issued capital stock option granted reserve sartorius stedim biotech share purchase option level sartorius stedim biotech majority allocated group senior shareholder sartorius ag sharebased payment exist managerial employee director fair value form socalled phantom stock unit service performed consideration allocation plan respective board member granted option measured reference fair certain number phantom stock year value option date allocation represent agreed amount money exercise order perform estimate group u stock possible four year binomialtype mathematic model depending certain requirement regarding performance sartorius ag share total fair value plan thus measured stock paid amount based share recognized expense spread full vesting price exercise date payment capped period plan expense recognized amount time share price time personnel cost offset increase reserve virtual option granted detail please cash received group upon exercise refer remuneration report fair value option recognized cash cash equivalent phantom stock unit disclosed follows fair value granted fair value number jan yearend phantom subscription particular dec stock unit price year paid exercisable k k k tranche phantom stock unit tranche phantom stock unit tranche phantom stock unit tranche phantom stock unit tranche phantom stock unit total consolidated financial statement note disclosure disclosure consolidated financial statement prepared described structure lead various relation going concern basis transaction related party transaction sartorius stedim biotech sa subsidiary presented note related party material event reporting date company eliminated consolidation disclosed note detail material event occurred reporting date transaction group related party belonging sartorius group disclosed number employee sale purchase commission average workforce employed year certain business area member sartorius group act contract manufacturer sartorius stedim biotech group vice versa respective related party transaction carried arm length principle disclosed table sale purchase general sale revenue purchase majority shareholder sartorius stedim k k biotech sa sartorius ag hold either directly indirectly subsidiary vl related party sartorius group finance sa controlling stake company equity capital voting sale revenue purchase right k k related party sartorius group organized two division sartorius group bioprocess solution mainly run sartorius stedim biotech group lab product service mainly run company sartorius certain product group sartorius stedim group structure lead fact group biotech portfolio sold sale force hold two subsidiary country sartorius entity arranging company partially share space staff sale sartorius stedim biotech group resource furthermore german group company paid commission amount million carry various central function accordingly million commission typically deliver service worldwide entity eg calculated percentage generated sale support company sartorius corporate revenue administration gmbh subsidiary sartorius ag incorporated numerous group function like group finance hr investor relation legal central marketing service charged within group significant extent also sartorius stedim biotech consolidated financial statement note disclosure management fee shareholder cost administration charge shared cost two sartorius stedim biotech sa board member described company also member sartorius ag executive board country share certain function cost paid german parent company underlying contract include mainly sublease service sartorius stedim biotech portion office space central administrative function remuneration charged sartorius accounting controlling human resource stedim biotech sa million management respect relevant charged sartorius stedim biotech gmbh company charge rent salary social security cost million expense service well pro rated profit margin service provide shareholder function like group financial reporting compliance investor relation significant contract context one performed mentioned sartorius sartorius stedim biotech gmbh germany corporate administration gmbh germany sartorius corporate administration gmbh service charged sartorius stedim company provides central service biotech sa amount million administrative function sartorius stedim million biotech gmbh group company calculation service fee typically includes surcharge total cost surcharge shareholder loan compliant arm length principle routine task following oecd eu guideline service described note sartorius stedim biotech approx million provided sartorius group raised loan parent company stedim biotech gmbh million sartorius ag credit million amount cover following function current utilization approx million charged interest based variable interest rate plus marketing communication ebusiness business armslength credit margin development environment health security factory maintenance finance human resource information technology central service general organization compensation key management personnel executive board management received following remuneration shortterm postemployment longterm termination sharebased total benefit benefit benefit benefit payment k k k k k k information please refer chapter corporate governance see page consolidated financial statement note statutory auditor report consolidated financial statement statutory auditor report consolidated financial statement free translation english statutory ii justification assessment auditor report consolidated financial statement issued accordance requirement article l french language provided solely convenience english speaking user statutory auditor report includes french commercial code code de commerce information specifically required french law report relating justification assessment whether modified information presented bring attention following matter opinion consolidated financial statement includes note accounting policy assumption explanatory paragraph discussing auditor assessment estimate consolidated financial statement certain significant accounting auditing matter assessment made purpose issuing audit refers significant judgment estimate opinion consolidated financial statement taken whole made management particularly concerning provide separate assurance individual account capitalization research development caption information taken outside consolidated expenditure impairment test goodwill financial statement report also includes information relating asset indefinite useful life specific verification information given group management report report read conjunction construed accordance french law periodend company systematically professional auditing standard applicable france performs impairment test goodwill asset indefinite useful life also assesses whether year ended december indication loss value longterm asset according term condition defined shareholder note goodwill intangible asset compliance assignment entrusted u consolidated financial statement annual general meeting hereby report year ended december work consisted assessing data audit accompanying consolidated financial assumption judgment estimate statement sartorius stedim biotech based reviewing test basis calculation justification assessment performed company comparing accounting specific verification required law estimate previous period corresponding consolidated financial statement achievement examining procedure implemented approved board director role management approve estimate verifying express opinion consolidated financial note consolidated financial statement statement based audit provide appropriate disclosure assumption option adopted company opinion consolidated financial statemets assessment made part audit conducted audit accordance professional consolidated financial statement taken whole standard applicable france standard require therefore contributed opinion formed plan perform audit obtain reasonable expressed first part report assurance whether consolidated financial statement free material misstatement audit iii specific verification involves performing procedure using sampling required law also verified technique method selection obtain accordance professional standard applicable audit evidence amount disclosure france information presented group consolidated financial statement audit also includes management report evaluating appropriateness accounting policy used reasonableness accounting estimate matter report fair made well overall presentation presentation consistency consolidated consolidated financial statement believe financial statement audit evidence obtained sufficient appropriate provide basis audit opinion marseille february opinion consolidated financial statement french original signed give true fair view asset liability financial position group december statutory auditor result operation year ended accordance international financial ernst young audit deloitte associés reporting standard adopted european union xavier senent christophe perrau annual financial statement sartorius stedim biotech sa note annual financial statement ssb sa note annual financial statement annual financial statement parent company balance sheet asset thousand depreciation amortization gross provision net net dec dec dec dec intangible asset property plant equipment financial investment total noncurrent asset inventory work progress receivables trade receivables third party receivables marketable security deposit cash equivalent total current asset prepaid expense currency translation adjustment total asset parent company balance sheet equity liability thousand dec dec share capital share premium reserve retained earnings carried forward profit period regulated provision total equity provision liability charge total provision liability charge loan borrowing trade payable tax social charge payable liability noncurrent asset liability total liability currency translation adjustment total equity liability annual financial statement ssb sa note annual financial statement parent company income statement thousand dec dec sale revenue inventory movement capitalized production cost depreciation amortization reversal operating income expense reallocation purchase consumed external charge service tax duty personnel cost addition amortization depreciation provision operating expense operating profit ebit net financing income expense profit loss ordinary activity exceptional income expense income tax net profit loss annual financial statement ssb sa note annual financial statement activity materiel event difference purchase price exercise cancelled share nominal value difference equal sixty sartorius stedim biotech sa includes million two hundred ninety thousand nine activity holding sartorius stedim biotech hundred seventysix euro ninetyseven group ownership share subsidiary also cent charged cover real estate related activity holding available premium thirtyseven million eight manufacturing activity site aubagne hundred eightyeight thousand nine hundred therefore sartorius stedim biotech sa present twentynine euro eighteen cent income statement including balance twentytwo million four hundred two thousand fortyseven income expense rental business euro seventynine cent item retained earnings income expense arising holding activity mainly dividend operation reduction share capital le share capital amounted nine million three hundred sixtynine thousand one hundred thirtyfive sartorius stedim biotech sa share capital euro eighteen cent divided fifteen million three hundred fiftynine beginning fiscal year share thousand two hundred thirtyeight capital company ten million three share nominal unit value sixtyone cent hundred ninety five thousand eight hundred six euro sixty six cent increase share capital year share capital company rose ten million three hundred ninety july board director using five thousand eight hundred six euro sixty delegation power granted six cent ten million four extraordinary shareholder meeting april hundred five thousand three hundred forty decides carry share capital increase eight euro twenty eight cent capitalization five million nine hundred stock option exercised reduced ii ninety thousand one hundred two euro nine million three hundred sixtynine thousand eightytwo cent drawn one hundred thirtyfive euro eighteen cent issue premium set forth rose iii fifteen million annual account company financial three hundred fiftynine thousand two hundred period closed december approved thirtyeight euro following extraordinay shareholder meeting held condition april reduction share capital share capital increase carried increase thirtynine cent nominal meeting july board amount fifteen million three hundred fifty director light authorisation granted nine thousand two hundred thirtyeight extraordinary shareholder meeting hold share comprising share capital company april reduced share capital nominal nominal unit value went sixtyone cent amount one million thirtysix thousand two one euro hundred thirteen euro ten cent cancelling entirety share acquired share buyback program accounting principle method authorised extraordinary shareholder meeting held april ie one million six parent company financial statement year hundred ninetyeight seven hundred ten ended december prepared share specified presented accordance french accounting rule amount share represents less ten per cent compliance principle prudence share capital company reporting distinct financial year pre date operation sumption going concern annual financial statement prepared accordance provision french commercial code accounting annual financial statement ssb sa note annual financial statement decree november crc regulation property plant equipment june revision french chart account property plant equipment ppe recognized acquisition value including installation sartorius stedim biotech sa listed compartment cost asset euronext paris stock exchange isin fr code also prepares consolidated financial depreciation calculated standard statement accordance ifrs standard economic life asset using straightline adopted european union december method noncurrent asset depreciated noncurrent asset straightline basis using following indicative period use noncurrent intangible tangible asset valued acquisition cost excluding cost incurred building twenty forty year acquisition improvement fixture fitting ten fifteen year intangible asset property plant equip plant equipment four ten year ment company applied french regulation crc office equipment three five year recodified article regulation motor vehicle four five year crc relative amortization depreciation impairment asset according property plant equipment valued component approach acquisition cost less depreciation impairment reported ongoing basis intangible asset financial investment following thus valuated heading incorporation cost patent software investment relate mainly shareholding subsidiary treasury share held within asset amortized straightline basis scope share buyback program using following indicative useful life recorded acquisition cost including fee linked acquisition incorporation cost one five year software one three year writedown provision may established take patent twenty year account particular either stock exchange price underlying asset subsidiary part implementation integrated software financial position prospect direct labor cost concerned included amount capitalized cost function time shareholding subsidiary subject impairment elapsed test intangible asset valued acquisition cost less amortization impairment reported ongoing receivables payable basis receivables payable recorded nominal value receivables whose collection doubtful subject provision doubtful debt annual financial statement ssb sa note annual financial statement noncurrent asset thousand intangible asset gross value dec increase decrease dec incorporation cost patent software license business goodwill intangible asset progress total amortization depreciation net amount property plant equipment gross value dec increase decrease dec land building plant equipment property plant equipment progress total amortization depreciation dec addition release dec building plant equipment total property plant equipment net increase tangible asset includes fixture fitting amount k asset construction new building acquired leasing contract amount k annual financial statement ssb sa note annual financial statement financial investment investment dec increase decrease dec shareholding writedown shareholding deposit guarantee treasury share writedown treasury share total following included financial meeting july board investment director light authorization granted extraordinary shareholder meeting held april share capital sartorius stedim reduced share capital nominal amount bioprocess sarl tunisian company one million thirtysix thousand two hundred thirteen euro ten cent share capital sartorius stedim cancelling entirety share acquired biotech gmbh company governed german law share buyback program ie one million six following merger sartorius stedim hundred ninetyeight thousand seven hundred ten group june share share capital sartorius stedim treasury share item corresponded aseptics sa french company acquired share repurchased average price euro total amount share capital sartorius stedim fmt therefore reduced amount sa french company created connection contribution asset transfer investment k trade receivables thousand maturity receivables yearend thousand type receivable net amount less year year deposit guarantee noncurrent asset advance payment account trade receivables personnel social security tax duty group receivables current asset prepaid expense total receivables annual financial statement ssb sa note annual financial statement group item receivables group subsidiary k relates current account cash advance provided sartorius stedim biotech gmbh sartorius stedim fmt sa sartorius stedim france tax duty k item primarily entail net tax receivable including french tax relief system k vat receivables maturity liability yearend thousand less type liability net amount year year year loan borrowing credit institution originally less year originally year current bank overdraft accrued interest trade payable including bill exchange advance payment account order tax social security payable liability noncurrent asset group associate total liability accrued expense included account represented k concerned following item type expense dec accrued banking charge supplier invoice received paid vacation including social charge bonus including social charge profit sharing social security payable tax payable employee profit sharing total charge payable parent company statement change exercise stock option resulting issue equity thousand share par value total k equity k share premium associated share capital increase december share capital k comprising share par value reduction share capital cancel treasury share amount change equity result k please refer part material event following event exercise annual financial statement ssb sa note annual financial statement increase share capital amount allocation retained earnings carried forward k modify nominal value share k please refer part materiel event exercise paid legal reserve k annual general shareholder meeting april dividend total k net dividend per approved appropriation net profit share paid treasury share excluded year k follows equity appropriation appropriation appropriation appropriation profit profit profit profit change increase decrease total number share share capital share premium merger premium legal reserve reserve balance carried forward dividend paid net profit appropriated profit reporting year regulated provision total stock option number share subscription option vested exercised date part policy motivating group senior executive sartorius stedim biotech sa granted potential stock option issued stock option number employee depending achievement future target risk provision thousand provision provision addition release provision type provision dec dec regulated provision accelerated amortization depreciation subtotal provision liability charge exchange risk cost taxation subtotal grand total annual financial statement ssb sa note annual financial statement market risk exposure net impact according consolidation rule french tax integration operating cash flow risk regime tax relief income k amount income tax fiscal settled december net amount sartorius stedim biotech sa tax foreign currency current asset liability integration regime k current future tax position thousand future income tax position result january company chose adopt tax paid advance expense recognized french tax integration regime within fiscal year deductible subsequent framework tax group lead company fiscal year group sartorius stedim biotech sa member company tax integration group tax paid advance unrecognized unrealized tax relief sartorius stedim aseptics sa gain sartorius stedim france sa sartorius stedim fmt sa sartorius stedim financière sa deferred tax recognized balance sheet member company report income tax integration tax regime parent temporary difference taxable income corporation benefit tax relief related expense follows consolidating gain loss member company contribution future tax position asset transfer dec increase solidarity contribution net movement currency translation difference employee profit sharing depreciation customer inventory total increase decrease solidarity contribution net movement currency translation difference employee profit sharing depreciation customer inventory total decrease future tax position increase solidarity contribution net movement currency translation difference employee profit sharing depreciation customer inventory total increase decrease solidarity contribution net movement currency translation difference employee profit sharing depreciation customer inventory total decrease future tax position annual financial statement ssb sa note annual financial statement operating income thousand sale revenue operating segment dec dec operating segment service total sale revenue geographical region dec dec geographical region france export eu country north american continent total sale revenue corresponds rent paid entity sartorius stedim fmt sa use premise located aubagne within operational activity breakdown income tax thousand dec dec profit income tax profit profit income tax tax charge tax tax charge profit tax gross taxable income exceptional income expense french tax integration relief net taxable income information director remuneration remuneration paid member board director director meeting attendance fee amounted k fee related fiscal year paid meeting attendance fee paid sartorius stedim biotech sa general management company fiscal part executive board remuneration recharged sartorius stedim biotech sa amount k annual financial statement ssb sa note annual financial statement offbalance sheet commitment financing group channeled thousand parent company sartorius ag time sartorius ag signed loan agreement dec dec sartorius stedim biotech gmbh secures type commitment comment financing sartorius stedim biotech group commitment given long term credit volume agreement guarantee bilateral million euro interest rate variable credit line credit margin based armslength principle see guarantee currency also note hedging contract commitment renting leasing parallel sartorius stedim biotech group commitment received reimbursed longterm syndicated loan contractual loan million negotiated september capacity credit institution commitment given concern company sartorius stedim biotech gmbh december sartorius group refinanced commitment connection lease syndicated loan facility led bnp paribas com summarized following table merzbank ag lbbw single million loan facility according loan agreement future year year year leasing k k k total buyback value tangible asset building improvments total payment cumulatives depreciation cumulative leasing historical value year payment year depreciation tangible asset building improvments total building operational st january information related party thousand affiliate parent company sartorius ag company owned sartorius stedim biotech sa sartorius stedim fmt sa sartorius stedim bioprocess sarl sartorius stedim aseptics sa sartorius stedim biotech gmbh company sartorius stedim biotech sa consoli dated financial statement sartorius ag weender landstrasse goettingen germany annual financial statement ssb sa note annual financial statement following find table main amount related party item dec dec investment trade receivables receivables trade payable liability income investment financial income finance expense annual financial statement ssb sa note annual financial statement following find table subsidiary shareholding reserve share loan premium change sale retained standing exvat earnings deposit share ownership book value advance financial net dividend dec capital appropriation share held granted pledge year profit received gross net sartorius stedim biotech gmbh euro sartorius stedim fmt sa euro sartorius stedim bioprocess sarl dinar euro sartorius icr ruble euro sartorius stedim aseptics sa euro reserve share loan premium change sale retained standing exvat earnings deposit share ownership book value advance financial net dividend dec capital appropriation share held granted pledge year profit received gross net sartorius stedim biotech gmbh euro sartorius stedim fmt sa euro sartorius stedim bioprocess sarl dinar euro sartorius icr ruble euro sartorius stedim aseptics sa euro annual financial statement ssb sa note statutory auditor report financial statement statutory auditor report financial statement free translation english report issued french relating justification assessment provided solely convenience englishspeaking user report read conjunction bring attention following matter construed accordance french law professional auditing standard applicable france note financial statement set rule accounting method relative year ended december valuation investment treasury share within scope assessment rule shareholder accounting principle company verified appropriateness accounting compliance assignment entrusted u method specified information annual general meeting hereby report provided note financial statement year ended december made sure correct application audit accompanying financial statement assessment made part audit sartorius stedim biotech financial statement taken whole justification assessment therefore contributed opinion formed specific verification information required expressed first part report law iii specific verification information annual financial statement approved board director also performed accordance professional standard applicable france role express opinion financial specific verification required french law statement based audit matter report fair presentation opinion financial statement consistency financial statement information given management report conducted audit accordance board director document addressed professional standard applicable france shareholder respect financial position standard require plan perform audit financial statement obtain reasonable assurance whether financial statement free material misstatement concerning information given accordance audit involves performing procedure using requirement article l french sampling technique method selection commercial code code de commerce relating obtain audit evidence amount remuneration benefit received director disclosure financial statement audit also commitment made favor includes evaluating appropriateness accounting verified consistency financial policy used reasonableness accounting statement underlying information used estimate made well overall presentation prepare financial statement financial statement believe audit applicable information obtained evidence obtained sufficient company company controlling company appropriate provide basis audit opinion controlled based work attest accuracy fair presentation information opinion financial statement give true fair view asset liability accordance french law verified financial position company december required information concerning identity result operation year shareholder holder voting right ended accordance french accounting properly disclosed management report principle marseille february ii justification assessment original signed statutory auditor accordance requirement article l ernst young audit deloitte associés french commercial code code de commerce xavier senent christophe perrau annual financial statement ssb sa note statutory auditor report financial statement supplementary information supplementary information information legal nature information legal nature general information issuer corporate purpose france abroad company purpose corporate name purchase develop administrate manage corporate name company portfolio equity security security voting right sartorius stedim biotech social right company regardless activity mean including way legal deed document issued com setting new company contribution kind pany always preceded followed word type social right subscription right société anonyme abbreviation sa merger purchase social right statement share capital heading article incorporation company company bylaw manage conduct coordinate activity subsidiary affiliate applicable registered office provide said company service administrative financial accounting legal registered office aubagne france nature opinion advise order zi le paluds avenue de jouques study research necessary phone number development growth office may transferred another location generally financial commercial département french county state industrial personal real property operation adjacent county state simple decision linked directly indirectly abovementioned board director subject ratification next corporate purpose complementary annual general shareholder meeting anywhere related similar purpose may promote else france decision taken extraordinary development accomplishment thereof general shareholder meeting trade commercial register ape code board director decides transfer registered office authorized revise bylaw company registered registre du result heading article company commerce et de sociétés de marseille bylaw number rcs b economic activity code ape z holding company activity legal form applicable law inspection legal document public limited liability company joint stock company registered office company société anonyme subject french legislation particularly french commercial code reference document may viewed registered office company website website amf validity date incorporation duration present reference document bylaw statutory auditor report financial company incorporated september statement last three fiscal year although société anonyme company duration report mail document historical year effective upon registration french financial information company trade commercial register registre du commerce subsidiary last three fiscal year evaluation et de sociétés unless subject dissolution declaration made expert extension provided present company bylaw document statutory statutory heading article document found registered office supplementary information information legal nature financial year shareholder meeting financial year also referred fiscal year convocation cover period twelve month beginning january ending december year annual ordinary general shareholder meeting convened take decision result revision bylaw extraordinary specific clause company bylaw general shareholder meeting called decide authorize direct indirect revision bylaw special meeting bring together holder form share specific class share consider revision right class share decision made share may nominative bearer form according general meeting binding shareholder shareholder choice share entitled even absent dissenting legally recorded account accordance incapable incapacitated heading article french law bylaw general meeting convened board director default independent auditor person thus empowered general appropriation profit meeting held registered office place stated notice convocation heading income statement summarizes income excerpt article bylaw form expense reporting year discloses timescale notice convocation governed difference deduction amortization depre french law ciation provision profit said reporting year least must deducted annual agenda profit reduced appropriate prior loss heading point excerpt article bylaw set legal reserve deduction cease obligatory legal reserve amount one notice letter call shall indicate tenth share capital obligatory deduction indication required law particularly resume whatever reason legal reserve agenda company electronic address written fall one tenth distributable profit question shareholder may sent eventually comprises profit reporting year less prior mention obligation collect opinion loss amount transferred reserve pursuant prior approval mass security share french law company bylaw increased holder giving access share capital profit brought forward profit distributed among shareholder proportion number meeting may deliberate matter share one hold annual general placed agenda may however remove one shareholder meeting may decide distribute director time amount taken reserve available expressly indicating reserve one shareholder representing percentage transfer made however dividend disbursed share capital required law may way priority annual profit condition time limit set forth law require reporting year except reduction capital inclusion agenda draft resolution distribution may made shareholder equity fall would consequently fall accordance article r r amount capital together reserve commercial code request made french law company bylaw permit shareholder register draft resolution distribute revaluation surplus distributable agenda written question sent may corporated full part headquarters registered letter recorded company capital however transferring delivery beginning publication meeting amount reserve pursuant french law announcement day general annual general shareholder meeting may transfer meeting delay day beginning amount considers necessary available publication meeting announcement reserve ordinary extraordinary reserve carry one published day general forward meeting date reception request company taken account supplementary information information legal nature request new item agenda must legal representative shareholder motivated request register draft resolution legally incapable incapacitated individual provided text draft resolution may representing corporate shareholder take part short explanation reason request meeting whether shareholder subject justification possession representation required share capital accordance regulatory rule shareholder may also postal voting using registration form sent company according moreover accordance article l law regulation acceptable paragraph labor code request draft registration must received company three resolution made work council added day date meeting agenda sent next day following publication meeting announcement case remote voting using electronic vote proxy vote given electronic signature vote heading point excerpt article bylaw made according condition current regulation meeting unable make valid decision due lack required quorum legal document relative legal information second meeting appropriate second shareholder made available meeting adjourned called least ten day registered office company advance form first meeting provision applicable administration admission meeting power management company heading point excerpt article bylaw board director every shareholder right attend general heading point excerpt article bylaw meeting participate discussion person proxy regardless number share subject legal exemption company directed held simple proof identity ownership board director composed minimum share right participate general meeting three member maximum eighteen subject condition share must recorded name shareholder composition board director made shareholder appointed broker either balance number men woman nominative share account held company bearer share account held authorized duration company existence broker zero hour paris time third working director shall appointed renewed office day prior meeting recording registration ordinary general meeting however case share bearer share account held merger director may appointed extra authorized broker must confirmed share ordinary general meeting deciding transaction certificate provided broker share certificate must attached postal voting form director must entire term office proxy form application admission least one share pa issued name shareholder behalf shareholder represented director term office three year appointed broker certificate must also supplied shareholder wish attend general director duty shall cease end ordinary meeting person received general meeting deciding account admission pa zero hour paris time third financial year elapsed held year term working day prior meeting office director concerned expires shareholder may represented another director may renewed office may shareholder spouse partner removed office time ordinary signed civil partnership furthermore general meeting may represented moral physical person choice accordance person may appointed director article l commercial reached age appointment would result code aim representative must present one third member board valid proof proxy director exceeding age proportion supplementary information information legal nature exceeded oldest director shall automatically bound company employment agreement deemed resigned end ordinary may exceed one third director office general meeting approving account financial year exceeded organization management board director director may individual legal entity director legal entity required upon board director elect chairman appointment appoint permanent among member individual representative subject condition determines remuneration set duration obligation incurs liability chairman term office may exceed though personally director without prejudice office director several liability legal entity represented person may appointed chairman board legal entity director terminates director age chairman mandate given permanent representative shall office exceeds age shall deemed promptly notify company registered letter automatically resigned decision well identity new permanent representative applies chairman represents board director event death resignation permanent organizes directs work report representative general meeting ensures proper operation company decisionmaking body ensures one director seat become vacant particular director two general meeting due death position fulfill duty resignation board director may proceed make appointment interim basis fill case absence impediment affecting seat board appointment must made chairman board director appoints acting within three month vacancy number chairman meeting director fallen minimum article association without falling board director appoints secretary statutory minimum may chosen either among director outside secretary shall replaced simple interim appointment made manner decision board board subject ratification next ordinary general meeting failing ratification decision meeting decision board taken act accomplished shall nonetheless remain valid board director meet upon call chairman often required interest number director fall company however director representing least one statutory minimum director remaining office third member board director may required immediately call ordinary meeting precisely indicating meeting agenda call fill vacant seat board board met within last two month director appointed replacement another shall ceo chairing board director may remain office remaining term office request chairman call board meeting predecessor specified agenda director individual cannot concomitantly meeting shall take place registered office hold five seat board director location indicated notice call supervisory board sociétés anonymes call meeting indicating agenda registered office metropolitan france subject sent least day beforehand letter telegram telex exception provided law fax call may verbal meeting may held immediately director agreement company employee may appointed director unless employment agreement corresponds board director validly deliberate effective employment shall lose benefit least one half director required employment agreement number director present represented supplementary information information legal nature board decision taken majority member present represented director shall receive information necessary acting chairman casting vote performance duty may obtain document considers useful general attendance sheet shall held signed management director participating board meeting board director may give delegation internal regulation established board authority representative choice within director may provide director participating limit authority law board meeting videoconference accordance article association applicable regulation deemed present purpose calculating quorum majority board may decide creation review provision shall apply adoption committee charge studying issue following decision board chairman submits appointment remuneration removal general management chairman ceo executive vice president heading article bylaw closing annual account consolidated account mode operation preparation management report report management group accordance article l commercial code company general board director deliberation recorded management ensured responsibility minute held accordance applicable law either chairman board director minute signed acting chairman individual appointed board one two director director title ceo copy excerpt minute board choice two mode operation director deliberation shall validly certified general management made board chairman ceo director board decision concerning choice mode operation general management taken power board director majority vote director present represented shareholder third party board director determines company informed choice made board director business guideline ensures condition set forth applicable implemented subject power expressly granted regulation law shareholder meeting within limit corporate object deal matter board director may modify option chosen relating proper running company time deliberation governs affair company change mode operation general dealing third party company management shall entail modification bound even act board director article association outside corporate purpose unless prove third party knew act ultra vires depending mode exercise chosen could reasonably unaware thereof board director chairman ceo shall ensure view circumstance specified mere responsibility general management publication article association company suffice establish proof thereof ceo appointed board director board director shall carry control set duration term office determines verification deems appropriate remuneration applicable restriction power supplementary information information legal nature performance duty ceo must also chairman may give rise damage decided age age limit exceeded without valid cause course term office ceo shall deemed automatically resigned new condition exercise voting right ceo shall appointed majority quorum heading article bylaw ceo may removed office time board director removal ceo annual extraordinary general meeting also chairman may give rise damage decided quorum calculated basis share without valid cause comprising share capital special meeting basis share class concerned power ceo net share entitled voting right virtue law ceo vested broadest power act circumstance name company double voting right conferred holder ceo shall exercise power within limit registered share fully paid corporate object subject power expressly registered name holder granted law shareholder meeting least four year board director event postal voting form received ceo represents company dealing company prior meeting third party company bound even act considered calculating quorum ceo outside corporate object condition timeframe set decree unless prove third party knew act ultra vires could reasonably right vote conferred share proportional unaware thereof view circumstance capital represent equal par value specified mere publication article every share capital income right carry right association suffice establish proof thereof one vote executive vice president event share pledged voting right exercised holder security upon motion ceo whether position issuing company may validly vote share filled chairman board director subscribed acquired taken pledge another person board director may name one share taken account calculate individual responsibility assisting quorum ceo title executive vice president voting take place vote cast show maximum number executive vice president hand sitting standing roll may exceed five call decided officer meeting agreement ceo board director information voting right shall determine scope extent power granted executive vice president limit bylaw voting right set remuneration event conversion bearer form converted share immediately forfeit double voting right regard third party executive vice president event capital increase incorporation executive vice president power reserve profit share premium double voting ceo right applies new share issued allocated free charge shareholder basis existing share upon cessation duty case already carry right heading article impediment affecting ceo executive vice company bylaw revision bylaw president shall retain unless otherwise decided unanimously passed general shareholder board director office authority meeting extraordinary session august appointment new ceo may cancelled general shareholder meeting convened extraordinary session ceo may removed office time ratification special meeting board director removal ceo beneficiary shareholder supplementary information information legal nature december relevant prior loss amount share double voting right total transferred reserve required french law share thus total voting right company bylaw interim dividend may exceed profit thus defined reimbursement dividend may required shareholder unless annual general shareholder meeting held distribution made violation legal least year within six month year end provision company determines consider financial statement year subject beneficiary aware illegality extension timeframe legal decision distribution time occurred could ignore annual general shareholder meeting may nature dividend occurs validly deliberate upon first convocation share reimbursement timebarred three shareholder present represented voting post year payment dividend dividend hold least one quarter share right collected within five year payment vote quorum required upon second timebarred convocation meeting decides basis majority vote held shareholder present represented including shareholder voting post liquidity contract excerpt bylaw heading article liquidity contract concluded crossing legal threshold sartorius stedim biotech sa stockbroker gilbert dupont following asset appeared shareholder whose shareholding cross legal liquidity account december threshold defined french law either upwards downwards must declare said crossing notification number share autorité de marchés financier pursuant law force bylaw company liquidity account cash balance provide additional threshold declaration information following asset appeared liquidity account date notification identification shareholder contract implementation issued within legal regulatory framework number share company authorized seek identity bearer shareholder liquidity account cash balance payment dividend major contract annual general shareholder meeting several service agreement entered power give every shareholder part entity division sartorius group dividend payable option receiving dividend sartorius stedim biotech group order enable share provided french law cash entity division benefit certain general administrative service term term payment dividend cash set general meeting default board among service agreement service agree director cash dividend must paid within ment highest volume importance maximum nine month end place sartorius stedim biotech gmbh reporting year unless timeframe extended sartorius corporate administration gmbh legal authorization however profit may subsidiary sartorius ag sartorius corporate distributed interim dividend prior administration gmbh provides general administrative approval annual financial statement service sartorius stedim biotech balance sheet prepared end entity sartorius group service include financial year certified independent among others accounting treasury management auditor discloses company realized payroll accounting human resource system profit since close previous financial year legal service sartorius corporate administration recognition necessary amortization gmbh invoice service basis internal depreciation provision well deduction external cost incurred plus margin supplementary information information legal nature service invoiced sartorius corporate administration gmbh sartorius stedim biotech gmbh totaled million apart abovementioned service agreement contract material obligation commitment concluded outside ordinary course company business member sartorius stedim biotech group party strategy sale marketing organization within sartorius stedim biotech group towards customer create valuable longterm relationship therefore example key account management endeavor conclude longterm framework contract customer total solution provider sartorius stedim biotech strives use contract cover entire product portfolio sartorius stedim biotech fit validated process customer supplementary information information legal nature registered trademark trademark application international registration name eu germany france country designated usa australia brazil mexico uk canada sartorius stedim au ch kr ru sg trademark biotech tr vn application reg progress bx ch de e trademark biostat reg progress fr pt application hydrosart maxicaps midicaps __________ minisart sartocheck reg progress sartocon virosart bx ch de dz eg e fr hu kp li mc pt ro r sartoflow ru sd vn trademark sartopore application de bx ch ___________________ flexboy jp flexel palletank raft evam nutrikit nutripoche biosafe de dk gb ch trademark flexact au cn jp kr u application flexsafe cn jp kr mx sg tr u reg progress apart trademark mentioned sartorius stedim biotech group owner applicant different trademark various country date indicated daymonthyear supplementary information information legal nature registered trademark trademark application name japan denmark finland ireland malaysia norway sweden china argentina india taiwan sartorius trademark trademark stedim trademark trademark biotech trademark application trademark application __________ trademark biostat reg progress application reg progress hydrosart maxicaps midicaps minisart sartocheck reg progress sartocon virosart sartoflow trademark sartopore application flexboy flexel palletank raft evam nutrikit nutripoche biosafe trademark trademark flexact application application flexsafe reg progress apart trademark mentioned sartorius stedim biotech group owner applicant different trademark various country date indicated daymonthyear supplementary information special report statutory auditor related party agreement commitment special report statutory auditor related party agreement commitment statutory auditor report related party agreement commitment free translation english report issued french agreement commitment submitted provided solely convenience englishspeaking user report read conjunction con approval general meeting shareholder strued accordance french law professional standard applicable france hereby inform advised agreement commitment authorized general meeting shareholder approve financial course year submitted general statement year ended december meeting shareholder approval accordance article l french commercial code shareholder code de commerce capacity statutory auditor company hereby report certain related party agreement agreement commitment already approved commitment general meeting shareholder required inform basis hereby inform advised information provided u term agreement commitment already approved condition agreement commitment general meeting shareholder whose indicated u may identified implementation continued year performance engagement required comment whether beneficial appropriate ascertain existence agreement commitment responsibility marseille february accordance article r french commercial code code de commerce evaluate french original signed benefit resulting agreement commitment prior approval statutory audtitors addition required applicable ernst young deloitte associés inform accordance article r french commercial code code de commerce xavier senent christophe perrau concerning implementation year agreement commitment already approved general meeting shareholder performed procedure considered necessary comply professional guidance issued national auditing body compagnie nationale de commissaires aux comptes relating type engagement supplementary information resolution submitted annual combined shareholder meeting april resolution submitted annual combined shareholder meeting april resolution submitted annual ordinary concerning consolidated account approved shareholder meeting consolidated financial statement year ended december disclosed net profit first resolution k presented transaction reflected financial statement summarized approval financial statement year ended report december discharge director third resolution annual shareholder meeting accordance quorum majority requirement ordinary assignment financial result year ended meeting shareholder considered december corporate account year ended december well report board director annual shareholder meeting acting report statutory auditor concerning quorum majority requirement ordinary financial statement approved financial meeting shareholder decided assign statement year ended december follows income year ended december disclosed net profit totaling presented transaction reflected financial statement summarized report legal reserve result annual shareholder meeting grant balance resulting deduction legal reserve full unreserved discharge director execution management duty said reporting year following added balance year earlier profit carried forward annual shareholder meeting approves overall amount expense referred article would yield distributable profit general tax code amounting well total amount dividend corresponding tax reaching disbursed shareholder annual shareholder meeting recognizes term balance resulting disbursement report chairman board director composition board remaining amount application principle equal treatment carried forward next year men woman board condition board director prepares share nominal value lead organizes work well proceeding internal payment net dividend valued control risk management introduced company report statutory auditor distributed amount report share eligible allowance applied physical people residing france referred second resolution article general code tax approval consolidated financial statement dividend payed april year ended december annual shareholder meeting accordance quorum majority requirement ordinary meeting shareholder considered corporate consolidated account year ended december well report board director report statutory auditor supplementary information resolution submitted annual combined shareholder meeting april hdistributed amount three last financial seventh resolution year amounted notice element compensation due income eligible tax rebate granted financial year income mr reinhard vogt executive vice president fiscal year ended dividend distributed dec annual shareholder meeting complying dec recommendation afepmedef dec code updated june deliberating accordance quorum majority requirement ordinary shareholder meeting give favorable fourth resolution opinion element compensation due granted financial year mr reinhard approval regulated agreement referred vogt executive vice president described article l subsequent commercial k code eighth resolution annual shareholder meeting accordance quorum majority requirement ordinary notice element compensation due meeting shareholder considered granted financial year special report statutory auditor concerning mr voleker niebel executive vice president regulated agreement referred article l subsequent commercial code recognizes annual shareholder meeting complying report conclusion stating absence recommendation afepmedef concluded regulated agreement agreement code updated june deliberating accordance continued past year quorum majority requirement ordinary shareholder meeting give favorable fifth resolution opinion element compensation due granted financial year mr volker fixing overall annual amount niebel executive vice president described attendance fee board director member k annual shareholder meeging accordance ninth resolution quorum majority requirement ordinary meeting shareholder approved overall notice element compensation due annual amount attendance fee allocated granted financial year preceding financial year amounting mr oscarwerner reif executive vice president annual shareholder meeting complying sixth resolution recommendation afepmedef code updated june deliberating accordance notice element compensation due quorum majority requirement granted financial year mr ordinary meeting shareholder give favorable joachim kreuzburg chairman chief executive opinion element compensation due officer granted financial year mr oscar werner reif executive vice president described annual shareholder meeting complying k recommendation afepmedef code updated june deliberating accordance tenth resolution quorum majority requirement ordinary meeting shareholder give favorable nomination mr annemarie graffin new opinion element compensation due member board director company granted financial year mr joachim kreuzburg chairman chief executive annual shareholder meeting accordance officer described k quorum majority requirement ordinary meeting shareholder decides appoint today mr annemarie graffin born may supplementary information resolution submitted annual combined shareholder meeting april french nationality new member board fourteenth resolution director company three year period expiring end annual shareholder meeting nominating salustro reydel deputy statutory acting related approval financial auditor statement year ended december annual shareholder meeting accordance eleventh resolution quorum majority requirement ordinary meeting shareholder considered nomination mr susan dexter new member board director report decides appoint board director company today six year period annual shareholder meeting acting account annual shareholder meeting accordance year ended december salustro reydel quorum majority requirement ordinary cours du triangle immeuble le palatin meeting shareholder decides appoint paris la défense cedex deputy statutory auditor today mr susan dexter born octobre replace auditex audit whose mandate expired american nationality new member board director company three year period resolution submitted expiring end annual shareholder meeting extraordinary shareholder meeting acting related approval financial statement year ended december fifteenth resolution twelfth resolution modification article section company bylaw renewing appointment member board director carried mr oscarwerner reif² annual shareholder meeting fulfilled quorum majority requirement pertaining annual shareholder meeting accordance extraordinary meeting shareholder quorum majority requirement ordinary considered board director report meeting shareholder considered board modified bylaw project decides modify article director report decides renew today section company bylaw follows appointment member board director exercised mr oscarwerner reif new three year end article added sentence period expiring end shareholder meeting acting related approval financial applies agreement intervening statement year ended december company another one hold entire capital directly indirectly deducting thirteenth resolution minimum number share required satisfying requirement article civil code nominating kpmg statutory auditor article l l commercial code annual shareholder meeting accordance rest article unchanged quorum majority requirement ordinary meeting shareholder considered sixteenth resolution board director report decides appoint today six year period annual modification article section shareholder meeting acting account company bylaw year ended december kpmg cours du triangle immeuble le palatin paris la annual shareholder meeting fulfilled défense cedex statutory auditor replace ernst quorum majority requirement pertaining young audit whose mandate expired extraordinary meeting shareholder considered board director report modified bylaw project decides modify article section company bylaw follows supplementary information resolution submitted annual combined shareholder meeting april shareholder right participate annual shareholder meeting vote person proxy regardless number share held upon simple production proof identity ownership share right participate annual shareholder meeting evidenced book registration security name shareholder intermediary acting behalf second business day preceding meeting midnight paris time either registered security account held company bearer security account held authorised intermediary bearer security authorised intermediary must deliver certificate attendance record registration security bearer security account held intermediary must attached postal voting ballot proxy admission card request prepared shareholder name behalf shareholder represented registered intermediary certificate attendance shall also issued shareholder would like physically attend meeting received admission card midnight paris time third business day preceding meeting shareholder may represented another shareholder spouse partner signed civil partnership furthermore may represented moral physical person choice accordance article l l commercial code aim representative must present valid proof proxy legal representative shareholder lacking legal capacity individual representing shareholder legal entity participate meeting whether personally shareholder seventeenth resolution authority formality annual shareholder meeting give full authority bearer original copy extract minute present annual shareholder meeting accomplish necessary procedure supplementary information information reference document annual financial report information reference document annual financial report declaration responsibility reference document annual financial report hereby certify taken reasonable received completion letter auditor measure effect information stating audited information contained present reference document contained reference document best knowledge accordance financial position financial statement fact make omission likely affect import read document entirety certify best knowledge historical financial information presented financial statement prepared accordance document discussed auditor report applicable accounting standard give fair found page reference view asset liability financial position document profit loss company activity included consolidation february management report page present fair review development performance business financial position company activity included consolidation well description main risk uncertainty exposed joachim kreuzburg chairman board ceo supplementary information information reference document annual financial report table reconciliation heading note european regulation april european order facilitate understanding present commission column right document concerning presentation sartorius corresponding page present document stedim biotech sa table left heading part european regulation n april page person responsible person responsible information certification person responsible registering document independent auditor name address independent auditor issuer selected financial information presentation selected historical financial information every year period covered financial information risk factor information issuer history development company corporate name commercial name issuer place registration number issuer date establishment life issuer registered office legal form issuer legislation governing operation country origin address investment principal investment including amount carried overview operation principal operation principal market dependence patent license contract competition organigram organizational chart description group list subsidiary property plant equipment significant existing planned property plant equipment environmental issue analysis financial situation result financial position operating profit cash position capital issuer capital short longterm cash flow borrowing condition financial structure expected source financing research development patent license information trend profit forecast estimate applicable governing management supervisory executive body composition governing management body nature family link amongst person conviction fraud within last five year least bankruptcy sequestration liquidation member governing body indictment andor official public sanction member governing body conflict interest level governing management body remuneration benefit remuneration paid benefit kind pension retirement benefit supplementary information information reference document annual financial report heading part european regulation n april page operation governing management body expiration date current mandate term office service agreement member audit remuneration committee issuer corporate governance employee workforce end period covered historical financial information shareholding capital employee shareholding capital principal shareholder crossing threshold double voting right control business transaction related party financial information issuer asset financial situation profit historical financial information result last five year consolidated financial result statement profit loss consolidated financial statement statement financial position statement profit loss statement cash flow statement change equity note consolidated financial statement verification annual historical information independent auditor report last financial information dividend distribution policy legal arbitration procedure significant change financial commercial situation additional information share capital amount issued capital number share authorized number share issued fully paid number share issued fully paid par value per share reconciliation number share outstanding beginning end year share representing capital applicable number book value face value share held behalf issuer subsidiary issuer amount convertible security exchangeable security security warrant information term acquisition right obligation authorized unissued capital undertaking increase capital information capital member group option agreed applicable conditionally unconditionally put option history share capital period covered historical financial information memorandum article association object purpose issuer member administrative management supervisory body right preference restriction attaching class existing share action required change right shareholder applicable condition governing manner annual general meeting extraordinary general meeting shareholder called including condition admission provision issuer article association statute charter bylaw would effect applicable delaying deferring preventing change control issuer provision article association statute charter bylaw governing ownership threshold shareholder ownership must disclosed condition imposed memorandum article association statute charter bylaw applicable governing change capital condition stringent required law major contract information provided third party declaration expert declaration interest applicable document accessible public information shareholding supplementary information afep medef code afep medef code information implementation provision afep medef code relating corporate governance listed company accordance provision article corporate governance code listed company effect date hereof code listed company referring code required precisely report reference document implementation provision case nonappliance one provision company required provide understandable relevant circumstantial information according rule apply explain recommended amf recommendation n september company indicate specific table provision applied related information general table afep medef code recommendation implemented article disposition code sartorius stedim biotech board director collegial body composition organization yes half organization board work likewise membership must board represented foreign suited shareholder makeup size nature firm director proof group business particular circumstance facing international dimension publication internal rule yes internal rule organization operation described internal rule synthetized document drawn published part full company website reference year entire reference document document published website board director market communication market corporation rigorous policy communication yes press release published analyst market certain practice selective disclosure company website intended assist analyst forecast result transmitted professional prohibited distributor order assure form communication must allow everyone access effective diffusion information time investor board ensure investor receive relevant information balanced enlightens strategy development model longterm strategy corporation offbalance sheet commitment risk listed company must equipped reliable procedure identification monitoring assessment commitment risk provide shareholder investor relevant information area purpose annual report specify internal procedure set yes rating company identify monitor offbalancesheet commitment evaluate published year corporation material risk reference document company must develop clarify information provided sheet commitment shareholder investor regarding offbalancesheet commitment outlined reference material risk disclose company rating financial rating document consolidated agency well change occurred financial year account supplementary information afep medef code implemented article disposition code sartorius stedim biotech separation office chairman board director chief executive officer corporation opts separation office chairman applicable chief executive officer appropriate task entrusted chairman board director addition conferred upon law must described option uniqueness dissociation function yes explaining essential shareholder third party fully informed chairman company choice made separation office chairman chief governance internal control executive officer maintenance position single office report motivation choice governance regard addition form disclosure required regulation company situation reference document annual report may serve medium disclosure shareholder entitled board report ground justification decision board director strategy internal rule board director consider decide upon transaction genuinely strategic importance review ad hoc committee appropriate internal rule board director specify case prior approval board director required yes board director setting related principle may differ according internal rule division group concerned including rule reference document year principle material transaction outside scope firm stated strategy subject prior approval board opposite entire element director integral part board director internal rule rule according board director informed corporation financial situation cash position commitment rule related external acquisition disposal also major investment organic growth internal restructuring action board director informed timely fashion corporation cash position appropriate take decision relating funding indebtedness board director general meeting shareholder communication shareholder yes annual shareholder shareholder meeting decisionmaking body area meeting place open open stipulated law also privileged moment company engage discussion company dialogue shareholder session must occasion strategy past year activity managing body report corporation business also functioning operation board director specialized committee audit governance within company compensation etc also opportunity genuine open dialogue shareholder board director must take care infringe upon specific power shareholder meeting transaction proposes modify fact law corporate purpose company basis contract founding corporation even change corporate purpose company involved board director must refer matter meeting shareholder transaction relates material part group asset business even change corporate purpose company involved board director must refer matter meeting shareholder transaction relates material part group asset business supplementary information afep medef code implemented article disposition code sartorius stedim biotech membership board director guiding principle composition board director yes board director board consider would desirable balance within committee composed membership within committee board member woman foreign director established particular regard representation men group point woman nationality diversity skill take appropriate action willingness pursue assure shareholder market duty international growth performed necessary independence objectivity diversity board publish reference document objective method result director suggests policy matter shareholder meeting nominate two independent woman director french american within board director woman men representation yes board director give regard representation men woman objective particular attention board shall reach maintain percentage least woman men representation woman within period three year least woman within board period six year shareholder meeting director suggests date listing company share regulated market shareholder meeting whichever later director permanent representative legal nominate two independent entity director representing employee shareholder taken woman director french account order determine percentage case american within board director representing employee director board comprises fewer nine member difference end six year number director gender may excess two specific assignment entrusted director applicable board decided confer special task upon director relate governance shareholder relation particular appointing lead director vice president task resource prerogative access must described internal rule representation employee representation employee applicable way director director representing employee company fall shareholder director representing employee entitled vote within scope board director collegial body assigned duty obligation appoint acting time interest company director director may selected board participate committee without prejudice legal provision specific director representing employee shareholder director representing employee right subject obligation particular relation confidentiality take responsibility member board minority shareholder desirable within board representative various yes company main specific group interest board could become shareholder take battleground vested interest instead representing shareholder responsibility conformity whole regard shareholder corporation controlled majority shareholder group direct distinct board shareholder acting concert latter assumes specific responsibility director one monitor shareholder direct separate like conflict interest board director majority shareholder must take particular care avoid possible conflict interest secure transparency information provided market fairly take interest account supplementary information afep medef code implemented article disposition code sartorius stedim biotech independent director independent director yes sartorius stedim biotech although quality board director cannot defined simply company controlled reference percentage independent director director sartorius ag suggests required honest competent active regularly attending nominate additional two involved important board director presence director significant proportion independent director order shareholder meeting satisfy expectation market also order improve independent director quality proceeding percentage would increase higher independent director account half member board widely held corporation without controlling shareholder controlled company independent director account least third director representing employee shareholder director representing employee taken account order determine percentage qualification independent director discussed appointment committee reviewed every year board director prior publication annual report board director must upon motion appointment yes intendant director committee review individually position member qualification reviewed basis criterion mentioned notify conclusion regularly board shareholder annual report shareholder meeting director nomination director appointed identification independent director additional two independent carried corporation management board director approved shareholder meeting board director may consider although particular director director meet criterion cannot held independent board director could owing specific circumstance person company thee defined ownership structure reason conversely board may consider director meet criterion nevertheless independent director criterion reviewed committee board order director qualify independent prevent risk conflict interest director management corporation group following employee executive director company yes independent director employee director parent company latter qualification reviewed yearly consolidates position previous board director five year shareholder meeting approves nomination executive director company corporation additional independent hold directorship directly indirectly employee director appointed executive director company currently office held office less five year director director board director could defined customer supplier investment banker commercial banker material company group significant part whose business corporation group account evaluation significant relationship company group must debated board criterion lead evaluation must explicitly stated reference document related close family tie executive director yes independent director qualification regularly auditor corporation within previous five year reviewed board director director corporation twelve year although may executive director chairman board may considered independent company justify based criterion set supplementary information afep medef code implemented article disposition code sartorius stedim biotech evaluation board director assessment board work yes year member sound corporate governance board director evaluate board director formal ability meet expectation shareholder entrusted autoevaluation board authority direct corporation reviewing time time performance based specific membership organization operation implies corresponding criterias functioning review board committee modality effective contribution member accordingly board think desirable balance membership committee created member consider time time adequacy organization operation performance task meeting board committee information board director meeting yes reference document number meeting board director committee indicates number held past financial year mentioned annual meeting level report must also provide shareholder relevant attendance past year information relating director attendance meeting board director frequency duration meeting board director held meeting allow indepth review discussion matter level attendance subject board authority applies meeting board committee audit compensation appointment nomination etc audit committee held meeting proceeding unambiguous minute meeting level attendance summarize discussion specify decision made particular importance since provide necessary record board done order carry duty without remuneration committee held unnecessarily detailed mention briefly question raised meeting level reservation stated attendance director access information law recognizes principle chairman chief yes internal rule includes executive officer bound disclose director document modality right information required performance duty information confidentiality manner right disclosure exercised related director confidentiality duty set internal rule board director board responsible necessary determining relevance document requested corporation must also provide director appropriate information throughout life corporation meeting board importance urgency information requires ongoing disclosure also include relevant information including criticism relating corporation article press financial analyst report conversely director bound request appropriate information consider necessary perform duty accordingly director considers able take part proceeding appropriate information bound say board order obtain necessary information director opportunity meet corporation principal executive manager even outside presence executive director latter case given prior notice supplementary information afep medef code implemented article disposition code sartorius stedim biotech director training director training yes start director one major condition appointing director function different training ability cannot expected priori every director session offered order specific prior knowledge corporation organization activity help accomplish director accordingly provided considers mission best applies necessary supplementary training relating corporation specialized member specific feature business market committee audit committee member provided time appointment information relating corporation specific accounting financial operational feature theration director term office time timescale term office yes conformed code without affecting duration current term duration director recommendation duration term office set bylaw status exceed maximum office term year four year shareholder called express director renewed election sufficient frequency three nomination director agreed next shareholder meeting renewed term staggered avoid replacement entire body favor smooth replacement director information director yes information annual report detail date beginning expiry iterated director director term office make existing staggering clear biographical presentation also mention director addition list office board director composition position held corporation nationality age principal position list name member board committee meeting shareholder asked appoint director extend term booklet notice calling meeting shareholder must contain biographical notice outlining curriculum vitae addition item required statute even though required law imperative bylaw yes status title iii art internal rule set minimum number share corporation within reference document concerned director must personally hold must appear provides information annual report andor booklet notice calling meeting shareholder committee board existence composition committee yes board director number structure committee determined compensation committee board however addition task assigned audit committee duty select law recommended compensation appointment suggest nomination new director executive director subject preparatory work director specialized committee board director board appointed specialized committee address particular right obligation concern creation committee shall event remove specialized committee matter purview board sole statutory specified internal rule decisionmaking authority allowed cause division within inherent committee board collegial body remain accountable performance duty committee act place board rather extension board facilitating work reason particular quality report committee board inclusion annual report description committee activity stressed committee board may contact exercising duty internal rule complies principal manager corporation informing chairman majority board director subject reporting back board recommendation formulated contact afep medef code committee board may request external technical study relating matter within competence corporation expense informing chairman board director board director subject reporting back board thereon event committee recourse service offered external consultant eg compensation consultant order obtain information compensation system level applicable main market committee must ensure consultant concerned objective supplementary information afep medef code implemented article disposition code sartorius stedim biotech committee must provided internal rule setting duty mode operation committee internal rule approved board may integrated internal rule board set separate provision committee secretariat task shall undertaken person nominated chairman committee agreement chairman existence crossdirectorships committee avoided audit committee existence yes board director board appoint audit committee duty audit committee inseparable board director legally bound approve corporate account prepare consolidated account approving account main occasion board assumes two essential duty review management performance verification reliability clarity information provided shareholder market composition yes referred audit audit committee member competent finance committee chairman financial accounting accountancy competency within description director background proportion independent director audit committee excluding audit committee director representing employee shareholder director representing composed employee taken account least equal two independent director third committee include executive director including chairman appointment extension term office audit committee chairman proposed appointmentsnominations committee specially reviewed board also desirable time review account yes audit committee committee consider major transaction connection examines least trimestral conflict interest could arisen basis main financial operation analysis time available reviewing account sufficient less two day review board account statutory auditor submit review account audit committee accompanied conclusion twice year presentation statutory auditor stressing essential point audit committee result statutory audit particular adjustment resulting audit significant weakness internal control identified auditor work also accounting method chosen also accompanied presentation chief financial officer describing corporation risk exposure material offbalancesheet commitment committee must interview statutory auditor regularly including yes audit committee meet interview without executive manager present statuary auditor least twice year statutory auditor must particular interviewed committee meeting dealing evaluation process preparing financial information review account order report execution task conclusion work committee steer procedure selection statutory yes audit committee pilot auditor submit recommendation board director regarding selection statuary statutory auditor proposed appointment shareholder auditor meeting committee shall suggest board procedure selection particular need make call tender must supervise call tender approve specification choice firm consulted making sure selection result appointment best bidder lowest bidder committee particular receive year following order respond arisen information statutory auditor subject green line european community group statement independence decided anticipate amount fee paid network statutory auditor problematic realizing tender company controlled company entity controlling october november company respect service directly related statutory december suggesting auditor assignment change statuary auditor information concerning service supplied respect task submitted directly related statutory auditor engagement shareholder meeting supplementary information afep medef code implemented article disposition code sartorius stedim biotech committee review statutory auditor risk weighing independence protection measure taken order reduce risk committee must particular ensure amount fee paid company group share fee turnover firm network likely impair statutory auditor independence functioning yes audit committee audit committee operating report board director secretary take minute provide board full information thereby facilitating latter meeting summary proceeding deliberation included reference document annual report include statement audit committee activity past financial year yes audit committee working method audit committee interview statutory auditor also intervention person responsible finance accounting treasury matter financial director risk possible hold interview committee wish without director qualified presence corporation executive management people specified within committee review consolidation scope applicable chairman internal control reason excluding certain company report committee able call upon outside expert needed making sure requisite skill independence regard effectiveness internal control risk management system committee ensure system exist implemented corrective action taken event significant weakness flaw end must informed main finding statutory auditor internal audit must interview responsible internal audit risk control give opinion organization service informed program internal audit receive internal audit report regular summary report committee shall examine risk material offbalancesheet commitment assess importance failure weakness communicated necessary inform board committee charge appointment nomination composition yes remuneration appointment nomination committee play essential role committee also charge shaping future company charge preparing nomination order future membership leadership body accordingly board avoid multiplication appoint member committee appointment specific committee nomination director executive director may may separate compensation committee appointment nomination committee separate applicable compensation committee recommendation relating latter membership mode operation also applicable see hereafter however unlike provision governing compensation committee chief executive officer shall associated appointment nomination committee proceeding event office chairman board director chief executive officer separate chairman may member committee supplementary information afep medef code implemented article disposition code sartorius stedim biotech allocation yes compensation committee charge submitting proposal board committee competency reviewing detail factor take account research examine select proceeding desirable balance membership board regard new application makeup change ownership corporation stock nomination board balance men woman board identification director evaluation potential candidate desirability extension term particular organize procedure nomination future independent director perform review potential candidate latter approached way committee selection nomination ad hoc committee established hand plan new member administrator committee charge compensation composition yes member committee include executive director compensation committee nonexecutives composed independent member majority independent director chaired independent director advised employee director member committee committee operating report board director provide yes audit committee board full information thereby facilitating proceeding secretary take minute report proceeding compensation committee meeting summary presented board deliberate issue relating deliberation supplied within compensation executive director without presence latter reference document annual report include statement compensation committee activity past financial year remuneration committee must ensure board director yes remuneration committee given best condition determine compensation working method specified benefit accruing executive director decision made internal control chairman board director report furthermore committee must informed compensation policy applicable principal executive manager executive director company purpose executive director attend meeting compensation committee number directorship executive noexecutive director executive director hold two directorship yes chairman exercise listed corporation including foreign corporation affiliated actually term office within group must also seek opinion board surveillance control carl accepting new directorship listed corporation zeiss ag office term within consultative committee case separate chairman board may draw specific recommendation issue taking account particular situation mission conferred himher noexecutive director hold four directorship listed corporation including foreign corporation affiliated group recommendation apply time appointment next renewal term office director keep board informed directorship held company including participation committee board company france abroad supplementary information afep medef code implemented article disposition code sartorius stedim biotech ethical rule director director compensation member board director compensation yes nonexecutives shall recalled method allocation director member committee compensation total amount determined meeting benefit attendance fee shareholder set board director take account take account way shall determine director actual attendance effective participation meeting board committee therefore include significant member different variable portion meeting recommended afep medef additional fee allocated specialized committee member natural director attendance meeting specialized committee give rise additional amount director fee similarly undertaking individual task vice president lead director may give rise additional fee payment extraordinary compensation subject application procedure related party agreement amount director fee reflect level responsibility assumed time need apply duty board must review adequacy level director fee regard duty responsibility placed director rule allocation director fee individual amount yes attendance fee payment thereof made director set annual stated specified clearly report reference document chairman report company corporate governance internal control termination employment contract case appointment executive director compensation executive director principle setting executive director compensation role yes compensation policy board director deliberated remuneration board director supervisory board responsible determining committee submission compensation executive director based proposal made board oscar werner reif compensation committee volker niebel joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech order determine said compensation relevant board committee must take account following principle comprehensiveness balance benchmark consistency understandability rule proportionality compensation policy allocation stock option grant free share yes compensation policy compensation executive director must appropriate balanced deliberated remuneration fair compensation must strengthen sense solidarity committee submission motivation within company board oscar werner reif volker niebel market benchmark may sole one executive director compensation depends work carried result joachim kreuzburg reinhard vogt representing group obtained also responsibility taken executive director bear sartorius ag compensation ultimate responsibility management team warrant higher compensation general policy award stock option policy deliberated decided level mother performance share debated within compensation house sartorius stedim biotech committee basis recommendation committee approved board director supplementary information afep medef code implemented article disposition code sartorius stedim biotech board director must monitor evolution component compensation several year regard corporate performance fixed compensation yes compensation policy fixed part may calculated differently depending whether deliberated remuneration executive director followed continuous career within company committee submission recruited outside company board oscar werner reif volker niebel unless principle fixed compensation may reviewed relatively exceptional element long interval eg every three year evolution stay moderated increase compensation must linked event affecting one year another one company must take account performance company applies component compensation including fringe benefit afep medef recommendation regard increase however company opts annual increase executive moderation director fixed compensation increase must moderated must respect principle consistency mentioned joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech variable compensation yes variable compensation board may decide award executive director annual multiannual policy reviewed variable compensation remuneration committee oscar werner reif volker niebel different form variable compensation may cumulative annual variable compensation cumulative amount must decided basis aforementioned multiannual set principle particular comprehensiveness proportionality company unless exceptional variable compensation must determined board director element evolution stay fixed period rule governing determination variable moderated one year compensation must consistent annual multiannual another one company applied assessment executive director performance company afep medef strategy variable compensation reward director recommendation regard performance progress company period increase moderation consideration share price must criterion measuring performance stock market price constitute element compensation variation joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech term variable compensation must understandable shareholder clear complete information must provided year annual report variable compensation must subject achievement precise course predetermined objective quantitative criterion must simple relevant objective measurable suited corporate strategy criterion must regularly reviewed order avoid adhoc adjustment also necessary pay considerable attention possible threshold effect generated quantitative criterion highly specific circumstance may warrant award extraordinary variable component qualitative criterion must defined precisely variable part qualitative criterion used limit must determined qualitative part allowing applicable exceptional circumstance taken consideration variable compensation must set level balanced relation fixed part variable part maximum percentage fixed part adapted business conducted company predefined board except justified case award variable compensation may restricted executive director event executive director leaf completion term envisaged assessment performance criterion payment variable part compensation must ruled unless exceptional circumstance justified board supplementary information afep medef code implemented article disposition code sartorius stedim biotech benefit taking position yes isnt benefit benefit taking position may granted new executive taking function director come company outside group case amount must made public determined nocompetition benefit yes executive director context implementation procedure related party post contractual non transaction stipulated law conclusion nocompetition competition obligation agreement must subject substantial reflection compensation accordance german law committee due fact sartorius stedim biotech sa controlled german company obligation last two year director left group time noncompetition clause waived terminated director claim half latest remuneration received company board must authorize conclusion nocompetition agreement length requirement nocompetition amount benefit taking account actual effective scope nocompetition requirement decision board must made public board anticipate conclusion agreement mention allows board cancel agreement director leaf board must announce whether nocompetition agreement upheld time director leaf particular director leaf company claim claime²d pension right event nocompetition payment exceed ceiling two year compensation fixed variable termination benefit also paid aggregate two benefit must exceed ceiling see supplementary pension scheme mentioned article l yes supplementary pension social security code senior executive executive director must scheme ae according comply condition prevent abuse responsibility executive director company supplementary pension scheme defined benefit must subject condition beneficiary must director employee company claiming pension right pursuant applicable rule order prevent abuse necessary impose certain additional rule without prejudice scheme closed new beneficiary may altered relevant benefit must taken account overall determination compensation basis general principle stated group potential beneficiary must materially broader sole executive director beneficiary must meet reasonable requirement seniority within company least two year determined board director benefit payment pension plan defined benefit year increase potential right shall progressive relation seniority scheme shall account percentage limited beneficiary compensation progression must described benchmark period taken account calculation benefit must cover several year necessary avoid period artificial increase compensation aimed increasing pension benefit necessary exclude scheme giving right immediately time high percentage total compensation end career supplementary information afep medef code implemented article disposition code sartorius stedim biotech addition information individual potential right particular reference income maximum percentage income supplementary pension scheme would confer must made public percentage may reference income fixed variable compensation thee reference period information executive director compensation awarding policy share option performance share law imposes company obligation disclose yes chairman part management report aggregate compensation benefit type company governance paid financial year executive director well internal control report compiles amount compensation benefit type information non director received financial year company executive executive group director compensation comprehensive information must provided shareholder clear view individual compensation paid executive director also policy applied company order determine compensation paid permanent information yes company applies executive director compensation component whether recommendation potential vested must publicly disclosed immediately meeting board approving relevant decision annual report must include chapter drawn support compensation committee informing shareholder compensation received executive director chapter must contain following detailed presentation policy determination yes company indicates compensation paid executive director particular rule information within part governing award annual variable part without jeopardizing dedicated compensation confidentiality may linked certain element within reference document determining variable part compensation presentation must indicate criterion basis variable part determined manner criterion applied financial year compared initial expectation whether individual director personal target attained must also necessary specify payment variable part partly deferred indicate condition method deferred payment finally must necessary specify rule governing award multiannual variable compensation without jeopardizing confidentiality may justified certain element determining variable part compensation must indicate criterion basis compensation determined payment multiannual variable part made manner criterion applied information concerning pension system commitment provided yes company indicates company taking account considerable variety pension information within part scheme necessary indicate whether executive director benefit dedicated compensation pension scheme group senior executive within reference document benefit specific pension scheme describe main feature scheme particular calculation method detailed presentation executive director individual yes company indicates compensation compared preceding financial year personal compensation also broken fixed component variable component although french commercial code impose obligation appears information relevant shareholder consists connecting variable component financial year respect calculated even though compensation paid following financial year therefore recommended disclose priority basis compensation thee respect financial year show summary table amount thee paid current preceding financial year aggregate individual amount director fee paid director yes company indicates rule allocating fee well rule governing total amount individual payment director fee awarded applicable general attendance fee management team respect corporate office held affiliate group supplementary information afep medef code implemented article disposition code sartorius stedim biotech description policy award stock option yes company indicates beneficiary explaining separately applicable specific information within part award policy applicable executive director particular dedicated compensation necessary indicate nature option purchase subscription within reference document option applicable criterion used define category beneficiary periodicity plan condition approved board regard exercise option dilutive impact option award summary table must show data relevant existing option plan used benchmark document description share award policy applicable employee yes company indicates certain category employee executive director information within part condition applicable criterion determined board dedicated compensation director dilutive impact share award within reference document manner stock option summary table must show data particular number performance share awarded executive director total number share awarded main beneficiary employee group valuation stock option performance share awarded yes company indicates executive director time award accordance information within part method used consolidated financial statement fraction dedicated compensation capital awarded executive director within reference document recommended comply standardized presentation attached schedule hereto director compensation item board must present compensation executive director yes company indicates annual general meeting presentation must cover element information within part compensation due warded end closed financial year dedicated compensation executive director within reference document applies afep medef fixed part recommendation annual variable part necessary multiannual variable part objective contribute determination variable part extraordinary compensation stock option performance share element longterm compensation benefit linked taking terminating office supplementary pension scheme benefit presentation followed advisory vote shareholder recommended shareholder vote one resolution presented chief executive officer chairman management board one resolution deputy chief executive officer member management board ordinary shareholder meeting issue negative opinion board acting advice compensation committee must discus matter another meeting immediately publish company website notice detailing intends deal opinion expressed shareholder general meeting supplementary information glossary glossary industrial productspecific term bioreactor freezethaw technology englishspeaking country bioreactor used vessel technology used controlled freezing thawing cultivating animal human cell culture medium non biological liquid liquid biologics englishspeaking country term also used synonymously fermentor system microorganism membrane chromatography bacteria yeast fungi multiply case vessel selective separation mixture substance adsorption used obtain cell part one metabolite specifically modified membrane membrane adsorbers flowing system capsule readytouse filter unit consisting filter housing hose membrane filter connector incorporated filter cartridge connection thin film foil made polymer porous piping structure film used filtration application crossflow monoclonal antibody term taken filtration technology instead directly synthetic antibody increasingly used flowing filter static filtration liquid flow medical diagnosis treatment perpendicularly filter surface prevents filter blockage resulting longer inservice life filter purification important step downstream processing disposable product single use cf singleuse product recombinant protein protein manufactured using genetically modified organism downstream processing example include pharmaceutical protein insulin collective term various step follow fermentation vaccine cell cultivation production biopharmaceuticals example separation purification concentration scaleup transfer scale increase size term used denote fda food drug administration progression process increase range lab u governmental agency responsible monitoring scale pilot scale process scale retaining food biotechnological medical veterinary technology material construction geometry pharmaceutical product throughout fermentation singleuse product see disposable technical process used produce transform intra extracellular substance help microorganism sterile filter sterilizinggrade filter membrane filter whose pore size usually smaller fluid management technology product processspecific validation test required technology system use handling sensitive biological confirm whether filter type selected delivers sterile filtrate liquid example transportation storage medium sterility test sterility testing test verify sample contains living viable substance validation systematic checking essential step facility research development production including testing pharmaceutical ensure product manufactured made reliably reproducibly desired quality supplementary information glossary business economic term amortization ia international accounting standard amortization relates exclusively potential reduction internationally recognized accounting principle value goodwill allocation purchase price intangible asset acquired carried accordance ifrs international financial reporting standard ifrs internationally recognized accounting principle cash flow investment rate short longterm management liquid fund cash ratio capital expenditure sale revenue balance inflow outflow fund pro forma derivative financial instrument pro forma presentation used annual report mean instrument hedging risk change figure include business generated stedim market price foreign currency consolidated first time june full previous year business generated sartorius stedim ebit plastic gmbh consolidated january full earnings interest tax fiscal year preceding year ebit margin supply chain management ratio ebit see ebit sale revenue setup coordinated control integrated flow material information finance supply chain entire value ebita added process earnings interest tax amortization related business combination amortization item refers tecdax amortization confirmed connection purchase price german stock index transaction service provider allocation ppa intangible asset acquired specified marketplace organizer deutsche börse ag ifrs standard treasury ebita margin short mediumterm liquidity management ratio ebita see ebita sale underlying ebita margin ebitda ratio operating ebita see underlying ebita sale revenue earnings interest tax depreciation amortization underlying ebitda ebitda margin ebitda see ebitda adjusted extraordinary item ratio ebitda see ebitda sale revenue extraordinary item amounted million previous year million essentially cover onetime expense fixed asset strategic group project integration acquisition related sum intangible asset property plant equipment item financial asset underlying ebitda margin free float ratio operating ebitda see underlying ebitda sale share public company freely available revenue investing public underlying consolidated net profit goodwill profit figure yielded adjustment extraordinary represents difference price paid company item amortization business combination refers business net asset goodwill form intangible exclusively purchase price allocation ppa intangible asset asset acquired according revised ifrs supplementary information adresses adresses europe france germany austria sartorius stedim biotech sa sartorius stedim biotech gmbh sartorius stedim austria gmbh zone industrielle le paluds augustspindlerstr modecenterstr avenue de jouques c goettingen vienna aubagne cedex phone phone phone fax fax fax infosartoriusstedimcom separationaustriasartoriuscom infosartoriusstedimcom sartorius stedim plastic gmbh belgium sartorius stedim fmt sa karlarnoldstr zone industrielle le paluds goettingen sartorius stedim belgium nv avenue de jouques c phone leuvensesteenweg b aubagne cedex fax vilvoorde phone infosartoriusstedimcom phone fax fax infosartoriusstedimcom sartorius stedim system gmbh lindreymensartoriuscom robertboschstraße sartorius stedim france sa guxhagen denmark zone industrielle le paluds phone avenue de jouques c fax sartorius stedim nordic aubagne cedex infosartoriusstedimcom hørskætten phone taastrup fax phone infobiotechfrancesartoriusstedimcom fax infodksartoriusstedimcom sartorius stedim aseptics sa zone industrielle de saux rue ampère hungary lourdes phone sartorius stedim hungária kft fax kagyló u infosartoriusstedimcom budakeszi phone fax ssbsartoriushu supplementary information ireland portugal uk sartorius stedim ireland ltd sartorius stedim spain sa sartorius stedim uk ltd unit business centre cisabel colbrand oficina longmead business centre stadium business park polígono industrial de fuencarral blenheim road ballycoolin road madrid epsom surrey kt qq dublin phone phone phone fax fax fax biotech_spainsartoriusstedimcom uksartoriussartoriusstedimcom infoirelandsartoriusstedimcom russia sartorius stedim lab ltd italy unit stonedale road sartorius icr ooo saintpetersburg stonehouse gloucestershire gl rq sartorius stedim italy spa rasstannaya str building letter phone via dellantella st petersburg fax antella bagno ripoli florence phone alanjohnsonsartoriusstedimcom phone fax fax russiasartoriuscom tab biosystems infoitalysartoriuscom york way spain royston herfordshire sg wy netherlands phone sartorius stedim spain sa fax sartorius stedim nl cisabel colbrand oficina infotapbiosystemscom westblaak polígono industrial de fuencarral kg rotterdamm madrid phone phone fax fax officenlsartoriuscom biotech_spainsartoriusstedimcom poland switzerland sartorius stedim poland sp zoo ul wrzesinska sartorius stedim switzerland ag kostrzyn ringstrasse phone tagelswangen fax phone biuroplsartoriuscom fax biotechswitzerlandsartoriusstedimcom supplementary information africa north america latin america tunisia usa argentina sartorius stedim bioprocess sarl sartorius stedim north america inc sartorius argentina sa km route de zaghouan orville drive int avalos bourbiâa bp tunisia bohemia new york becs munro phone phone buenos aire fax fax phone infosartoriusstedimcom infosartoriusstedimcom fax sartoriusargsartoriuscom sartorius stedim biotech sarl allpure technology inc km route de zaghouan progress avenue brazil bourbiâa bp tunisia new oxford pa phone phone sartorius brasil ltda fax fax avenida senador vergueiro infosartoriusstedimcom salesallpureinccom são bernardo campo cep sp sartorius stedim integrated service sarl tap biosystems phone km route de zaghouan montchanin road fax bourbiâa bp tunisia greenville de sartoriusbrsartoriuscom phone phone fax fax mexico infosartoriusstedimcom infotapbiosystemscom puerto rico sartorius de méxico sa de cv circuito circunvalación poniente sartorius stedim filter inc ciudad satélite carretera int estado de méxico barriada arturo lluveras phone po box fax yauco puerto rico sartoriusmxsartomexcom phone fax marcoslopezsartoriuscom supplementary information asia pacific china singapore australia sartorius stedim biotech beijing co ltd sartorius stedim singapore pte ltd sartorius stedim australia pty ltd yu road tianzhu airport science park road unit rodeo drive industrial park zone b capricorn dandenong south melbourne shun yi district beijing singapore science park ii victoria phone singapore phone fax phone fax enquirycnsartoriusstedimcom fax infoaustraliasartoriusstedimcom chooleepangsartoriusstedimcom india south korea sartorius stedim india pvt ltd jakkasandra sartorius korea biotech co ltd kunigal road th floor solid space nelamangala bangalore pangyoyeokro phone bundanggu seongnamsi fax gyeonggido biotechindiasartoriuscom phone japan fax infosartoriuscokr sartorius stedim japan kk th floor daiwa shinagawa north bldg vietnam kitashinagawa shinagawaku tokyo sartorius representative office phone unit c th floor tower big building fax pham hung street infosartoriuscojp dinh tu liem hanoi malaysia phone fax sartorius stedim malaysia sdn bhd sartoriusvnhnvnnvn lot l e b enterprise technology park malaysia bukit jalil kuala lumpur phone fax ehtansartoriuscommy address visit website internet wwwsartoriuscom supplementary information local presence worldwide local presence worldwide america bohemia ny usa wilmington de usa new oxford pa usa mexico city mexico yauco puerto rico são paulo brazil buenos aire argentina sale production production sale supplementary information local presence worldwide europe africa dublin ireland barcelona spain royston uk goettingen germany stonehouse uk guxhagen germany epsom uk poznan poland vilvoorde belgium budapest hungary aubagne france vienna austria lourdes france tagelswangen switzerland florence italy mohamdia tunisia asia paciﬁc beijing china shanghai china seoul south korea tokyo japan hanoi vietnam bangalore india kuala lumpur malaysia singapore singapore melbourne australia supplementary information financial schedule analyst conference sfaf paris france march annual general shareholder meeting aubagne france april payment dividends april publication firstquarter figure april publication firsthalf figure july publication ninemonth figure october publication preliminary figure fiscal january annual general shareholder meeting aubagne france april publication firstquarter figure april subject approval annual general shareholder meeting contact petra kirchhoff andreas theisen vice president director corporate communication ir investor relation phone phone petrakirchhoffsartoriuscom andreastheisensartoriuscom publication published financial reporting system firesys sartorius stedim biotech sa michael konrad gmbh corporate communication frankfurt main germany c aubagne cedex france photography peter ginter editorial deadline lohmar germany february published february translation original frenchlanguage document de référence sartorius stedim biotech sa sartorius stedim biotech group reference document zone industrielle le paluds avenue de jouques c aubagne cedex france phone fax infosartoriusstedimcom wwwsartoriusstedimcom sartorius stedim biotech group reference document sartorius stedim biotech sa printed germany publication oge order